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HerPesvirus infections in immunocomPromised Patients; general asPects
Background
The family of Herpesviridae contains hundreds of herpesviruses of which eight natural-
ly infect humans (Table 1).1 Herpes simplex virus type 1 (HSV-1), varicella-zoster virus 
(VZV) and cytomegalovirus (CMV) are the human herpesviruses that are investigated 
in this thesis. All are double-stranded DNA viruses with a lipid envelope.1 Infections 
with these herpesviruses are among the most commonly encountered viral infections, 
occurring in virtually any indivdual.2 
Table 1. Human herpesviruses.
Virus Name Abbreviation
Human herpes virus 1 Herpes simplex virus type 1 HSV-1
Human herpes virus 2 Herpes simplex virus type 2 HSV-2
Human herpes virus 3 Varicella-zoster virus VZV
Human herpes virus 4 Epstein-Barr virus EBV
Human herpes virus 5 Cytomegalovirus CMV
Human herpes virus 6 Human herpes virus 6 HHV-6
Human herpes virus 7 Human herpes virus 7 HHV-7
Human herpes virus 8 Kaposi’s sarcoma-associated herpes virus HHV-8
Herpesviruses are extremely well adapted to their host as they establish widespread 
lifelong latent infection in humans while causing only low morbidity in healthy individ-
uals. At the first encounter with a herpesvirus, primary infection occurs in which active 
viral replication leads to death of the infected cells and to the production of infectious 
progeny virus, so called lytic infection.1 Primary infection can be either asymptomatic 
or symptomatic. Examples of common symptomatic primary herpesvirus infections are 
infectious mononucleosis due to Epstein-Barr virus (EBV) or CMV3 and chickenpox due 
to VZV.4
 After this phase of lytic viral replication, a stage of merely inactive infection occurs 
which is called latent infection.1 Latency persists throughout life and is controlled by 
antiviral immune responses; at times of diminished immunity reactivation towards lytic 
viral infection can occur.5;6 Waning antiviral immunity can be seen as an age-dependent 
phenomenon in otherwise healthy persons and lead to the common, usually mild reac-
tivations of herpesviruses.1;2;7-11 Because reactivation causes viral shedding at mucosal 
surfaces it contributes to viral spread between individuals.2 As such, the latent infection 
contributes to the high prevalence of herpesvirus infections. Furthermore, viral reac-
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tivation may cause symptomatic disease. Common and well known manifestations of 
herpesvirus reactivation are, for example, herpes labialis due to HSV-112 and shingles 
due to VZV. 4 
Infections in immunocompromised patients
Both primary infections and reactivations from latency are more frequent and more 
severe in immunocompromised individuals. The more frequent occurrence of primary 
infections is mostly a feature of infections in transplant recipients and is due to the risk 
of transmission of herpesviruses by transplantation of cells, tissues or organs latently in-
fected with herpesviruses. This mode of transmission puts transplant recipients at risk of 
acquisition of a viral infection at a time when they are maximally immunosuppressed.13 
 The more frequent and more severe reactivations in patients with acquired immuno-
deficiencies occur because immunity against herpesviruses can be severely impaired.13 
For example patients with hematological malignancies receiving chemotherapy and es-
pecially hematopoietic stem cell transplant (HSCT) recipients have a temporarily sup-
pressed or eradicated bone marrow function and thus no production of immune cells 
of any kind.13 Recipients of a solid organ transplant receive immunosuppressive medi-
cation that suppresses mainly T-cell function, although in the induction phase shortly 
after transplantation and in case of rejection they also receive broader (including B-cell) 
immunosuppressants.10;11 Severe herpesvirus reactivations in such patients may cause 
systemic symptoms, such as fever due to CMV,14 or may cause organ manifestations, 
such as VZV retinitis,4 or malignancies (EBV-related lymphoma).15 
 Asymptomatic herpesvirus reactivation is commonly indicated as herpesvirus infec-
tion, whereas a symptomatic reactivation is called herpesvirus disease. Not all immu-
nosuppressed patients develop severe or protracted herpesvirus infection or disease. 
Various factors may contribute to the successful prevention or control of herpesvirus 
reactivations, including antiviral immunity16-27 and antiviral treatment28-34.
Treatment and treatment failure
Different antivirals can be used to treat infections with HSV-1, VZV and CMV (Table 2). 
Various strategies for preventing disease due to herpesvirus infections in immunosup-
pressed patients have been developed. Both prophylaxis, preemptive and symptom-
atic treatment are applied. In prophylactic regimens antivirals are administered from 
the time a patient is at risk of infection, whereas in preemptive regimens antivirals are 
initiated when viral infection is diagnosed before symptomatic infection has occurred 
(Figure 1). Symptomatic treatment is initiated when viral infection becomes clinically 
manifest (Figure 1). 
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All three strategies can be effective at prevention of morbidity and mortality, but all 
have their disadvantages as well. Prophylaxis has a high number needed to treat and 
high costs of medication, while preemptive treatment has the requirement and the costs 
of regular diagnostic monitoring. Symptomatic treatment does not prevent disease but 
can only reduce the duration and severity of symptoms and is usually considered infe-
rior and risky. The optimal approach for the various herpesvirus infections in different 
patient categories at risk has not been established completely.30;35-37 
Treatment of herpesvirus infections with antiviral medication aims at reduction of viral 
replication and hence limitation of symptoms of infection. Eventually, only antiviral im-
munity can cause a return to asymptomatic latent infection. Antivirals merely suppress 
viral replication awaiting restoration of antiviral immunity. Continuing viral replication 
despite antiviral medication is considered virological failure of treatment. This may be 
accompanied by persistent or progressive symptoms, which is considered clinical treat-
ment failure. 
Table 2. Antiviral agents used for the treatment of infections with HSV-1, CMV and VZV.
Agent Abbreviation Route of administration Active against
Aciclovir ACV Intravenous/ oral HSV, VZV
Valaciclovir vACV Oral HSV, VZV
Ganciclovir GCV Intravenous/ oral CMV (HSV, VZV)
Valganciclovir vGCV Oral CMV (HSV, VZV)
Foscarnet FOS Intravenous HSV, VZV, CMV
Cidofovir CDV Intravenous/ topical HSV, VZV, CMV
Figure 1. Treatment strategies for herpesvirus infections.
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Treatment failure, either virological or clinical can have various causes (Figure 2). First-
ly, it may be due to a profound state of immunodeficiency in which the patient’s im-
mune system is unable to control viral replication to any extent. Secondly, inadequate 
dosing or impaired drug absorption of antivirals can play a role. Lastly, resistance of 
the virus to antivirals can cause failure of treatment. These factors are interrelated; 
resistant virus that is less fit may only survive in an immunocompromised host and 
high levels of viral replication due to immunodeficiency increase the chance of viral 
resistance (see below).
Antiviral resistance
Resistance of herpesviruses to antivirals is the result of spontaneously occurring muta-
tions during viral replication (Figure 3a). The proportion of spontaneous mutants in 
a viral population depends on the error rate of the viral DNA polymerase and on the 
site of the mutations; mutations in viral enzymes that are crucial to viral replication 
are mostly ‘lethal’ to the virus and such mutants will disappear from the viral popula-
tion.38-41 In the absence of adequate antiviral immunity, viral replication levels are high 
which increases the chance of a resistance associated mutation occurring. Upon selec-
tion pressure due to the administration of an antiviral agent, a resistant mutant subpop-
ulation may become dominant over the wildtype susceptible population (Figure 3b). 
This is more likely to occur during prolonged therapy and when there is no complete 
inhibition of viral replication, for example due to low levels of the antiviral drug at the 
site of replication.38;42 The latter can be due to incorrect drug dosing, impaired drug 
absorption or poor penetration of the drug in so called sanctuary sites, such as the cere-
brospinal fluid or the eye. 
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Resistance to antivirals can be detected by culturing a viral isolate in the presence of 
antivirals and measuring the concentration of antiviral that inhibits viral replication in a 
so called plaque reduction assay. The success of this phenotypical approach depends on 
the ability to obtain a viral isolate, which can be difficult for some viruses and body sites 
(e.g. VZV and CMV in plasma or cerebrospinal fluid). Culture based assays may select 
for the best replicating viral subpopulation which can lead to false-susceptible results. 
Furthermore, this type of assay is time consuming and labor intensive. An alternative 
approach is to detect resistance-associated mutations in the viral genome in a clinical 
sample by molecular techniques. This approach avoids the need for culture and is fast 
Figure 3a. Illustration of development of resistance in uncomplicated herpesvirus infection.
Figure 3b. Illustration of development of resistance in complicated herpesvirus infection.
Spontaneous resistant mutants appear during treatment and disappear after cessation of treatment and after clearance 
of the infection by the immune system in uncomplicated infections (3a). When immune restoration does not occur and 
persistent infection with high viral loads necessitates prolonged treatment, the resistant subpopulation may become 
dominant (3b). 
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and technically easy to perform. However, its applicability depends on the knowledge 
of the significance of mutations. If this knowledge is not complete or if there is a fre-
quent occurrence of polymorphisms, phenotypical confirmation remains necessary.
HerPes simPlex virus tyPe 1
Background
Primary HSV-1 infection occurs by inoculation of susceptible (usually oral) mucosal sur-
faces or minor skin lesions through direct contact.43 After viral replication at the inocu-
lation site, the virus traverses the neuroepithelial gap and is transported to a ganglion, 
most often the trigeminal ganglia in case of HSV-1.6;12 Latent infection is maintained 
for life in the infected ganglia. The seroprevalence of HSV-1 in adults depends on geo-
graphic area and socioeconomic class and is on average between 50% and 85%.44-48 
 The mechanisms of HSV-1 reactivation are not well understood, but immune control 
by T-cells appears to play a pivotal role in the prevention of reactivation.6;12;43;49 The 
rate of reactivation may be influenced by the site of infection,50 local (micro)trauma,51;52 
exposure to UV light53-56 and, possibly, hormonal factors54;57-59 and psychosocial stress-
ors.60;61 Upon reactivation, viral replication is reinitiated and HSV-1 travels back along 
the nerves to the skin or mucosa which leads to local shedding of infectious virus.43 Pri-
mary infection can be asymptomatic, but can also lead to ulcerative stomatitis.62 Reacti-
vation is most often asymptomatic, but can also lead to painful blistering or ulceration 
of the affected skin or mucosa.2;12;43 
Infections in immunocompromised patients
The most common manifestation of HSV-1 reactivation in immunocompromised pa-
tients, such as HSCT recipients is (peri)oral ulceration.13;63 Oral herpetic lesions can 
cause severe pain and difficulties with eating and drinking.43 However, chemotherapy 
with or without total body irradiation can lead to ulcerative oral mucositis as well.64-68 
Chemoraditation usually causes ulcerations of the non-keratinized oral mucosa, where-
as HSV-1 infection usually affects the keratinzed oral mucosa.. However, HSV-1 infec-
tion may also occur at sites of chemoradiation induced mucositis or aggravate this.69 
Therefore, in clinical practice it can be difficult to distinguish different causes of ulcer-
ations. In addition, a possible role for other Herpesviruses such as CMV70 and EBV71 in 
oral ulceration has been suggested. Knowledge on the relative contribution of chemo-
radiation and herpesvirus infection to oral ulceration after HSCT is relevant to guide 
prevention and treatment strategies. 
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Treatment and treatment failure
Oral ulcerations due to HSV-1 in immunocompromised patients are commonly treated 
with aciclovir (ACV) or its oral prodrug valaciclovir (vACV).35;72 vACV and ACV have 
identical working mechanisms. ACV is a deoxyguanosine-analogue which is built into the 
viral DNA by the viral DNA-polymerase during replication and then inhibits viral replica-
tion (Figure 4).73 Aciclovir only becomes active after phosphorylation by a viral thymidine 
kinase (TK) and two subsequent phospohrylation steps by cellular kinases (Figure 4).74 
Second line antivirals are TK independent viral DNA polymerase inhibitors (Figure 4), 
foscarnet75;76 (FOS) and cidofovir77-79 (CDV). However, both drugs are nephrotoxic.
 Especially in immunocompromised patients debilitating and prolonged HSV reac-
tivations can occur despite antiviral treatment.13 The relative contribution of antiviral 
resistance to persistent HSV infections is unknown.
Antiviral resistance
The prevalence of ACV resistance has been shown to be very low in immunocompetent 
subjects (<1%), whereas in immunocompromised patients with HSV-1 infections, resis-
Figure 4. Mechanisms of HSV resistance to antivirals.
Aciclovir (ACV) is activated through phosphorylation by firstly a viral thymidine kinase (TK) and seondly cellular 
kinases. The other antiviral agents, cidofovir (CDV) and foscarnet (FOS) do not depend on phosphorylation by viral 
enzymes. After phosphorylation all antivirals inhibit viral replication by the viral DNA polymerase. Resistance associ-
ated mutations can occur in the viral TK gene (ACV resistance) or in the viral DNA polyermase gene (ACV, FOS and 
CDV resistance). Picture adapted from: Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. 
Antimicrob Agents Chemother. 2005, 49(3): 873-83.
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tance levels up to 27% have been described.80-82 Investigating antiviral susceptibility of 
HSV-1 to antivirals can be done using various techniques. Sequence analysis of a viral 
isolate is the fastest approach. Resistance to ACV in HSV-1 is mostly caused by muta-
tions in the UL23 gene of the viral TK or in the UL30 gene of the viral DNA polymerase 
(Figure 4).83-85 Sequencing of these genes may reveal a resistance conferring mutation, 
but since nucleotide variations are common, mutations of unknown significance are 
also found frequently.83-85 In such cases, phenotypical susceptibility testing of HSV-1 is 
required which is traditionally performed by a plaque reduction assay.86 This type of as-
say is labor intensive and time consuming and, hence, results are often not available in 
a clinically relevant time frame. Real-time pcr based phenotypical susceptibility assays 
may overcome these limitations and facilitate timely diagnosis of antiviral resistance.87;88 
varicella-zoster virus
Background
Primary VZV infection occurs by aerosol transmission or through direct contact.89 After 
viral replication in the respiratory epithelium, VZV infects T-cells in Waldeyer’s ring 
and then viremia distributes the virus throughout the body via infected T-cells.90;91 
There is uncertainty whether skin involvement occurs only after a second viremia or 
results directly from the first viremia.89-93 The seroprevalance of VZV appears to be cli-
mate dependent and reaches 95% during childhood in temperate climates but only 50% 
in tropical areas yet increases thereafter.94-96 
 Lifelong latent infection is established in dorsal root ganglia and cellular immuno-
defiency predisposes to reactivation.89 Upon reactivation, viral replication is reinitiated 
and VZV travels back along the nerve to the skin of the corresponding dermatome.89 
Both primary infection and reactivation are usually symptomatic; primary infection 
cuases the clinical picture of chickenpox with disseminated itching vesicles, whereas 
reactivation causes the clinical picture of herpes zoster or shingles with a dermatomal 
painfull vesicular eruption.93 In addition, cutaneous VZV reactivations can lead to post-
herpetic neuralgia with long-lasting and severe morbidity.89
Infections in immunocompromised patients
The most common manifestation of VZV reactivation in immunocompromised patients 
is herpes zoster; this can be dermatomal but is often disseminated in severely immuno-
deficient patients.63 VZV infection occurs in 30-40% of HSCT recipients in the first year 
after transplantation.34;97 Visceral, retinal en neurological infections can occur in this 
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patient category and cause serious morbidity and mortality.23;63;89;93;98-101 Visceral dis-
semination occurs especially in patients with graft-versus-host disease.97
Treatment and treatment failure
To prevent dissemination or other serious manifestations of VZV reactivation, treatment 
with antiviral agents is given to immunodeficient patients with clinical signs of herpes 
zoster. Most VZV reactivations respond to treatment with ACV or vACV or related an-
tiviral agents 99;102, but both progressive and persistent infections despite treatment can 
occur in severely immunocompromised patients 101;103 This can be due to immunologi-
cal failure and to insufficient drug levels, but resistance of the virus to the antiviral treat-
ment has been described as well.104-110 
Antiviral resistance
Resistant VZV has not been shown in immunecompetent patients with primary VZV 
infections or herpes zoster,111;112 but it has been demonstrated in AIDS-patients with 
treatment unresponsive VZV reactivations.104-107 The prevalence of antiviral resistance 
in hemato-oncological patients and HSCT recipients is unknown, with only some case 
reports and case series described thus far.107-110 
 Similar to HSV-1 (Figure 4), VZV resistance to (v)ACV is mainly due to mutations in 
the viral TK gene of VZV, or, in rare cases, in the viral DNA polymerase.105;108-110;113;114 
Resistance can be diagnosed by culture of the virus in the presence of antiviral agents, 
but culture-based techniques are difficult because VZV is a slowly growing and highly 
cell-associated virus.115 Furthermore, VZV often cannot be cultured from clinical sam-
ples such a plasma or cerebrospinal fluid. Direct sequence analysis of the target genes in 
clinical samples is possible in various types of clinical samples and avoids selection by 
culture. However, it is not completely clear in which sample type to look for resistance 
as compartmentalization of resistant strains has been described.108 
cytomegalovirus
Background
Primary CMV infection occurs through direct contact of susceptible mucosal surfaces 
with infectious body fluids such as saliva and urine, through sexual contact or perina-
tally, either in utero or from breast milk.116-118 CMV has a very broad cell tropism includ-
ing epithelial cells, endothelial cells and polymorphonuclear cells.5;119 After a phase of 
viremia, CMV infects many cell types in the body, where subsequently latent infection 
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is established.5;13;14;120 The latent presence in various tissues explains the transmission 
of CMV to recipients of blood transfusions or stem cell and organ transplants.5;13;14;120
 The seroprevalence in adults varies with ethnicity and socioeconomic status from 
40% up to 100% in developing countries.44;94;121-123 Primary infection is mostly asymp-
tomatic, but a mononucleosis syndrome can occur.3 Reactivation from latency is known 
to occur but is asymptomatically in healthy individuals.1;117;120 
Infections in immunocompromised patients
In immunocompromised individuals both primary infection and reactivation can af-
fect virtually any organ system, with symptoms ranging from fever and malaise to 
pneumonitis and hepatitis.14;120 Reactivation occurs more often and is more frequently 
symptomatic in immunocompromised persons.1;117;120 Manifestations of CMV infection 
in immunocompromised patients vary with the underlying disease, the type of the im-
munodeficiency and the pre-existing CMV immunity. For example, AIDS-patients often 
suffered from CMV chorioretinitis in the era when effective anti-retroviral treatment 
was unavailable, whereas this manifestation is rare in transplant recipients.124 HSCT 
recipients suffer mostly from CMV pneumonitis or colitis, whereas those organs are less 
commonly affected in solid organ transplant recipients.124 
 In CMV seronegative individuals, the receipt of a solid organ from a CMV sero-
positive donor transfers CMV to the recipient. This causes a primary infection at a time 
when induction immunosuppressive agents are administered and therefore has a high 
risk of symptomatic and severe disease.125;126 In contrast, CMV seropositive recipients of 
a solid organ transplant already have pre-transplant immunity to CMV which decreases 
the risk of CMV reactivation and of a severe course of CMV infection.125;126 In the set-
ting of HSCT the situation is reversed. CMV seropositive recipients of an HSCT from a 
seronegative donor are at a greater risk of severe disease, because of the latently present 
CMV in the recipient who acquires the CMV-naïve immune system from the seronega-
tive donor.124;127 
 Furthermore, because adaptive immunity is severely suppressed in organ transplant 
recipients in the early phase after transplantation, the innate immune system probably 
plays a pivotal role.128-130 Common single nucleotide polymorphisms in the genes cod-
ing for members of e.g. the lectin complement pathway can have potentially important 
functional implications for the control of CMV infections.128;131-133 
Treatment and treatment failure
CMV infections can be treated with ganciclovir (GCV)30;36;37;134 or its oral prodrug val-
ganciclovir (vGCV).135;136 vGCV and GCV have identical working mechanisms. GCV is 
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a deoxyguanosine-analogue which is built into the viral DNA by the viral DNA-poly-
merase during replication and then inhibits viral replication (Figure 5).134;137-140 Ganci-
clovir only becomes active after phosphorylation by a viral kinase (UL97) and two sub-
sequent phosphorylation steps by cellular kinases (Figure 5).141;142 FOS75;76 and CDV77-79 
directly target the viral DNA polymerase of CMV and can be used for treatment as well 
(Figure 5).
Because symptomatic CMV infection, especially CMV end organ disease, is associated 
with high morbidity and mortality, most treatment regimens aim at prevention of CMV 
disease. In high risk solid organ transplant recipients (seropositive donor, D+, seroneg-
ative recipient, R-) prophylaxis is often administered and few prospective comparisons 
with preemptive treatment have been performed.37;143 For HSCT recipients a preemp-
tive approach is usually preferred to minimize drug toxicity, especially myelosuppres-
sion. However, in a preemptive setting, viral DNA can often be detected for days to 
weeks during and after treatment.144-147 The significance and optimal management of 
this finding is unclear.
Figure 5. Mechanisms of CMV resistance to antivirals.
Ganciclovir (GCV) is activated through phosphorylation by firstly a viral kinase (UL97) and seondly cellular kinases. 
The other antiviral agents, cidofovir (CDV) and foscarnet (FOS) do not depend on phosphorylation by viral enzymes. 
After phosphorylation all antivirals inhibit viral replication by the viral DNA polymerase. Resistance associated muta-
tions can occur in the viral UL97 gene (GCV resistance) or in the viral DNA polyermase gene (GCV, FOS and CDV re-
sistance). Picture adapted from: Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob 
Agents Chemother. 2005, 49(3): 873-83.




Only few earlier studies exist in which resistance has been systematically studied in 
HSCT recipients and none used sensitive CMV monitoring techniques such as real-
time pcr.148;149 Also, the contribution of antiviral resistance to viral persistence despite 
antiviral treatment is largely unknown. In renal transplant recipients varying rates of 
resistance have been described; it is unknown which preventive strategy encompasses 
the lowest risk of development of antiviral resistance. 150-154 
 GCV resistance mutations in clinical isolates mainly map to the viral kinase gene 
UL97 (Figure 5).154-158 After prolonged treatment, mutations in the viral polymerase gene 
UL54 can also emerge (Figure 5).158;159 Sequencing analysis is the fastest method for sus-
ceptibility testing of CMV, which often cannot be cultured. Alternative molecular tech-
niques for mutation detection have been studied to reduce hands on time and post-PCR 
processing,160-162 but focused on fixed genome positions known to be involved in anti-
viral drug resistance and, hence, may have missed mutations at other sites. Compared 
to mutation detection by Sanger based sequencing techniques or by real-time pcr, mass-
spectrometry based comparative sequence analysis combines the possibility of detection 
of all nucleotide variations within a target gene with reduced hands on time due to the 
automation of post-PCR processing and analysis.163-165 Application of this technique may 
facilitate studying and diagnosing antiviral resistance in CMV infections. 
scoPe of tHis tHesis
The research described in this thesis aims to study determinants of the course and out-
come of treatment of herpesvirus infections in immunocompromised patients. Both 
viral factors, such as antiviral resistance, and patient factors, including immunological 
parameters, were investigated. Techniques to study antiviral resistance were optimized 
for use in a clinical diagnostic setting. The aim of this research is to improve and facili-
tate management of herpesvirus infections in immunocompromised patients.
In chapter two the development and validation of a real-time pcr based phenotypical 
technique to study susceptibility of HSV-1 to antiviral drugs in a routine diagnostic set-
ting is described. 
In chapter three the role of HSV-1, EBV and CMV in oral ulcerations in HSCT recipients 
is investigated. Also the course of the oral HSV-1 infections in this setting and the occur-
rence antiviral resistance are described. 
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In chapter four the course of VZV infections in hematological patients is studied includ-
ing the role of antiviral resistance in persistent infections. Systematic analysis of the 
occurrence and localization of resistant VZV is described.
In chapter five the application of a novel technique using mass spectrometry-based 
comparative sequencing to detect ganciclovir resistance in CMV is addressed. 
In chapter six determinants of the response to antiviral treatment of CMV infections in 
HSCT recipients are studied, including resistance to antivirals. 
In chapter seven the response to treatment and the occurrence of antiviral resistance 
are compared between a preemptive and a sequential prophylactic-preemptive treat-
ment regimen for CMV in D+R- renal transplant recipients. 
In chapter eight the role of gene polymorphisms influencing components of the innate 
immunity, mannose-binding lectin and ficolin-2, on CMV infection after orthotopic liver 
transplantation (OLT) is investigated. 
In the discussion, implications for management of herpesvirus infections in immuno-
compromised patients as well as suggestions for further research are described.
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Background: Susceptibility testing of herpes simplex virus type 1 (HSV-1) is traditionally 
performed by a plaque reduction assay (PRA), but this is labor intensive, time consum-
ing and has a manual read out. 
Objectives: The goal of this study was to develop an internally controlled real-time PCR-
based phenotypical susceptibility test for HSV-1 that is suitable for use in a clinical di-
agnostic setting.
Study design: A DNA reduction assay (DRA) was developed and validated on a test 
panel of 26 well-characterized isolates of varying susceptibility to aciclovir or foscar-
net, including low-level resistant isolates. The DRA consisted of pre-culture of a clinical 
sample for 48 hours and subsequent culture in the presence of antivirals for 24 hours. Vi-
ral DNA concentration in the culture lysates was measured by an internally controlled 
quantitative real-time HSV-1 PCR and corrected for cell count and lysis by beta-globin 
PCR. DRA results were compared to results from PRA and sequence analysis.
Results: DRA results were in accordance with PRA results for both aciclovir and foscar-
net susceptibility and appeared to have good discriminative value for low-level resis-
tance due to UL30 gene mutations. Although the direct application of DRA in clinical 
samples appeared not possible, short pre-culture of 48 hours was sufficient and ensured 
results within a clinically relevant time frame of 5 days.
Conclusions: DRA is an accurate, rapid and easy to perform phenotypical susceptibility 
test for HSV-1.
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background
Severe and persistent infections with herpes simplex virus type 1 (HSV-1) are common 
in immunocompromised patients, especially patients receiving chemotherapy and 
hematopoietic stem cell transplants, and are frequently associated with antiviral resis-
tance.1 The fastest approach to HSV-1 susceptibility testing is sequence analysis of the 
UL23 gene of the HSV-1 thymidine kinase that catalyzes a necessary phosphorylation 
step of aciclovir or of the UL30 gene of the HSV-1 DNA polymerase. Sequencing of these 
genes may reveal a resistance conferring mutation, but since nucleotide variations are 
common, mutations of unknown significance are also found frequently.1-4 In such cases, 
phenotypical susceptibility testing of HSV-1 is still required which is traditionally per-
formed by a plaque reduction assay (PRA).5 PRA requires viral titration and prolonged 
incubation until viral cytopathogenic effect (CPE) is visible and is labor intensive, sub-
jective and time consuming. 
Faster phenotypical assays using more sensitive and objective endpoints are preferable. 
Real-time PCR has previously been applied successfully to measure viral concentrations 
in HSV-1 phenotypical susceptibility tests.6;7 Stranska et al6 measured inhibition of viral 
DNA replication by antivirals in culture supernatant, which may be less indicative of 
intracellular viral replication. The protocol described by Thi et al7 measured viral DNA 
in cells but used crude cell lysate in an uncontrolled PCR. 
objectives
The goal of this study was to design, optimize and validate a rapid internally controlled 
real-time PCR-based phenotypical susceptibility test for HSV-1 for routine use in a clini-
cal diagnostic setting. 
study design
Viral isolates and clinical samples 
For DNA reduction assay (DRA) validation using viral isolates (Table 1), susceptible ref-
erence strain HSV F (ATCC number VR-733 Manassas, VA, USA), and 25 previously 
characterized viral isolates from 14 patients that were clinically suspected of having a 
resistant virus and that had been sent for susceptibility testing to an external laboratory 
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or that were described in previous studies were used.8-10 The test panel included pre-
treatment viral isolates if available. Aliquots of viral isolates were stored at -80°C. For 
DRA validation directly on clinical samples (swabs), the clinical samples from which 
isolates #5 and #17 had been cultured and 7 randomly selected HSV-1 positive clinical 
samples were used. 
UL23 and UL 30 gene sequence analysis 
Genotypical resistance analysis was performed by cycle sequencing after PCR ampli-
fication on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems). Amplification 
and sequencing primers and PCR conditions are shown in Table 2. UL23 amplification 
was performed in 50 µl containing 25 µl HotStart Taq mastermix (Qiagen, Hilden, Ger-
many) and 15 pmol of each primer. For UL30 amplification, nested PCR was necessary 
for clinical samples, but not for viral isolates. PCR and nested PCR were performed 
in 50 µl containing 1 µl Advantage®-GC 2 Polymerase mix (Clontech, Westburg, Leus-
den, The Netherlands), 10 µl Advantage®-GC 2 PCR Buffer, 25 µmol GC-melt, 0.2 mM 
dNTP mix and 15 pmol of each primer. All cycle sequencing reactions were performed 
in 20 µl containing 2 µl Big Dye Terminator v1.1 (Applied Biosystems, Carlsbad, CA, 
USA), 6 µl sequencing buffer and 8 pmol primer. The detection limit of the assay was 
around 1000 copies/ml for the UL23 gene and around 5000 copies/ml for the UL30 gene. 
Sequences were compared to pre-treatment isolates if available and to the sequence of 
HSV F.
Plaque Reduction Assay
The protocol M33-A Antiviral Susceptibility Testing: Herpes Simplex Virus by Plaque Reduc-
tion Assay of the Clinical and Laboratory Standards Institute5 using Vero cells was modi-
fied by including the use of microcrystalline cellulose (Avicel® RC/CL, FMC BioPoly-
mer, Philadelphia, USA) as overlay.11 For viral titration, the overlay consisted of 1.5 ml 
of 0.6% Avicel® RC/CL in sterile water mixed 1:1 with 2x EMEM without phenol red 
(Gibco) with 4% FCS and 4 mM glutamine. After incubation, cells were fixed with for-
malin and, after aspiration of the overlay, stained with crystal violet. For PRA, the over-
lay consisted of twofold serial dilutions of aciclovir (acycloguanosine, Sigma-Aldrich, 
Schnelldorf, Germany) or foscarnet (sodium phosphonoformate tribasic hexahydrate, 
Sigma-Aldrich) in 2x EMEM without phenol red with 4% FCS and 4 mM glutamine 
mixed 1:1 with 0.6% Avicel® RC/CL in sterile water. The aciclovir concentration range 
was 0,12 to 16 mg/L and for foscarnet the concentration range was 16,7 to 400 mg/L. 
Isolates having an IC50 value ≥ 2 mg/L for aciclovir or ≥ 100 mg/L for foscarnet were 
considered resistant.5
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Real-time PCR based phenotypical susceptibility test
DRA was performed on supernatants from either HSV-1 culture isolates (Table 1) or di-
rectly on positive clinical samples inoculated onto A549 cells and incubated for 48 hours. 
Supernatants from pre-cultured clinical samples were diluted 1:100 in EMEM regardless 
of viral titers whereas stored viral isolates were diluted to obtain viral loads between 
104 and 107 copies/ml. A confluent monolayer of Vero cells was cultured in 24 wells 
plates. Subsequently 300 µl of the diluted sample was added to each well after removal 
of culture medium. After one hour of incubation at 37°C in a humidified atmosphere 
of 5% CO2 the inoculum was removed and replaced by 1 ml of aciclovir or foscarnet 
in EMEM with 5% FCS. The concentration range of the serial dilutions (6 dilutions per 
isolate) of aciclovir was 0.12 to 16 mg/L and for foscarnet 8.35 to 100 mg/L. All samples 
were assayed in quadruplicate and incubated for 24 hours.  
 Then, after removal of the culture medium, 200 µl of AL Lysis buffer (QIAamp® DNA 
Mini and Bloodkit, Qiagen) spiked with Phocid Herpes Virus (PhHV, kindly provided by 
Dr. M Schutten, Erasmus Medical Center, Rotterdam, The Netherlands) was added to the 
monolayer and incubated for 15 minutes at room temperature. Lysate was harvested and 
all wells were rinsed with 200 µl PBS to include any remaining viral DNA which was then 
added to the lysate. After addition of 20 µl Proteinase K (Qiagen), samples were incubated 
10 minutes at 56°C and 10 minutes at 95°C. Samples were mixed with 200 µl ethanol 100% 
and transferred to a Qiamp® mini spin column (Qiagen) and centrifuged for 1 minute at 
6000 x g. Washing steps were omitted to limit hands on time. DNA was eluted in 200 µl 
AE buffer (Qiagen) by centrifugation for 1 minute at 6000 x g. A real-time PCR for beta-
globin and a multiplex real-time PCR for PhHV and HSV-1 were performed on a CFX96 
real-time detection system (Bio-Rad, Veenendaal, The Netherlands). Primers, probes and 
PCR conditions are shown in Table 2. PCRs were carried out in 50 µl volume containing 
25 µl HotStart Taq mastermix (Qiagen) and 4 mM MgCl2 (5 mM for beta-globin). 
 For quantitation, a standard of HSV-1 (cultured field isolate or ATCC KOS strain VR-
1493D) was calibrated using a quantitated DNA control of the HSV-1 MacIntyre strain 
(Advanced Biotechnologies Inc., Columbia, MD). PhHV served as an internal control 
for DNA extraction and PCR inhibition12 and those wells that were outliers in the PhHV 
PCR (more than 3 CT-values different from assay average) were considered inhibited 
and were excluded from the analysis. The beta-globin PCR was performed as a control 
for cell concentration and cell lysis for which the same exclusion criteria were used. The 
concentration of antiviral agents to inhibit viral DNA replication by 50% (IC50) was cal-
culated after plotting the viral concentration versus the concentration of antiviral agent. 
Provisional resistance breakpoints were adapted from Thi at al.7 and set at ≥0.23 mg/L 
for aciclovir and at ≥ 13 mg/L for foscarnet. 





PRA and sequence analysis of the UL23 and UL30 genes were repeated on aliquots of 
the viral isolates to be used for DRA. PRA results for aciclovir were concordant with 
genotypic analysis in 25 isolates including 11 with no mutations in either the UL23 
or UL30 genes, 13 with a mutation in UL23, and 1 with a mutation in UL30. One 
isolate (#25) had a UL30 mutation but was susceptible to aciclovir by PRA but with 
an elevated IC50 of 1.03 mg/L (Table 3). PRA results for foscarnet were concordant in 
23 isolates, including 10 with no mutations and 13 with a mutation in UL23, failed 
in one isolate (#2) and were discordant with genotypical analysis in the two isolates 
with UL30 mutations (#24 and #25, Table 3). Both isolates #24 and #25 showed di-
minished susceptibility to foscarnet although not meeting the proposed resistance 
criteria according to CLSI.
 DRA was validated for aciclovir on all isolates and for foscarnet in UL30 mutants 
and in a subset of UL23 mutants. DRA failed in one isolate (#9). DRA results (Ta-
ble 3) for aciclovir were in concordance with genotyping of all 25 isolates using the 
provisional breakpoint of 0.23 mg/L, but not in concordance with PRA for 1 isolate 
(#25). By DRA, IC50 values of all 15 UL23 and UL30 mutants, including isolate #25, 
were at least at least 2.8-fold the tentative breakpoint and 6.4-fold the IC50 value of 
the susceptible reference isolate. DRA results (Table 3) for foscarnet were concordant 
with genotypical results in the 8 tested isolates, but were not concordant with PRA in 
two isolates (#24 and #24) . These UL30 mutants had IC50-values that were at least 
1.7 fold the tentative breakpoint and at least 2.5 fold the IC50 value of the susceptible 
reference isolate. 
Clinical samples
DRA was applied to 9 clinical samples (Table 4) and demonstrated aciclovir resistance in 
two UL23 mutants (Table 4) and failed in one of the clinical samples that had a relatively 
low viral load after 48 hours of pre-culture (7.9×104 copies/ml). 
discussion
This study optimized and validated a protocol for phenotypical susceptibility testing of 
HSV-1. A fast and easily applicable protocol was developed that compared very well to 
results obtained by genotypical tests and by PRA. Although only tentative breakpoints 
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exist for susceptibility testing of HSV-1 using a real-time-PCR based approach, classifica-
tion of the DRA results according to the tentative breakpoints adopted from Thi et al.7 
resulted in very high concordance. DRA failed in only one isolate. 
DRA provided results within five days after sampling (Figure 1). No visible viral CPE 
is required when viral replication is measured by sensitive methods such as real-time 
Table 3.  UL23 and UL30 sequence analysis, plaque reduction assay and DNA reduction assay 














mg/L mg/L mg/L mg/L
HSV-F none 0.08 21.9 ACV S FOS S 0.10 8.75 ACV S FOS S
#1 none 0.10 21.3 ACV S FOS S 0.08 n.d. ACV S FOS n.d.
#2 none 0.45 failed ACV S FOS n.d. 0.06 n.d. ACV S FOS n.d.
#3 none 0.16 18.2 ACV S FOS S 0.12 n.d. ACV S FOS n.d.
#4 none 0.09 26.0 ACV S FOS S 0.07 n.d. ACV S FOS n.d.
#5 none 0.15 19.4 ACV S FOS S 0.07 n.d. ACV S FOS n.d.
#6 none 0.23 16.7 ACV S FOS S 0.12 n.d. ACV S FOS n.d.
#7 none 0.28 11.4 ACV S FOS S 0.08 n.d. ACV S FOS n.d.
#8 none 0.28 17.8 ACV S FOS S 0.18 n.d. ACV S FOS n.d.
#9 none 0.06 10.5 ACV S FOS S failed failed failed
#10 none 0.11 35.7 ACV S FOS S 0.08 12.81 ACV S FOS S
#11 UL23 16.21 11.3 ACV R FOS S 2.65 n.d. ACV R FOS n.d.
#12 UL23 15.16 16.3 ACV R FOS S 3.67 n.d. ACV R FOS n.d.
#13 UL23 11.20 10.1 ACV R FOS S 0.76 n.d. ACV R FOS n.d.
#14 UL23 11.82 12.5 ACV R FOS S 6.17 n.d. ACV R FOS n.d.
#15 UL23 15.56 9.1 ACV R FOS S 2.40 n.d. ACV R FOS n.d.
#16 UL23 13.92 25.0 ACV R FOS S 3.18 5.98 ACV R FOS S
#17 UL23 16.70 17.4 ACV R FOS S 3.06 n.d. ACV R FOS n.d.
#18 UL23 37.95 25.0 ACV R FOS S 4.62 4.81 ACV R FOS S
#19 UL23 6.88 25.0 ACV R FOS S 2.42 9.11 ACV R FOS S
#20 UL23 10.55 15.5 ACV R FOS S 1.63 n.d. ACV R FOS n.d.
#21 UL23 6.15 21.6 ACV R FOS S 4.69 n.d. ACV R FOS n.d.
#22 UL23 6.33 5.8 ACV R FOS S 0.67 n.d. ACV R FOS n.d.
#23 UL23 14.25 11.7 ACV R FOS S 0.95 5.63 ACV R FOS S
#24 UL30 5.81 88.7 ACV R FOS S 0.64 22.13 ACV R FOS R
#25 UL30 1.03 43.4 ACV S FOS S 0.99 29.73 ACV R FOS R
IC50 values greater than or equal to resistance breakpoint (see text) in bold. ACV = aciclovir; DRA = DNA reduction 
assay; FOS = foscarnet; n.d. = not determined; PRA = plaque reduction assay; R = resistant; S = susceptible.
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PCR and hence incubation time can be reduced compared to PRA. Pilot experiments us-
ing both susceptible and resistant isolates showed comparable IC50 values over broad 
ranges of viral inoculum, given sufficient viral input (10.000 copies/ml), hence allowing a 
fixed dilution of pre-cultured clinical samples without the need for viral titration. Hands 
on time could be reduced by the use of a simplified DNA isolation procedure. DRA was 
applicable to all clinical samples with a viral load of at least 10.000 copies/ml. In the final 
format of quadruplicate testing the coefficient of variation of the log-transformed viral 
concentrations was 5% on average. On average 0.3 wells were excluded per 24-wells assay 
because of PCR inhibition and 1.2 wells because of insufficient beta-globin concentration.
As shown in previous studies,1-3 mutations of unknown significance are commonly 
found in HSV-1 clinical isolates and a pre-treatment sample for comparison of mutations 
is often not available. Three isolates contained UL30 mutation Asp-672→Asn which has 
recently been described both as a natural polymorphism2 and as an aciclovir and foscar-
net resistance-associated mutation.13 Phenotypical susceptibility tests showed aciclovir 
and foscarnet susceptibility in an isolate with no other resistance-associated mutations 
making Asp-672→Asn unlikely as a resistance-associated mutation. This nicely demon-
strates the usefulness of phenotypical susceptibility testing. 
Figure 1
Time frame (workings days) of suscep-
tibility testing by DNA reduction assay 
versus plaque reduction assay.
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Low level resistance to aciclovir and foscarnet due to mutations in the UL30 gene is pos-
sibly more accurately detected by DRA than by PRA. Both our PRA and PRA performed 
initially (by others) showed a level of resistance around or below the specified break-
point, as previously described for UL30 mutations A719V and S724N.8;10;14;15 This may 
be due to the specific UL30 gene mutations or because low-level resistance or interme-
diate susceptibility may not be accurately defined by the CLSI breakpoints.5 Neverthe-
less, DRA consistently showed increased IC50 values above the tentative breakpoints in 
these isolates. Because knowledge on the clinical significance of such mutations is lack-
ing, it would be interesting to study how infections with such isolates should be treated.
Some limitations apply to the DRA. Firstly, without a short pre-culture, no viral replica-
tion was observed in DRA, but our protocol was suitable for clinical samples after a fixed 
short term pre-culture. This may be due to the low inoculum present in clinical samples, 
although pre-culture did not increase viral loads very much. It can also be related to 
the short duration of incubation of the DRA, although prolonging the assay to 48 hours 
did not solve the problem. Possibly, adaptation of virus to cell culture is necessary for a 
successful DRA. To study the possible selection pressure during pre-culture of a clinical 
sample, nine clinical samples were cultured for 48 hours. The nucleotide sequence of 
the entire UL23 gene was compared between the clinical samples and the viral isolates 
after 48 hours of pre-culture (Table 4) and no differences were found.  
 Secondly, the detection limit of DRA precluded its use for weakly positive samples. 
This limitation may be partly overcome by adaptation of the dilution in samples with a 
lower viral load, which was applied successfully in one of our clinical samples in which 
a 1:10 diluted culture supernatant was used instead of 1:100 (Table 4). Finally, the assay 
was validated for HSV-1 only.
In clinical diagnostics, a genotypical approach has the advantages of speed and techni-
cal ease. A two-step approach may therefore be practical in this setting, starting with 
UL23 and UL30 gene sequencing of, preferably, a pre- and on-treatment sample and 
subsequent phenotypical confirmation of resistance if mutations of unclear significance 
are encountered. A multicenter trial evaluating assay applicability and reproducibility 
and the clinical outcome in relation to the tentative breakpoints, should confirm the role 
of DRA in phenotypical susceptibility testing of HSV-1. 
In conclusion, DRA is an accurate, rapid and easy to perform phenotypical susceptibil-
ity test for HSV-1. 
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Background: Ulcerative oral mucositis and infection are frequent complications in HSCT 
recipients. The aim of this study was to investigate the relationship between oral ulcer-
ations and HSV-1, EBV and CMV excretion and the presence of aciclovir resistant HSV-1 
strains in HSCT recipients. 
Methods: This prospective observational study included 49 adult patients that under-
went allogeneic HSCT. Twenty-six patients received myeloablative and 23 received 
non-myeloablative conditioning. Ulcerations on non-keratinized and keratinized oral 
mucosa were scored and oral rinsing samples were taken twice weekly. Viral loads were 
determined by real-time PCR. Samples from patients remaining HSV-1 positive despite 
antiviral treatment were studied for resistance to antivirals. 
Results: Having an HSV-1 or EBV DNA positive sample was a significant predictor for 
ulceration of keratinized mucosa. HSV-1 was a significant predictor for ulcerations on 
non-keratinized mucosa as well. Persistent HSV-1 infection occurred in 12 of 28 patients 
treated with antiviral medication and aciclovir resistant HSV-1 was found in 5 persistent 
infections. 
Conclusions: In conclusion, HSV-1 is a predictor of ulcerations on non-keratinized as well 
as keratinized oral mucosa following HSCT. The role of EBV deserves further study. Per-
sistent HSV-1 replication despite antiviral treatment is common and is due to resistance 
in 18% of treated patients.
proefschrift.indd   38 8-10-2012   19:20:58
Herpesviruses and oral ulcerations after Hsct
39
introduction
Ulcerative oral mucositis is a frequent and serious complication in patients receiving a 
hematopoietic stem cell transplant (HSCT). Previous studies reported that between 76% 
and 89% of patients undergoing myeloablative HSCT suffered from oral mucositis;1-5 
reduced-intensity regimens may decrease the prevalence as well as the severity of oral 
mucositis.2 Patients reported that oral mucositis was the single most debilitating side ef-
fect of HSCT conditioning.6 Furthermore, it is associated with lower survival.7
 Following chemotherapy or HSCT, reactivation of latent HSV-1 occurs frequently.8-10 
In such patients, HSV-1-induced ulcers may develop at the typical non-keratinized pre-
dilection sites for oral mucositis induced by chemoradiation (e.g., floor of mouth, buccal 
and labial mucosa, lateral side and tip of the tongue, and soft palate) and may aggravate 
mucositis, or be confused with this condition.8 In addition, HSV-1- induced ulcerations 
may develop at keratinized oral mucosa and peri-orally, where mucositis as a result of 
chemoradiation is very uncommon. These sites include the hard palate, the dorsum of 
the tongue, the gingiva and the vermillion lip. However, HSV-1 reactivation may also 
result in asymptomatic shedding.8;11 It is unknown whether the viral load in an oral 
sample can distinguish between asymptomatic and symptomatic HSV-1 reactivation. 
Also, it is unknown whether prolonged HSV-1 excretion in HSCT recipients despite 
antiviral treatment is caused by the profound immunosuppressed status of HSCT re-
cipients, or due to resistance of the virus to the antiviral medication. The prevalence 
of antiviral resistance has been shown to be very low in immunocompetent subjects, 
whereas in immunocompromised patients with HSV-1 infections, resistance levels up 
to 27% have been described.12-14 
A possible role for other Herpesviruses such as CMV15 and EBV16 in oral ulceration 
has been suggested but their role has at present only been supported by a very limited 
number of studies.9 Shedding of EBV in the saliva of healthy carriers occurs frequent-
ly17 whereas oral shedding of CMV, apart from congenital or primary infection, is seen 
mostly in immunocompromised patients.18
 To our knowledge, no studies have been performed that prospectively sampled 
HSCT patients, regardless of the presence of oral ulcers, and quantitatively analyzed 
the presence of HSV-1, EBV and CMV DNA. Also, no data are available on the differ-
ential role of herpesvirus excretion on ulcerations at oral sites that may be affected by 
chemoradiation-induced oral mucositis (non-keratinized mucosa) and at sites atypical 
for chemoradiation-induced mucositis (keratinized mucosa). Therefore, the aim of this 
study in adult HSCT recipients was to prospectively explore the relationship between 
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the presence and localization of oral ulcerations and the duration and amount of HSV-1, 
EBV and CMV DNA shedding in the oral cavity. Furthermore, persistence of HSV-1 




Data were collected from 49 adult patients that underwent HSCT for hematological ma-
lignancies at the Leiden University Medical Center between November 2006 and June 
2009. The medical ethical committee of the Leiden University Medical Center approved 
of this study. All patients gave their informed consent. Oral assessment data were noted 
on standardized forms, whereas other data, including HSV, CMV and EBV serostatus 
were retrieved from patient charts and from the laboratory information system.
Transplantation protocol
T cell-depleted transplantation was performed either according to a reduced inten-
sity conditioning (RIC) protocol or a myeloablative conditioning (MAC) regimen as 
described previously.19-21 Prophylaxis for GVHD was only administered to recipients 
of grafts from matched unrelated donors in the MAC regimen (cyclosporine 3 mg/kg 
intravenously starting on day -1). During granulocytopenia, all patients received oral 
selective digestive tract decontamination, antifungal prophylaxis and, in case of mye-
loablative conditioning, systemic streptococcal prophylaxis. All patients received a basic 
oral care regimen aimed at preventing accumulation of dental plaque and keeping oral 
tissues moist and free of debris. Antiseptic washings were not part of basic oral care. Pa-
tients did not receive antiviral prophylaxis. In case of an oral lesion suspect of HSV-1 in-
fection, sampling was performed using a sterile cotton swab and patients were treated 
with intravenous aciclovir or oral valaciclovir at the discretion of the treating physician.
Oral assessment
Oral assessment was performed twice weekly starting before or shortly following HSCT 
conditioning until hospital discharge by one trained investigator. Any type of oral ul-
ceration was recorded in all patients. Mucositis was scored according to the WHO cri-
teria.22 For the WHO score ulcerations were evaluated at non-keratinized oral mucosal 
sites only. Ulcerations on keratinized oral mucosa and the vermillion lips were assessed 
and noted separately. .
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Sampling
Oral rinsing samples were taken at each oral assessment. Patients were asked to rinse 
their mouth for 30 seconds with 10 ml of a 0.9% saline solution. Samples were frozen in 
-20°C within 3 hours after collection and stored at -80°C until analysis. 
Viral load determination
DNA was isolated from a 200 ml aliquot of the samples with the MagNA Pure LC Total 
Nucleic Acid Isolation Kit using a MagNA Pure LC Instrument (Roche Diagnostics, Al-
mere, The Netherlands). Viral loads were determined by real-time PCR on a CFX96TM 
optical reaction module (Bio-Rad, Veenendaal, The Netherlands). Real-time PCRs for 
beta-globin, CMV, EBV, Phocine Herpesvirus (PhHV) and HSV-1 were performed as 
previously described.23-25 PhHV served as an internal control for DNA extraction and 
PCR inhibition and the beta-globin PCR was performed as a control for cell concentra-
tion in the samples. 
Resistance analysis
Samples from patients whose samples remained positive despite antiviral treatment for 
at least 5 days were studied for development of resistance by comparing pre-treatment 
samples with subsequent samples during treatment as long as samples remained posi-
tive. In addition to the oral rinsing samples, samples routinely submitted to the clinical 
microbiology laboratory for diagnosis of HSV-1 were included in the resistance analysis. 
Resistance was determined by sequencing the viral thymidine kinase (TK) gene, and in 
case of TK mutations, by additional sequencing of the viral DNA-polymerase gene.25 
Phenotypical susceptibility testing was performed on viral isolates containing muta-
tions of unknown significance, as described elsewhere.25
Statistical analysis
Possible predictors of ulcerations at non-keratinized and keratinized mucosa were ana-
lyzed separately in all patients. Positive samples with viral loads below 250 copies/ml 
were set at 125 copies/ml to correct for imprecise quantification at very low loads. To 
adjust for skewness of the data, 10log transformed viral and beta-globin loads were used 
in the analysis. To correct for cell count in an oral sample, the beta-globin load was in-
cluded as a predictor in the model. WHO mucositis scores were recoded into a binary 
variable: mucositis WHO grade 0-1 was scored as no ulceration present and mucositis 
WHO grade 2-4 was scored as ulcerative mucositis present. In view of the repeated 
measurements of ulcerative mucositis and ulcerations on keratinized mucosa within 
patients, the outcome was modeled as a repeated measures logistic regression. Param-
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eters were estimated using the Generalized Estimating Equations procedure in SPSS 
with first-order autoregressive correlation structure and a robust estimation procedure. 
Univariable analysis of potential predictors was performed with p-values <0.20 as a 
criterion for possible inclusion in a multivariable model.
results
Patient characteristics and oral assessment outcomes
The characteristics of the 49 patients participating in this study are summarized in Ta-
ble 1. The mean duration of hospitalization was 27 days. During the assessment phase, 
33 patients (67%) developed ulcerative mucositis and maximum WHO grade 2, 3 and 4 
occurred in 23, 7 and 3 patients respectively. During the assessment phase 23 out of 48 
(due to missing data on 1 patient) patients (48%) developed an ulceration on the kera-
tinized intra-oral mucosa or the vermillion lip. There was a weak, but significant, asso-
ciation between the peak mucositis score and the length of stay in the hospital (Spear-
man’s rho=0.31, p=0.036). 
Oral ulcerations and viral loads
HSV-1 could be analyzed in 191 samples and was detected in 23 patients (47%) starting 
at a median of 2 days before HSCT (range -8 days to + 6 days). Most HSV-1 positive 
samples occurred between days 4 to 6 after HSCT. The median HSV-1 DNA load in the 
55 positive samples was 105,3 copies/ml (range 102,1-107,4 copies/ml). HSV-1 DNA was 
detectable in 24 of 61 samples (39%) from patients with ulcerations on non-keratinized 
mucosa (“ulcerative mucositis”) and in 30 of 129 samples (23%) from patients without 
ulcerative mucositis (Figure 1). In 31 of 45 samples (69%) from patients with ulcerations 
on the keratinized areas of the mouth HSV-1 DNA was detected, whereas it was de-
tectable in 24 of 140 samples (17%) from patients without ulcerations on keratinized 
mucosa (Figure 1). Of the 55 HSV-1 positive samples 7 (13%) were from patients with 
ulcerative mucositis, 14 (25%) from patients with ulcerations on keratinized mucosa, 
17 (31%) from patients with ulcerations at both locations and 17 (31%) from patients 
without any ulceration at the time of sampling. In the case of 15 of the 17 samples (88%) 
from patients without ulcerations, ulcerations occurred directly preceding or following 
sampling within days. There was no difference in the presence or the load of HSV-1 
between patients in the MAC and RIC conditioning regimens (data not shown). 
 From 18 patients at 24 sampling moments both oral rinsing samples and swabs from 
oral lesions were available; 20 samples (83%) showed concordant results (12 were HSV-
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Table 1. Patient characteristics.




age (mean; SD) 48.8; 13.6 years
diagnosis
Acute myeloid leukemia 19 (39%)
Multiple myeloma 10 (20%)
Acute lymphoblastic leukemia 5 (10%)
Non-Hodgkin lymphoma 5 (10%)
Myelodysplastic syndrome 3 (6%)
Chronic myeloid leukemia 2 (4%
Hodgkin lymphoma 2 (4%)
Chronic lymphocytic leukemia 2 (4%)
Others 1 (2%)
donor type
Matched Sibling 17 (35%)




Reduced intensity 24 (49%)
length of stay in the hospital (mean; SD) 27; 8.9 days












1 cord blood donor for two patients, mismatched related donor for one patient, autologous transplant in one patient
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Figure 1. Detection of herpesviruses and presence of oral ulcerations.
Percentage of HSV-1 (top), EBV (middle) and CMV (bottom) DNA positive samples from patients with or without oral 
ulcerations at the time of sampling.
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1-positive and 8 were HSV-1-negative in both samples types), whereas 4 showed dis-
cordant results (all were negative oral rinsing samples with a positive swab). In two of 
the discrepant cases, swabs were weakly positive (Ct-value above 34) and in the other 
two cases swabs were from ulcerations on the lip.
 EBV and CMV could be analyzed in 186 samples. EBV was detected in 12 patients 
(24%) with a median load of 103,8 copies/ml (range 102,1-105,7 copies/ml) in the 35 posi-
tive samples. CMV was detected in 6 patients (12%) with a median load in the 9 positive 
samples of 102,5 copies/ml (range 102,1-104,1 copies/ml). EBV was detected in 6 of 59 sam-
ples (10%) from patients with ulcerative mucositis, in 29 of 126 samples (23%) from 
patients without mucositis, in 12 of 44 samples (27%) from patients with ulcerations on 
keratinized mucosa and in 19 of 136 samples (14%) from patients without ulcerations on 
keratinized mucosa (Figure 1). For CMV, these percentages were 10,2%, 2,4%, 6,8% and 
4,4% respectively (Figure 1). 
Predictors of oral ulcerations
In uni- and multivariable analyses, the presence of HSV-1 DNA in a sample (Table 2) was 
a significant positive predictor of having ulcerative mucositis (multivariable OR=2.62, 
p=0.049) and of having ulcerations on the keratinized mucosa (multivariable OR=4.37, 
p=0.003). The HSV-1 DNA load was a significant predictor of both ulcerative mucositis 
and of ulcerations on keratinized mucosa in the univariable analysis (OR=1.17, p=0.023 
and OR=1.41, p<0.001, respectively) In multivariable analysis, HSV-1 DNA load was 
a positive predictor of ulcerations on keratinized mucosa (OR=1.35, p=0.0005), but it 
was no predictor of ulcerative mucositis (OR=1.18, p=0.08). No threshold of the HSV-
1 DNA load could be established above which all samples were derived from patients 
with oral ulcerations (Table 3). 
 The presence of EBV DNA, but not the EBV DNA load, was a positive predictor of ul-
cerations on keratinized mucosa (multivariable OR=3.82, p=0.02, Table 2). Neither the 
presence nor the load of EBV DNA were significant predictors of ulcerative mucositis in 
the multivariable analysis.
 CMV was not a significant predictor of ulcerative mucositis or of ulcerations on ke-
ratinized mucosa. Interestingly conditioning regimen was no significant predictor of ul-
cerative mucositis or ulcerations on the keratinized mucosa. Sex, age, body mass index, 
donor type and time after HSCT were no significant predictors of oral ulcerations either.
Persistent HSV-1 and viral resistance
Twenty-nine patients had at least one HSV-1-positive oral rinsing sample or oral swab of 
whom 28 received antiviral treatment for 5 days and 12 (43%) still had detectable levels 
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of HSV-1 after 5 days of antiviral treatment. Clinical data were available in 11 of the 
12 patients and all patients suffered from oral ulcerations. No mutations were found in 
pre-treatment samples, but resistance-associated mutations in the TK-gene were found 
in on-treatment isolates from 5 patients with treatment failure (Table 4); a frameshift 
mutation (insG@436) known to confer ACV resistance 26 was found in 4 patients and a 
substitution (G59W) in one patient (GenBank Accession Number JN191624). The G59W 
substitution has not been described before in a clinical isolate. Phenotypical susceptibil-
ity testing showed ACV-resistance in the isolates with mutation G59W (IC50-value 20-
fold of pre-therapy isolates without mutation). No resistance-associated mutations were 
found in the viral DNA-polymerase gene of these samples. 
discussion
The aim of our study was to prospectively investigate the relationship between Herpes-
virus excretion and the presence of oral ulcerations. In our study the presence of HSV-1 
was a significant positive predictor for ulcerations on non-keratinized and keratinized 
mucosa. Primary HSV-1 infection may cause ulcerative stomatitis resembling the typi-
cal presentation of HSV-1 reactivation in immunocompromised patients; therefore a 
causative role for HSV-1 in oral ulcerations in these patients is very plausible. Our find-
ings support the use of antiviral prophylaxis in HSV-seropositive HSCT recipients.27 A 
previous study found an association between HSV-1 and stomatitis in autologous HSCT 
recipients as well,28 whereas another study failed to establish a relationship between the 
presence of HSV-1 and mucositis in HSCT recipients.4 The use of antiviral prophylaxis 
Table 3.  The number and percentage of samples coming from patients with oral ulcerations at the 
time of sampling given for various HSV-1 load thresholds. 
Viral load in oral 





n n % n % n %
< 1000 copies/ml 136 34 25,2 17 13,1 47 34,6
≥ 1000 copies/ml 49 22 44,9 28 57,1 34 69,4
≥ 10.000 copies/ml 39 17 43,6 23 59,0 28 71,8
≥ 100.000 copies/ml 32 13 40,6 19 59,4 22 68,8
≥ 1.000.000 copies/ml 13 7 53,8 8 61,5 10 76,9
≥ 10.000.000 copies/ml 6 4 66,7 4 66,7 5 83,3
total 185 56 45 81
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probably limited the role of HSV in this latter study.4 No other studies performed stan-
dardized and prospective quantitative sampling in all patients, with and without oral 
ulcers or used sensitive real-time PCR. 
Although the HSV-1 load was a predictor of ulcerations on the non-keratinized mu-
cosa, a clear quantitative relationship was difficult to establish. No cut-off value of the 
HSV-1 load could be established above which all samples were derived from patients 
with oral ulcerations, irrespective of correction for the betaglobin load. Various factors 
may contribute to this phenomenon, such as the presence of non cell-associated virus 
in the sample, the unknown interval between virus detection and the development of 
ulcerations and the unknown significance of viral dynamics. Possibly the increase in 
load is more predictive than the actual load. However, truly asymptomatic shedding 
without preceding or subsequent oral ulceration was found in only 2 samples. There-
fore, in the absence of antiviral prophylaxis, prompt initiation of antiviral treatment 
upon detection of HSV-1 DNA in an oral sample may be warranted, regardless of the 
virus quantity. 
Persistent HSV-1 shedding despite treatment occurred in 43% of the treated patients and 
resistance-associated mutations were found in 18% of the treated patients. Of course, 
sensitive detection of HSV-1 DNA by real-time PCR after ulcerations have healed may 
account for part of the persistence. Nevertheless, resistance to antivirals appears to play 
a role in persistent infections in a relevant proportion of patients. The prevalence of 
resistant HSV-1 in our study as assessed by sequence analysis is comparable to previous 
studies in HSCT recipients using different methodologies to detect resistance. In a set-
ting of antiviral prophylaxis, HSV-1 resistance was demonstrated by viral culture in 27% 
of patients with HSV.13 In other studies, a prevalence of resistance of 14% was found us-
ing a colorimetric yield reduction assay14 and of 18% using another colorimetric assay.12 
The retrospective analysis of resistance in our study hampers addressing the clinical 
significance of the infections with resistant HSV-1. We can only speculate that faster 
healing of oral ulcerations would have occurred if treatment had been switched early 
and in all patients with resistant isolates, but a role for viral susceptibility testing in case 
of persistent symptomatic HSV-1 infection seems clear. 
 Mutation G59W has not been described in a clinical isolate before. The mutation is 
located in the ATP-binding site of the TK protein and it has been selected in vitro under 
selection pressure with brivudin29 and ACV30 and an ACV-resistant HSV-2 isolate with 
mutation G59P has been found in an AIDS-patient.31 This makes the G59W mutation 
the likely cause of the ACV-resistant phenotype of the isolate in our study.
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The presence of EBV in a sample was an independent predictor of oral ulcerations on 
the keratinized mucosa, but not of ulcerative mucositis. The rate of EBV shedding of 25% 
was comparable to a previous study using DNA hybridization which detected EBV in 
mouth washes from 19% of HSCT patients.32 EBV has clearly been associated with oral 
hairy leukoplakia in various categories of immunocompromised patients.33 Its role in 
oral ulcerations is not well-known. Recently, EBV positive oral ulcers with Hodgkin-like 
features that responded well to reduction of immunosuppression have been described 
in immunosuppressed patients, including one HSCT recipient.34 Also, EBV-associated 
oral lesions resembling oral hairy leukoplakia with extensive mucosal ulceration have 
been described in an HSCT recipient.16 In our patient group oral EBV shedding was not 
a predictor of systemic EBV complications, as there was no difference in the occurrence 
of EBV plasma DNAemia or the occurrence of post-transplant lymphoproliferative dis-
order between patients with or without EBV in the oral samples (data not shown). The 
possible role for EBV in oral lesions in HSCT recipients is currently very unclear but 
certainly merits further study.
 No relationship between the presence of CMV in the oral cavity and oral ulcerations 
was found. Furthermore, the occurrence of oral CMV shedding and the viral loads were 
low, despite the fact that half of the patients were seropositive for the virus prior to 
HSCT.
In our patient group 67% of the patients developed ulcerative mucositis during hospi-
talization, which is a lower percentage than reported previously.1-5 Although Takahashi 
et al.2 reported a profound decrease in the presence of ulcerative mucositis when pa-
tients underwent RIC conditioning instead of a MAC regimen, the conditioning regi-
men was not a significant predictor of oral ulcerations in our study. The important role 
of HSV-1 in the development of oral ulcerations in the absence of antiviral prophylaxis 
in our study possibly masks the effects of the conditioning regimen. In addition, the 
fact that RIC and GvHD prophylaxis regimens vary between our hospital and that of 
Takahashi et al.2 may account for some differences as well.
In order to obtain a standardized and quantitative oral sample, oral rinsing samples 
were used. Results from oral rinsing samples were concordant with results from swabs 
from intraoral ulcerations, with discrepancies only in the case of lesions on the lips or 
in the case of weakly positive swabs. Since taking a rinsing sample is less painful than 
swabbing an ulceration, oral washings might be a suitable alternative for viral diagnos-
tics of intraoral ulcerations. 
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A possible limitation of our study is the co-occurrence of various types or oral ulcer-
ations with a different etiology simultaneously, which is expected to occur in this se-
verely immunocompromised patient category. In patients in whom both types of ulcer-
ations occur, risk factors for oral each type of ulceration, including viral shedding, may 
be interrelated. 
In conclusion, reactivation of HSV-1 is an important factor in ulcerations involving the 
non-keratinized and keratinized oral mucosa after HSCT in the absence of antiviral pro-
phylaxis. Persistent HSV-1 replication despite antiviral treatment is common and is due 
to resistance in a relevant proportion of patients. Oral shedding of EBV may play a role 
in ulcerations on the keratinized mucosa, but the mechanism of action remains to be 
elucidated. 
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Background: Varicella-zoster virus (VZV) infections are a relevant cause of morbidity and 
mortality in hematological patients and especially in hematopoietic stem cell transplant 
(HSCT) recipients. The present study aimed to investigate the prevalence and clinical 
significance of viral persistence and antiviral resistance by systematically analyzing all 
episodes of VZV diagnosed in our laboratory in pediatric and adult hematological pa-
tients between 2007 and 2010.
Methods: Patient charts were reviewed to document patient and disease characteristics. 
VZV loads were determined in all available clinical samples from the day of diagnosis 
and thereafter. Persistent VZV infection was defined as a VZV infection that lasted at 
least seven days. Analysis of resistance was performed in all patients with persistent 
VZV infection by sequence analysis of viral thymidine kinase and DNA polymerase 
genes.
Results: In total 89 episodes occurred in 87 patients of whom 65 were recipients of an 
allogeneic HSCT. Follow up samples were available in 54 episodes. Persistent VZV was 
demonstrated in 32 of these episodes (59%). Complications occurred in 16 of the per-
sistent episodes (50%) versus 2 of 22 non-persistent episodes (9%). Mutations possibly 
associated with resistance were found in 27% of patients with persistent VZV, includ-
ing patients with treatment unresponsive dermatomal zoster that progressed to severe 
retinal or cerebral infection. 
Conclusions: In hematological patients, VZV related complications occur frequently, 
especially in persistent infections. Antiviral resistance is a relevant factor in persistent 
infections and needs to be investigated in various affected body sites, especially when 
clinical suspicion of treatment failure arises.
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introduction
Varicella-zoster virus (VZV) reactivations can be dermatomal but also disseminated 
in severely immunodeficient patients.1 After hematopoietic stem cell transplantation 
(HSCT) visceral, retinal and neurological VZV infections can occur and result in serious 
morbidity and mortality.1-8 Most VZV reactivations respond to treatment with aciclovir 
(ACV), valaciclovir (vACV) or related antiviral agents,3;9 but persistent and progressive 
infections can occur despite treatment.5;10 This can be due to immunological failure to 
control viral replication6;11-13 or due to insufficient drug levels, but resistance of the virus 
to the antiviral treatment has been described as well.14-20 
Resistance of VZV to antiviral drugs has not been reported in immune competent pa-
tients with primary VZV infections or herpes zoster,21;22 but it has been demonstrated in 
AIDS-patients, hemato-oncological patients and HSCT recipients with treatment unre-
sponsive VZV reactivations.14-20 The prevalence of antiviral drug resistance and its rela-
tive contribution to persistent VZV infections in hemato-oncological patients and HSCT 
recipients is unknown because only case reports and case series have been published 
thus far. In addition, it is unclear which sample type should be analyzed to determine 
resistance as compartmentalization of resistant strains has been described.15 Systematic 
analysis of the occurrence and localization of resistant VZV in immunocompromised 
patients with persistent VZV can guide treatment and diagnosis of VZV resistance in 
this patient group.
The aim of this study was to determine the prevalence and clinical significance of per-
sistent VZV infections and the contribution of antiviral resistance to persistence in he-
mato-oncological patients, including HSCT recipients.
Patients and metHods
Patient data
Patients attending the Leiden University Medical Center, a tertiary care and teaching 
hospital in the Netherlands, with hematological malignancies and HSCT recipients 
(adults and children) diagnosed with VZV (laboratory confirmed by PCR and/or cul-
ture) between 01-01-2007 and 01-01-2010 were identified from the laboratory informa-
tion system. Patient charts were reviewed to document patient and disease character-
istics. VZV related complications were classified as recurrence in case of reappearance 
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of skin lesions after initial regression and as dissemination in case of progression of skin 
lesions outside the initially affected (and adjacent) dermatomes or spread to visceral 
organs, the eye and/or the central nervous system (CNS).
Antiviral treatment
In our hospital, immunocompromised patients with a VZV infection are commonly 
treated with intravenous ACV for at least five days. Prophylaxis with (v)ACV was not 
routinely given. Individual antiviral treatment data were obtained from the hospital 
pharmacy database and from patient charts. 
VZV load determination
Sampling frequencies for follow up had been left to the discretion of the treating phy-
sician. The original samples used for VZV diagnosis were retested for confirmation. 
VZV loads were additionally determined in all available clinical samples from the day 
of diagnosis and thereafter until two consecutive VZV negative samples were found. 
Also EDTA plasma samples sent to the laboratory for other diagnostics than VZV were 
included. Samples included swabs from skin lesions, plasma, serum, cerebrospinal fluid 
(CSF), aqueous humor and bronchoalveolar lavage (BAL) samples. Persistent VZV in-
fection was defined as a VZV infection lasting at least seven days.
 DNA was isolated with the MagNA Pure LC Total Nucleic Acid Isolation Kit-High 
Performance using a MagNA Pure LC Instrument (Roche Diagnostics, Almere, The Neth-
erlands). A multiplex real-time PCR for VZV and Phocine Herpesvirus (PhHV) as inter-
nal control for DNA extraction and PCR inhibition was performed on a CFX96 real-time 
detection system (Bio-Rad, Veenendaal, The Netherlands) as previously described.9;23 For 
quantitation, a standard of VZV (cultured field isolate or ATCC KOS strain) was calibrated 
using a quantitated DNA control (Advanced Biotechnologies Inc., Columbia, MD, USA). 
Analysis of resistance
Analysis of resistance was performed in all patients with a persistent VZV infection. The 
first positive sample of each patient was analyzed as well as subsequent VZV positive 
samples. Resistance was analyzed in samples from different body sites, when available. 
Analysis was performed by cycle sequencing after PCR amplification of the entire thy-
midine kinase (TK) gene. The detection limit of the assay was 2000 copies/ml. In case of 
possible resistance-associated TK mutations or in patients treated with foscarnet (FOS) 
or cidofovir (CDV), part of the DNA polymerase (POL) gene containing most previously 
described resistance conferring mutations was sequenced as well.24;25 
 Amplification and sequencing primers and PCR conditions are shown in Table 1. 
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Additional primers (Table 1) were used to confirm the deletion of codon 220 in patient 5 
(Table 4). Amplification was performed in 50 µl containing 25 µl HotStart Taq mastermix 
(Qiagen, Hilden, Germany) and 15 pmol of each primer. All cyclesequencing reactions 
were performed on bulk amplification product in 20 µl containing 2 µl BigDye Ter-
minator v1.1 (Applied Biosystems, Carlsbad, CA, USA), 6 µl sequencing buffer and 8 
pmol primer. Sequence analysis was performed on an ABI Prism 3100 Genetic Analyzer 
(Applied Biosystems). Sequences were compared to the sequence of the Dumas strain 
(Genbank Accession Number NC_001348) and to pre-treatment samples of the patient.
results
Patients and episodes
Characteristics of the 87 included patients are shown in Table 2. Of the 87 patients, 
65 (75%) were recipients of an allogeneic HSCT in whom VZV episodes occurred at a 
median of 153 days after HSCT (range -23 days to +4.8 years). VZV occurred significant-
ly earlier after HSCT in children than in adult HSCT recipients (median of 26.5 versus 
44 days, p<0.001 Mann-Whitney test). 
 Characteristics of the 89 VZV episodes are shown in Table 3. One episode of chick-
enpox occurred in a seronegative patient, whereas all other episodes were herpes zos-
ter in seropositive patients. One patient experienced 3 separate episodes of VZV with 
months to years between the episodes. Complications were documented in 21 episodes 
(24%, 95% confidence interval (CI) 15-32%) and consisted of recurrence, dissemination, 
retinitis, encephalitis, 2 other complications and 3 episodes during which patients died 
while having VZV in combination with other infectious and/or hematological problems. 
Antiviral treatment was administered in 61 of the 62 episodes (98%) where treatment 
was documented (Table 3).
Virological data
VZV was detected at the initial presentation in plasma samples in 16 episodes (18%), in 
both plasma and swabs in 24 episodes (27%), in swabs only in 47 episodes (53%), in plas-
ma and BAL samples in 1 episode (1%) and in CSF in 1 episode (1%). The average viral 
load in swab samples at diagnosis was 2.6×108 copies/ml. Plasma samples were avail-
able at diagnosis in 49 episodes and were positive in 41 episodes (84%) with an average 
viral load of 2.8×107 copies/ml. Of the patients with a dermatomal zoster at presentation 
69% had a positive plasma VZV DNA load, whereas all patients with a generalized or 
visceral zoster as their initial manifestation had VZV DNA positive plasma.
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Follow up 
On average 4.5 samples were available per episode. Follow up samples were available 
for at least one week after the diagnosis from 54 episodes in 53 patients. Characteristics 
of these patients and episodes are shown in Table 2 and 3. Due to the retrospective na-
ture of the study, more samples for analysis and follow up were available from HSCT 
recipients compared to non-HSCT recipients (mean of 5.4 versus 1.8 samples, p=0.003, 
Student’s t-test) and in episodes with complicated VZV compared to uncomplicated 
VZV (mean of 9.6 versus 2.9, p<0.001, Student’s t-test).
Table 2. Patient characteristics
Total cohort Cohort with follow 
up samples
n (%) n (%)
age Child (<18 years) 31 (36) 20 (38)
Adult (≥ 18 years) 56 (64) 33 (62)
sex male 51 (59) 33 (62)
female 36 (41) 20 (38)
hematological disease ALLa 18 (21) 12 (23)
AMLb 25 (29) 17 (32)
CLLc 3 (3) 2 (4)
CMLd 3 (3) 2 (4)
myelodysplastic syndrome 4 (5) 4 (8)
Hodgkin lymphoma 5 (6) 0 (0)
non-Hodgkin lymphoma 3 (3) 1 (2)
multiple myeloma 10 (11) 5 (9)
aplastic anemia 4 (5) 1 (2)
thalassemia 5 (6) 4 (8)
other 7 (8) 5 (9)
hematological treatment chemotherapy 15 (17) 4 (8)
autologous HSCT 4 (5) 2 (4)
NMAe HSCT 20 (23) 14 (26)
MAf HSCT 45 (52) 33 (62)
other 3 (3) 0 (0)
HSCT donor type haploidentical 4 (6) 4 (9)
MSDg 30 (46) 19 (40)
MUDh 30 (46) 23 (49)
cord blood 1 (2) 1 (2)
Total 87 53
a ALL = acute lymphoblastic leukemia, b AML = acute myeloid leukemia, c CLL = chronic lymphocytic leukemia
d CML = chronic myeloid leukemia, e NMA = non-myeloablative conditioning, f MA = myeloablative conditioning, g 
MSD = matched sibling donor, h MUD = matched unrelated donor




Persistent VZV was demonstrated in 32 of 54 episodes with follow up (59%, CI 46-72%). 
Plasma samples were positive by PCR in 29 of the 32 persistent episodes and were not 
available for the remaining 3 episodes where only positive swabs were available. Addi-
tional sample types besides plasma were available and positive in 17 persistent episodes. 
Time since HSCT and conditioning regimen were not associated with occurrence of per-
sistence. Persistence occurred in all VZV episodes in patients with a haploidentical do-
nor (n=4) and in the only patient with a cord blood donor. Antiviral treatment was giv-
en in 26 episodes and was unknown in 6 episodes. Persistence occurred after cessation 
of antiviral treatment in 6 episodes (23%) and during antiviral treatment in 20 episodes 
(77%). The median duration of VZV positivity was 27.5 days (range 7-179 days) in the 
32 persistent episodes. The peak VZV load in plasma was higher in persistent episodes 
than in non-persistent episodes (median load of 3.2×104 copies/ml versus 6.4×103 cop-
ies/ml, p=0.039, Mann-Whitney test).
Table 3. VZV episodes.
Total cohort Cohort with follow 
up samples
n % n %
presentation chickenpox 1 (1) 0 (0)
dermatomal 53 (60) 33 (61)
generalized cutaneous 14 (16) 7 (13)
visceral/ eye/ CNS 10 (11) 10 (19)
unknown 11 (12) 4 (7)
antiviral treatment none 1 (1) 0 (0)
vACV 14 (16) 6 (11)
ACV 13 (15) 9 (17)
ACV & vACV 25 (28) 19 (35)
ACV & FOS 2 (2) 2 (4)
ACV & vACV & FOS 5 (6) 5 (9)
ACV & FOS & CDV 2 (2) 2 (4)
unknown 27 (30) 11 (20)
complication none 68 (76) 36 (67)
recurrence 9 (10) 9 (17)
dissemination 3 (3) 3 (6)
retinitis 3 (3) 3 (6)
encephalitis 1 (1) 1 (2)
death 3 (3) 1 (2)
other 2 (2) 1 (2)
Total 89 54
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 Complications occurred in 16 of 32 persistent episodes (50%, CI 32-68%) versus 2 
of 22 non-persistent episodes (9%, CI 0-21%, p=0.002, Chi-Square, Figure 1). In pedi-
atric patients, complicated episodes occurred earlier after HSCT than uncomplicated 
episodes (median of 5 versus 33 days, p=0.025 Mann-Whitney test). Time after HSCT 
was not associated with the occurrence of complications in adult patients. Condition-
ing regimen was not associated with complications. Three of the four patients with a 
haploidentical donor and the only recipient of a cord blood transplant suffered from 
complications.
Resistance
Resistance analysis could be performed in 22 of the 32 persistent episodes, because in 
10 episodes the VZV load was either insufficient to enable sequence analysis or sam-
ples were unavailable. Mutations developed during persistence in 6 of the 22 (27%, 
CI 8-46%) investigated episodes (Table 4, Figure 1). Two patients (patients 1 and 2) had 
mutations in VZV TK that had previously been associated with ACV resistance. In one 
Figure 1. Occurrence of persistence, complications and resistance.
Episodes with follow up samples at least 1 week after diagnosis are depicted (n= 54). The dotted line separates non-
persistent (n = 22) from persistent VZV episodes (duration at least 1 week, n = 32). Complicated episodes (n = 18) are 
depicted by gray bars and episodes with resistant virus (n = 6) are shown in black.
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of the patients (patient 3) we found both previously characterized (premature stop co-
don 38 and 171) and novel mutations (premature stop codon 69 and 307, GenBank ac-
cession numbers JQ745671 and JQ745672). These mutations were alternately present 
in subsequent plasma and CSF samples. Two patients (patients 4 and 5) were found 
to have mutations that have not been described in association with resistance before. 
Patient 4 had a deletion of codon 220 in the VZV DNA present in plasma (GenBank 
accession number JQ745673) and in a subsequent CSF sample. Patient 5 had two differ-
ent previously uncharacterized mutations (T70I and P40S, GenBank accession numbers 
JQ745669 and JQ745670) in two different samples, both of which are outside conserved 
or functional domains of VZV TK making their role as resistance associated mutation 
unclear. A DNA polymerase mutation of unknown significance (S689N, GenBank acces-
sion number JQ745674) was found in patient 6 after treatment with ACV, FOS and CDV. 
This mutation is outside functional domains of the viral DNA polymerase, but adjacent 
mutations at codon 684 [26] and 692 [27] have been associated with FOS resistance. No 
resistance associated mutations were found in the DNA polymerase gene in samples 
from the 5 patients with TK mutations.
 Clinical details on the patients with mutations in VZV TK and POL are shown in 
Table 4. Two adult HSCT patients (patient 1 and 5) presented with recurrent skin le-
sions that responded well to retreatment with aciclovir. One pediatric patient (patient 6) 
presented with persistent cutaneous zoster that eventually recovered. In contrast, two 
pediatric patients (patient 2 and 3) with resistant VZV presented with treatment unre-
sponsive dermatomal zoster that progressed to severe retinal infection with unfavor-
able outcome. One pediatric patient (patient 4) presented with persistent skin lesions 
and keratitis that progressed into encephalitis. 
 All 6 patients with mutations in VZV developed VZV related complications, ver-
sus 9 of 16 (56%, CI 31-81%) patients with persistent VZV without mutations (p=0.12, 
Fisher’s Exact test). The median duration of VZV was 92.5 days (range 26-179 days) in 
patients with persistent VZV with mutations versus 29 days (range 7-126 days) in pa-
tients with persistent VZV without mutations (p=0.015, Mann-Whitney test). 
discussion
VZV infections are a relevant cause of morbidity and mortality in hemato-oncological 
patients.3;28 Case reports on the sometimes severe and protracted course of infection in 
such patients have previously been published.15;16;19;29 Our present study is among the 
first to report a systematical investigation of the prevalence and clinical significance of 
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viral persistence and antiviral resistance by analyzing all episodes of VZV diagnosed in 
our laboratory in hematological patients between 2007 and 2010. It was demonstrated 
that 24% of all episodes of VZV in this patient group were associated with complica-
tions such as recurrence, dissemination or severe organ manifestations. In patients from 
whom follow up samples were available, VZV was shown to be persistent in 59% of 
the episodes, despite the use of antiviral treatment in the majority of cases. Persistent 
episodes were associated with complications in 50% of the cases and possible resistant 
virus was identified in 27% of these cases.
Persistence of VZV DNA in whole blood or blood mononuclear cells after dermatomal 
zoster has been described as a common phenomenon lasting several months in immu-
nocompetent individuals.30;31 Persistence in our study was defined as the presence of a 
positive PCR of any relevant sample available at least 7 days after the diagnosis. Firstly, 
this was chosen in accordance with common antiviral treatment policies10 that advocate 
a treatment course of about 7 days at the end of which the treating clinician has to de-
cide whether or not to continue or change treatment if the patient has either clinical or 
virological signs of infection. Secondly, 7 days was chosen in order to include as many 
patients as possible in the resistance analysis. Persistence was found to occur in various 
body sites simultaneously in many episodes. As expected, the peak VZV load was as-
sociated with persistence, since the time to clear viral infection is most likely related to 
the viral load both of which are related to the immunosuppressive state of the patient.
Persistence was associated with complications in half of the cases. It appears that com-
bined clinical and virological persistence may predict complications. Our findings are in 
accordance with the previous finding that the clinical course of VZV is correlated to the 
plasma load.9 In pediatric patients, VZV infection early after HSCT was associated with 
a higher frequency of complications, which can be explained by the severe immunosup-
pressive state of the patient at that time. In adult patients, this relation was not found, 
possibly due to differences in transplantation protocols or in the occurrence of GvHD. 
Possibly, donor type is of importance as well with persistence and complications occur-
ring frequently in recipients of a haploidentical or cord blood transplant, all of whom 
were children.
In 27% of the episodes of persistent VZV, possible resistance associated mutations were 
detected suggesting potential antiviral resistance. Resistance to antivirals is the result 
of spontaneously occurring mutations during viral replication, especially when replica-
tion levels are high due to the absence of adequate antiviral immunity. Upon selection 
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pressure by the administration of an antiviral agent, particularly during prolonged ther-
apy and when there is no complete inhibition of viral replication, as in sites with  poor 
penetration of the drug, such as the cerebrospinal fluid or the eye, a resistant mutant 
subpopulation may become dominant. In our study, resistance was found at various 
times after diagnosis and also in various sites including CNS and eye.15 Interestingly, 
patient 3 even had four different mutations that were never detected simultaneously 
under continuous treatment with vACV and ACV. Possibly, a mixture of mutant viruses 
was present of which the relative amounts varied over time. Additional sequencing and 
real-time PCR with specific probes failed to identify various mutant viruses in a single 
sample, probably because of the relatively low load of the variants in the samples (data 
not shown).
Although antiviral resistance mutations occurred at a rather high frequency, clinical 
treatment failure cannot always be explained by antiviral resistance, as lack of antiviral 
immunity or insufficient dosing of antivirals may play a role as well.18;19 These factors 
emphasize the need for timely and comprehensive diagnostics in complicated and per-
sistent cases of VZV in immunocompromised patients. As the majority of VZV was de-
tected in samples from which VZV cannot be cultured,35 nucleotide sequence analysis 
of the genes most involved in antiviral resistance15;16;18;19;36;37 was chosen to diagnose 
resistance. Several new mutations were found, that might be clinically relevant because 
they appeared under antiviral therapy. However, due to the lack of viral isolates, we 
could not confirm their actual contribution to resistance, which remains to be estab-
lished. Comparing sequences between pre-treatment and on-treatment samples from 
a patient can partly overcome this problem. Marker transfer studies may be another 
approach, but are not routinely available in most laboratories.37
Some limitations apply to our study. Firstly, due to the retrospective nature of the study 
more samples were probably available from patients with clinically persistent or com-
plicated infection in whom the treating clinician found an indication for diagnostics 
and for follow up. Therefore, both attrition and selection bias towards more persistence 
and more complications in the part of our cohort that had sufficient follow up samples 
is likely, despite the fact that about 45% of the included samples consisted of plasma 
samples submitted for other diagnostic requests. For accurate estimation of the risks and 
interrelations of complications, persistence and resistance, a prospective study includ-
ing all VZV episodes in hematological patients is required. Secondly, due to limitations 
in the sensitivity of sequence analysis in comparison to the diagnostic assay, resistance 
could not be determined in patients with low VZV loads and thus the potential role in 
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low-level persistence could not be established. Also, the VZV DNA extracted from CSF 
and eye samples was often difficult to amplify. This may be related to low viral loads in 
some of these samples, but may also be due to the presence of fragmented viral DNA.38
Previous studies have demonstrated the efficacy of long term (v)ACV prophylaxis in pre-
venting VZV after HSCT.32-34 Many of the patients in our cohort were HSCT recipients 
and VZV was found to occur at a broad range of time points after HSCT. It is likely that 
prophylaxis can prevent VZV related complications in periods of maximum immunode-
ficiency after HSCT. However, the optimal timing and dosage remain to be established. 
In conclusion, in hematological patients, VZV related complications occur frequently, 
especially in persistent infections. Antiviral resistance is a relevant factor in persistence 
and needs to be investigated timely and in samples from various body sites as soon as 
clinical or virological suspicion of persistence or other complications arises.
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Background: Persistent infections with herpesviruses such as human cytomegalovirus 
(HCMV) frequently occur after solid organ or stem cell transplantation, and are due to 
either failure of the host to immunologically control the virus or emerging resistance 
of the virus to the antiviral drug(s) used. Antiviral therapy can be guided by viral drug 
susceptibility testing based on screening for known resistance-inducing mutations in 
the viral genome. Mass spectrometry-based comparative sequence analysis (MSCSA) 
might be advantageous for this purpose because of its suitability for semi-automation.
Objectives: The applicability of MSCSA to detect sequence polymorphisms and drug 
resistance-inducing mutations in the HCMV genome was investigated.
Study design: We analyzed the 3’ part of the HCMV UL97 gene, which encodes the ki-
nase that is activated by the commonly used anti-HCMV drug ganciclovir. Sequences 
obtained by MSCSA of material from HCMV-infected patients (43 samples) and the 
HCMV type strain were compared to conventional cycle sequencing results.
Results: In 94.1% of all samples the results obtained by MSCSA of the UL97 gene were 
identical to those from conventional cycle sequencing. The threshold to detect mutant 
sequences in a mixture with wildtype material was 20% using either technique. Further-
more, MSCSA was successfully applied to study the development of drug resistance in 
a patient who developed encephalitis due to ganciclovir-resistant HCMV.
Conclusions: MSCSA was found to be equally accurate compared to conventional cycle 
sequencing in the analysis of UL97 of HCMV.
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background
Human cytomegalovirus (HCMV) is a beta-herpesvirus with an approximately 235-kbp 
double-stranded (ds) DNA genome that encodes at least 165 gene products.1 Primary 
infection in adult, immunocompetent individuals is mostly mild or asymptomatic.2 
However, as with other herpesviruses, infections with HCMV can cause major prob-
lems after solid organ or stem cell transplantation (SCT). When the host fails to immu-
nologically control the virus infection, HCMV can persist for weeks and cause severe 
morbidity and mortality. Antiviral drug resistance is relatively rare,3-5 but can occur in 
immunocompromised patients after prolonged antiviral therapy.6-11 HCMV infections 
are commonly treated with ganciclovir (GCV) or its orally administered prodrug val-
ganciclovir (vGCV).12;13 Activation of this deoxyguanisone analogue requires three suc-
cessive phosphorylation steps carried out by the kinase encoded by the viral UL97 gene 
and two cellular kinases.14 This yields the active triphosphate form of the drug that 
selectively inhibits the viral DNA polymerase UL54 by disrupting viral DNA synthe-
sis.15 GCV resistance mutations in clinical isolates mainly map to the viral kinase gene 
UL97,16-19 but after prolonged treatment mutations in the viral polymerase gene UL54 
can also emerge.19;20 In the case of a persistent infection, drug susceptibility testing of 
the virus can support antiviral therapy management.
objectives
We have evaluated the application of a recently developed method for mass spec-
trometry-based comparative sequence analysis (MSCSA) to the identification of drug 
resistance-associated mutations in HCMV. The results were systematically compared to 
those obtained using a conventional cycle sequencing method. Furthermore, we stud-
ied the development of antiviral drug resistance in a SCT patient who developed en-
cephalitis caused by a GCV resistant HCMV mutant.
study design
Virus strains and patient samples
Forty-three CMV DNA positive clinical samples (EDTA-plasma) from forty-three differ-
ent (immunocompromised) patients with HCMV infection were selected for compari-
son of single nucleotide polymorphism (SNP) detection. Clinical and antiviral treatment 
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data were derived from patient charts (see Table S1).5 Additionally, nine plasma-EDTA 
and four cerebrospinal fluid (CSF) samples from a case patient with HCMV encephalitis 
(see below) were included for analysis of GCV resistance. DNA was isolated from all 
samples with the MagNa Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics) 
using a MagNA Pure LC Instrument (Roche Diagnostics). HCMV strain AD169 was ob-
tained from American Type Culture Collection, Manassas, VA, USA. HCMV DNA loads 
were determined by real-time PCR.21
Mass spectrometry-based comparative sequence analysis (MSCSA) and cycle sequencing
The MassARRAY® /iSEQTM – comparative sequence analysis technique (Sequenom, 
San Diego, USA;22 ) uses PCR amplification of a target and its subsequent in vitro tran-
scription to produce RNA strands that are cleaved to produce a sequence-specific set of 
fragments for analysis by mass spectrometry. The obtained spectra are then compared 
to theoretical spectra derived from a database with reference sequences.
 A schematic representation of the MSCSA and cycle sequencing approaches for 
HCMV UL97 analysis is provided in Figure 1. The 3’ region of the HCMV UL97 gene 
was PCR amplified in two amplicons, UL97AB and UL97CD, of 469 and 468 bp, respec-
tively, by use of T7 promoter-tagged forward primers and SP6-tagged reverse primers 
(see Table 1). PCR reactions were performed in a 10-ml volume in 384-well microtiter 
plates, as previously described.5
 The sample was further processed by shrimp alkaline phosphatase treatment, in vi-
tro transcription, and Cor U-specific RNaseA cleavage, according to the manufacturer’s 
instructions and using a MassARRAY® Liquid Handler (Matrix + FusioTM Chip Mod-
ule; Sequenom, San Diego). The fragments resulting from RNA cleavage were diluted in 
double-distilled water and desalted with clean resin (Sequenom), transferred to a Spectro-
CHIP array (Sequenom), and analyzed by matrix-assisted laser desorption ionization time-
of-flight (MALDI-TOF) mass spectrometry (MassARRAY Compact Analyzer, Sequenom). 
The acquired spectra were analyzed using iSEQTM Software Version 1.0.0.2.
 A set of reference sequences was created for both the 97AB and the 97CD amplicon, 
based on previously published UL97 sequences from HCMV clinical isolates that were 
GCV-sensitive in phenotypic assays.23 The set was later supplemented with three and nine 
sequences for amplicons 97AB and 97CD, respectively, derived from clinical isolates from 
Leiden University Medical Center (GenBank accession numbers GU992367–GU992375).
Cycle sequencing reactions were performed on an ABI Prism
3100 Genetic Analyzer (Applied Biosystems) after PCR amplification of the 3’ region 
of the UL97 gene from all samples, as previously described (see Figure 1).5 Assembled 
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Figure. 1. Schematic overview of HCMV UL97 genotyping by MSCSA and cycle sequencing. 
Step 1. After isolation of CMV DNA from patient samples, each sample was analyzed by either method. Step 2. 
(MSCSA) Amplification of the 3’ part of the HCMV UL97 gene in two amplicons (UL97AB and UL97CD) by use of T7 
promoter-tagged forward primers and SP6-tagged reverse primers. Step 3. In vitro transcription of both amplicons by 
T7 and SP6 RNA polymerase (two reactions with each enzyme). Step 4. C- or U-specific RNaseA cleavage of plus and 
minus sense RNA transcripts. Step 5. Acquisition of MS-spectra of the resulting RNA cleavage products. Using these 
four base-specific cleavage reactions per sample each nucleotide in the sequence is specifically probed. Step 6. Com-
parison of the acquired MS spectra using iSEQTM Software Version 1.0.0.2, which lists the best-matching sequence from 
a database of reference sequences and any additional sequence variations for each target region. Step 7. Assembly of the 
amplicon 97AB and 97CD sequences. Step 8. (cycle sequencing) Amplification of the 3’ part of the HCMV UL97 gene in 
one amplicon. Step 9. Four cycle sequencing reactions were performed per PCR product. Step 10. Assembly of the four 
obtained sequences. Step 11. Comparison of MSCSA and cycle sequencing results. Nucleotide differences compared to 
the UL97 sequence of AD169 were defined as SNPs.
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UL97 sequences were aligned to the sequence of the AD169 strain (GenBank accession 
number X17403) and SNPs were defined as nucleotide variations compared to this refer-
ence sequence. Data from both methods were compared (Figure 1, Step 11).
Analysis of mixed wild-type and mutant sequences
HCMV gene UL97 and a region of gene UL96 were cloned by inserting a 2.9 kb BglII-
XhoI restriction fragment from construct pHB524 (kindly provided by Dr. Albert Zim-
merman and Dr. Hartmut Hengel, Düsseldorf, Germany) into a pBluescript KS-derived 
(Stratagene) shuttle vector with the appropriate restriction sites. A 434-base pair frag-
ment from this plasmid (corresponding to position 1587–2021 in UL97) was replaced by 
a PCR-amplified UL97 gene product from an HCMV isolate of the encephalitis patient 
described below, introducing a C1781T mutation (encoding a A594V amino acid sub-
stitution) and three translationally silent mutations. Wild-type and mutant constructs 
were mixed in various ratios to give a final plasmid DNA concentration of 1 ng/ml.
results
Comparing the accuracy of MSCSA and cycle sequencing
To assess the accuracy of MSCSA, we analyzed amplicons 97AB and 97CD derived from 
43 clinical samples and from the HCMV type strain AD169 in duplicate. This set includ-
ed plasma samples from 43 immunocompromised patients containing GCV-sensitive 
and GCV-resistant HCMV. The sequences obtained were verified by conventional cycle 
sequencing and every mismatch with the AD169 sequence was defined as a SNP. The 
97AB or 97CD PCR amplification needed for MSCSA analysis failed for some of these 
samples (in 40 of 176 reactions). As a result, amplicon 97AB could be analyzed in 35 sam-
ples and amplicon 97CD in 43 samples, and duplicate reactions were available for 22 
and 36 samples, respectively. The detection limit for clinical samples was comparable for 
both techniques (10 log3.6 copies/ml), although especially the amplification of the 97AB 
amplicon regularly failed for samples with lower viral loads (see Table S2).
 After optimization of the reference database, 128 MSCSA sequences (94.1%) were 
identical to the cycle sequencing data of the same sample. Discrepancies were found 
in 8 samples, with one sequence containing a SNP recognized by MCSCA and seven 
by cycle sequencing only (Table 2). Accordingly, 97.2% of the SNPs were recognized by 
both methods. Overall more than 58 kb of UL97 sequence were analyzed by both meth-
ods, with as few as eight (0.01%) nucleotides differing between the MSCSA and cycle 
sequencing-derived sequences.
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Fifty-eight reactions were performed in duplicate, which revealed that the variability 
between independent MSCSA experiments was low: for 56 samples (96.6%) identical 
MSCSA results were obtained. Discrepancies between duplicate MSCSA sequences or 
between MSCSA and cycle sequencing results were confirmed in two thirds of samples 
by cycle sequencing of the MSCSA PCR product (see Table S2).
 Seven of the analyzed patient samples contained GCV resistance associated muta-
tions.16;25-28 Of these, four samples containing A594V; C592G, A591V and L595F substi-
tutions in UL97 were identified by cycle sequencing and subsequently confirmed by 
MSCSA analysis. Three other resistance-associated SNPs could not be verified by MSC-
SA as PCR reactions failed due to low viral loads (in two samples; M460I and M460V) 
or probably due to the presence of mixed viral populations resulting in discrepancies 
between MSCSA and cycle sequencing results (C603W; see above and Table S2).
 To mimic the clinical situation of a patient in which a drug resistant viral subpopu-
lation begins to emerge due to the selection pressure of antiviral treatment, samples 
containing a mixture of wild type and mutant (C1781T) UL97 plasmids were analyzed. 
Using either method, the mutation and three translationally silent SNPs could be de-
tected in mixtures containing 20% or more of the mutant sequence.
Application of MSCSA to a case of HCMV encephalitis after SCT
A 52-year old female with relapsed acute myeloid leukemia, secondary to myelodys-
plastic syndrome, received a haplo-identical T-cell depleted peripheral blood SCT after 
a myeloablative conditioning regimen. The patient was seropositive for HCMV, whereas 
the donor was seronegative. The patient was treated according to a preemptive HCMV 
treatment protocol, which was guided by HCMV DNA loads in plasma.21 The patient’s 
plasma became positive for HCMV DNA at 27 days after transplantation and she was 
treated with oral vGCV, 900 mg twice daily for two weeks. Because of persistent low 
levels of HCMV DNA and a lack of T cell recovery, treatment with a reduced vGCV 
dose was started at day 45 after transplantation (450 mg twice daily) and continued for 
4 months. However, during the last month of treatment, HCMV DNA loads steadily 
increased and resistance to GCV was suspected. This was treated with intravenous GCV 
(5 mg/kg twice daily) for two weeks and, subsequently, with valganciclovir (900 mg 
twice daily) and foscarnet (60 mg/kg three times daily) for two weeks.29
 Because the patient developed cognitive and neurological impairments, CSF was 
analyzed, which revealed a HCMV DNA load of 10 log 6.7 copies/ml. Other causes of 
encephalitis were excluded and MRI of the brain showed diffuse non-specific white 
matter abnormalities, supporting the diagnosis of HCMV encephalitis. Combination 
treatment with foscarnet (60 mg/kg three times daily) and GCV (5 mg/kg twice daily) 
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was started, followed after two months by cidofovir (5 mg/kg once weekly for three 
weeks). Unfortunately, the patient died from urosepsis.
 Using MSCSA and cycle sequencing, plasma samples taken between days 38 and 
53 showed no mutations, but later a mixture of wild-type and C1781T mutant UL97 
sequences was detected (Figure 2). This mutation, specifying a A594V mutation in the 
UL97encoded kinase is known to be associated with resistance to GCV.25;30 It remained 
present in subsequent DNA samples isolated from plasma. The HCMV DNA extracted 
from CSF samples also contained mixed sequences with this mutation.
discussion
In immunocompromised patients, information on the presence or absence of drug re-
sistance-associated mutations may help to guide treatment of persistent or recurrent 
Figure 2. Case report.
In a patient with a persistent HCMV DNA load, despite antiviral treatment with valganciclovir (vGCV) and ganciclovir 
(GCV), encephalitis developed and high levels of HCMV DNA were found in the cerebrospinal fluid (CSF). Sequence 
analysis of the HCMV UL97 gene, derived from nine plasma and four CSF samples, was performed in duplicate using 
cycle sequencing and MSCSA and revealed consistently wild-type isolates (circles), mixed sequences (wild-type UL97 and 
the mutant encoding the A594V substitution; triangles) or exclusively mutant virus (squares). The results between both 
methods matched for all samples tested. vGCV2 × 900: twice a day 900 mg vGCV; vGCV2 × 450: twice a day 450 mg vGCV.
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HCMV infections. In such situations, virus characterization needs to be sensitive, ac-
curate, and rapid in order to be of clinical relevance. We investigated the applicability 
of an MSCSA method for automated high-throughput DNA sequence analysis for the 
detection of sequence polymorphisms and drug resistance-inducing mutations in the 3’ 
region of the HCMV UL97 gene, and compared the results to cycle sequencing analy-
sis of the same genome region. This method was previously developed by Sequenom 
and validated for genotyping of Neisseria meningitidis. The method was presented as a 
highly reproducible alternative to sequence analysis methods relying on chain termina-
tion by dideoxynucleotide incorporation.22 Recently the first reports on the use of this 
technique for viral genotyping were published.31;32
We conclude that Sequenom’s MassARRAY protocol, in combination with the iSEQ soft-
ware, can be equally accurate compared to conventional sequencing techniques (see 
Table 2). The presence of mixed virus populations in patient samples may have contrib-
uted to the differences between duplicate MSCSA experiments and between MSCSA 
and cycle sequencing experiments, as the presence or absence of the discrepant SNPs in 
the MSCSA sequences were confirmed in many of the samples by cycle sequencing of 
the MSCSA PCR product. The use of two amplicons to cover the UL97 region of interest 
resulted in a clinically relevant detection limit of 10 log3.6 HCMV copies per ml. The 
sensitivity of mutation detection in the mixed plasmid DNA samples was comparable 
to cycle sequencing as well. We would like to stress that the accuracy of SNP detection 
by MSCSA is largely dependent on the quality (and quantity) of the sequences in the 
reference database, as performance improved considerably when the databases were 
supplemented with new sequences (data not shown).
Various genotypic screening methods have been developed for mutation detection 
in viral genomes, including that of HCMV, each with its own advantages and limita-
tions.33-35 Some methods allow rapid screening, but only of fixed genome positions 
known to be involved in antiviral drug resistance. MSCSA combines the possibility of 
detection of all nucleotide variations within a designated region of a viral genome with 
reduced hands on time due to the automation of post-PCR processing and analysis. 
Recently developed deep-sequencing methods allow for detection of minor variants 
of HCMV in patients36, but are laborious and may be less suitable in a clinical setting. 
MSCSA is performed in a 96-well format and the experimental processing of one plate 
(48 samples, as the UL97 gene was amplified in two amplicons) is comparable to the 
workload of conventional cycle sequencing of about 32 samples: results are obtained in 
about twelve hours, of which four hours are hands-on time. The costs for the analysis 
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of one sample by MSCSA (two amplicons) are estimated to be twice as high as com-
pared to cycle sequencing (one amplicon): the needed chemicals and disposables were 
estimated to cost around twelve to fourteen euro (excl VAT). Optimization of the PCR 
step in MSCSA (e.g., PCR amplification of the 3’ end of UL97 using a single amplicon, 
instead of the current two) would further reduce the average processing time and cost 
needed for MSCSA.
The MSCSA method evaluated here was successfully applied to a case of HCMV enceph-
alitis, a rare complication after SCT that is attributed to antiviral drug resistance.37-40 In 
agreement with previous cases, the prolonged use of GCV in combination with failing 
T-cell immune recovery likely contributed to the progression of infection in this patient. 
The association in this case between the treatment with a low dose of vGCV, motivated 
by possible myelotoxicity of the drug, and the subsequent development of resistance 
and viral encephalitis is compelling although not completely proven. Based on the re-
sults presented in this study, we conclude that MS-based comparative sequence analysis 
constitutes a reliable medium to high-throughput screening method that can be applied 
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Table S1. Details about the patient samples that were analyzed by MSCSA and cycle sequencing.
Patient underlying disease1) antiviral treatment CMV load polymorphisms/
mutations2)(days) (10log copies/ml)
AD169 ATCC strain N.A. N.A. none
1 RT GCV 8d 5,2 none
2 myc fun none 6,3 none
3 SCT vGCV 2d FOS 6d 3,6 none
4 NHL GCV 4d 4,3 none
5 SCT GCV 6d 4,3 C592G
6 RT none 5,9 D605E
7 RT vGCV 14d 4,2 R686Q
8 RT none 4,8 none
9 RT none 3,5 H469Y
10 RT none 4,8 none
11 RT vGCV 15d 3,8 N510S, D441N
12 RT vGCV 50d 4,9 N510S; A594V
13 RT vGCV 70d 4,0 A478T; N510S; A594V
14 SCT vGCV 3d 4,5 none
15 RT none 5,0 none
16 RT none 3,6 N467S
17 RT none 5,3 none
18 RT none 5,6 none
19 RT vGCV 60d GCV 13d 3,3 H469Y; C603W
20 RT vGCV 28d 3,5 E575K
21 SCT none 4,0 none
22 SCT vGCV 14d 4,5 H469Y
23 SCT vGCV 48d GCV 22d FOS 14d 4,6 none
24 SCT none 3,4 none
25 SCT vGCV 14d 4,5 none
26 RT GCV 13d 4,8 none
27 SCT vGCV 4d GCV 2d 4,5 none
28 post partum hepatitis unknown 4,0 none
29 renal disease unknown 5,8 none
30 unknown unknown 4,9 H469Y
31 RT GCV 2d 3,9 none
32 RT none 4,9 none
33 SCT none 4,3 none
34 SCT vGCV 66d GCV 25d CDV 3 doses 3,9 A591V or L595F
35 OLT GCV 18d 3,4 none
36 HIV none 4,6 none
37 SCT vGCV 3d 4,3 none
38 SCT none 4,9 none
39 RT vGCV 65d GCV 39d 3,1 M460V
40 SCT vGCV 26d 6,5 none
41 RT vGCV 45d GCV 39d 2,3 M460I
42 SCT none 5,1 none
43 OLT GCV 25d 4,5 none
1)  CDV = cidofovir; d = days; FOS = foscarnet; GCV = ganciclovir; MSCSA = mass spectrometry-based comparative 
sequence analysis; myc fun = mycosis fungoides; N.A. = not applicable; NHL = non-Hodgkin lymphoma; OLT = 
orthotopic liver transplantation; RT = renal transplantation; SCT = stem cell transplantation; vGCV = valganciclovir. 
2)  resistance associated mutations in bold.16;25-28 Polymorphisms/mutations were identified by cycle sequencing of the samples.
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Background: Treatment of cytomegalovirus (CMV) infections after stem cell transplanta-
tion (SCT) does not always lead to a rapid viral response. The causes of treatment failure 
may be either viral resistance or immunological failure to control viral replication. This 
study investigated the response to preemptive treatment in CMV infections in order to 
define risk factors for treatment failure, including the role of antiviral resistance.
Methods: Adult recipients of allogeneic T-cell depleted SCT were studied retrospectively 
(n = 92). CMV infections were treated with (val)ganciclovir according to a CMV DNA 
load based preemptive strategy. Treatment failure was defined as a CMV DNA load of 
1000 copies/ml or more after at least 2 weeks of treatment. Resistance was analyzed by 
nucleotide sequence analysis of the UL97 and UL54 genes in the first CMV DNA posi-
tive sample and in samples during treatment failure.
Results: Treatment failure occurred in 26 of the 47 preemptively treated patients (55%) 
and in 39 of 86 (45%) treatment episodes. The risk of treatment failure was increased 
during first treatment episodes (p = 0.01) and during the use of immunosuppressive 
medication (p = 0.02). Antiviral resistance was found in only 1 patient (4%) with treat-
ment failure. 
Conclusions: A slow response to preemptive antiviral treatment occurred frequently in 
CMV infections in SCT recipients. Antiviral resistance was observed but played a minor 
role in treatment failure.
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introduction
Preemptive therapy of cytomegalovirus (CMV) infections based on virological moni-
toring has been proven effective and has become common practice after hematopoi-
etic stem cell transplantation (SCT) in many centres. Quantitative viral load measure-
ments can additionally be used for monitoring treatment responses. In this way, it 
has been shown that preemptive treatment of CMV infections after SCT does not 
always lead to a rapid, complete and sustained viral response. By sensitive assays 
such as real-time PCR, viral DNA can be detected for days to weeks after treatment,1;2 
frequently considerably longer as compared to detection of pp65 antigenemia. The 
clinical significance of prolonged CMV DNAemia is not always clear. It may predict 
recurrence of CMV DNAemia or development of CMV disease, but persistent infec-
tions may also be cleared spontaneously or respond to a repeated treatment course 
without complications.1;3;4 The causes of viral DNA persistence despite antiviral treat-
ment may be viral resistance on the one hand or immunological failure to control 
viral replication on the other. Risk factors associated with treatment failure and in 
particular the role of resistant CMV in a preemptive treatment setting after SCT are 
largely unknown. 
 In guiding treatment of persistent CMV infections, it is important to know the 
contribution of the various causes of treatment failure. This study investigated the 
occurrence and risk factors of failure of preemptive treatment of CMV infections in 
SCT patients, focusing on the possible role of antiviral resistance.
metHods
Patient data
Consecutive adult recipients of an allogeneic T-cell depleted stem cell transplant be-
tween 2005 and 2008 at risk for CMV (donor and/or recipient CMV seropositive) were 
included (n = 92). Follow-up was one year after transplantation. T cell-depleted trans-
plantation was performed either according to a reduced intensity conditioning protocol 
or a myeloablative conditioning regimen as described previously 5-7. In the absence of 
graft versus host disease (GvHD) or graft failure, patients received donor lymphocyte 
infusion for treatment of mixed chimerism or relapsed disease, at least 3 months (me-
dian of 187 days) after transplantation.




CMV DNA loads in EDTA plasma were determined prospectively by quantitative real-
time PCR as previously described.8 A preemptive treatment protocol8 with valganci-
clovir (vGCV, 900 mg twice daily for 14 days) was applied based on CMV DNA load. 
Treatment was initiated if the load exceeded 104 copies/ml or was above 103 copies/ml 
combined with an at least tenfold increase in comparison to the preceding week. Sub-
sequent DNAemia episodes were treated if the load was above 105 copies/ml or above 
104 copies/ml and increasing at least tenfold in one week. Treatment was continued as 
long as the CMV DNA load was above these thresholds. Symptomatic CMV infection 
was treated with intravenous ganciclovir (GCV, 5 mg/ kg twice daily for 14 days). Oral 
ganciclovir was not applied.
Data collection
Patient and treatment data were collected retrospectively from patient charts. The 
recorded baseline data are shown in Table 1. The follow-up data included the use of 
antiviral medication, the use of immunosuppressive medication (therapeutic, i.e. non-
prophylactic, use of systemic corticosteroids, cyclosporine, rituximab) and the total lym-
phocyte count, signs and symptoms of CMV end-organ disease9 and patient survival. 
Renal function was recorded to check for adequate dosing of antiviral medication. 
Analysis of resistance
Analysis of resistance was performed by nucleotide sequence analysis of CMV DNA 
from plasma samples as previously described.10 The amplified region ranged from co-
don 370 to 708 of the UL97 gene, covering all previously described mutations.11 Se-
quence analysis of codon 262 to 1169 of the UL54 gene was performed on DNA isolates 
with UL97 mutations or from patients using foscarnet or cidofovir. Sequences were 
compared to the sequence of the GCV susceptible AD169 strain and to pre-treatment 
samples from the patient. Baseline resistance was determined in the first sample from 
each patient containing at least 1000 copies/ ml of CMV DNA. Resistance during treat-
ment was determined by analysis of subsequent plasma samples containing at least 
1000 copies/ ml of CMV DNA after at least two weeks of treatment of CMV infection. 
Genotypic resistance was defined as the presence of resistance-associated mutations 
that have been published previously (as proven by marker transfer).
Statistical analysis 
CMV DNAemia was defined as any detectable CMV DNA load in plasma. A treatment 
episode was defined as a period of antiviral treatment of 14 days. Treatment failure was 
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defined as the presence of at least 1000 copies/ ml of CMV DNA in plasma at the end of a 
treatment episode. In view of the repeated measurement of treatment failure as a binary 
variable (failure yes/no) within patients, the outcome was modelled as a repeated mea-
Table 1. Baseline characteristics of the 92 patients.
  Patients
  n (%)
Sex  
 Male 54 (59)
Age  
 Years (mean, range) 48 (21-70)
Underlying disease  
 ALL 9 (10)
 AML 29 (32)
 CLL 3 (3)
 CML 9 (10)
 MDS 5 (5)
 MM 14 (15)
 Other 23 (25)
Transplant type  
 Peripheral blood stem cells 91 (99)
 Bone marrow 1 (1)
Conditioning regimen  
 Myeloablative 48 (52)
 Non-myeloablative 44 (48)
Donor type  
 Matched sibling donor 51 (55)
 Matched unrelated donor 39 (42)
 Other1 2 (2)
Serostatus donor  
 CMV-seropositive 56 (61)
Serostatus recipient  
 CMV-seropositive 75 (82)
Serostatus combination  
 Donor -/ recipient + 36 (39)
 Donor +/ recipient - 17 (19)
 Donor +/ recipient + 39 (42)
Total  92 (100)
Abbreviations: ALL = acute lymphoblastic leukaemia, AML = acute 
myelogenous leukaemia, CLL = chronic lymphocytic leukaemia, CML 
= chronic myelogenous leukaemia, MDS = myelodysplastic syndrome, 
MM = multiple myeloma
1 haplo-identical related donor (n = 1), mismatched related donor (n = 1)
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sures logistic regression. Parameters were estimated using the Generalized Estimating 
Equations procedure in SPSS 16 (SPSS Inc., Chicago, IL, USA) with first-order autoregres-
sive correlation structure and a robust estimation procedure. Univariable analyses of po-
tential predictors was performed with p-values <0.20 as a criterion for possible inclusion 
in a multivariable model.
results
CMV infections
Plasma samples and treatment data were available from all 92 transplanted patients at 
risk for CMV (donor and/or recipient CMV seropositive). Baseline characteristics of the 
patients are shown in Table 1. CMV DNAemia was detected in 67 of all 92 patients (73%). 
Pre-emptive treatment for CMV infections was administered in 47 of 67 patients with 
CMV DNAemia; in total 96 treatment episodes occurred of which 86 were evaluable with 
respect to treatment response. CMV treatment was initiated after a median of 33 days 
after transplantation. CMV disease occurred in five patients; three patients with pneu-
monitis, one patient with encephalitis and one patient with retinitis. During the first year 
after transplantation 30 patients (33%) died, including the five patients with CMV disease.
Treatment failure 
Treatment failure occurred in 55% of the treated patients (26 of 47), corresponding to failure 
in 39 of 86 (45%) treatment episodes. In 4 of the failing episodes (4.7%) the viral load increased 
during treatment, in 17 episodes (19.7%) the viral load remained stable above 1000 copies/ml 
despite treatment and in 18 episodes (20.9%) the viral load decreased but remained above 
1000 copies/ml (Figure 1). Nineteen patients (73%) experienced a single episode of treatment 
failure, three patients (12%) had persistent treatment failure lasting multiple episodes of an-
tiviral treatment and four patients (15%) had recurrent episodes of treatment failure. 
 In 25 of the 26 patients (96%) treatment failure occurred during the first treatment 
episode. The cumulative duration of all treatment episodes in the first year after trans-
plantation was 15 and 29 days (median) in the patients without and with treatment fail-
ure respectively. CMV disease was present in 4 of 26 treated patients with (recurrent or 
persistent) treatment failure (15%) and in 1 of 21 patients (4.8%) without treatment failure 
(odds ratio 3.63, p = 0.27).
 In univariable analysis (Table 2), the risk of treatment failure was increased during first 
treatment episodes, during the therapeutic use of immunosuppressive medication and in 
patients with a higher CMV load at the start of treatment. Conditioning regimen, donor 
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type, CMV serostatus, lymphocyte counts and the timing after SCT were not significant 
predictors of treatment failure. Underdosage of antiviral medication (defined as a dosage 
lower than valganciclovir 900 mg twice daily or ganciclovir 5 mg/kg twice daily excluding 
cases of dose adjustments for impaired renal function) was associated with a decreased 
occurrence of treatment failure (Table 2). In multivariable analysis (Table 2), the risk of 
treatment failure was increased during first treatment episodes and during the use of im-
munosuppressive medication.
Antiviral resistance
Resistance development could be monitored by analyzing baseline samples from 58 
of 67 patients with CMV DNAemia and follow-up samples from 23 of 26 patients with 
Figure 1.  Cytomegalovirus (CMV) treatment episodes categorized according to viral kinetics and 
treatment failure. 
Treatment course and failure could be evaluated in 86 of 96 treatment episodes (14 days of antiviral treatment). Treat-
ment failure was defined as the presence of at least 1000 copies/ ml of cytomegalovirus DNA in plasma after at least two 
weeks of treatment. A change in viral load of ≥ 0,5 10log copies/ml was considered an increase or decrease.
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treatment failure. Each patient with treatment failure was investigated for antiviral re-
sistance in samples every two weeks until the CMV DNA load fell below 1000 copies/ml. 
The median number of samples for each patient was 2 (range 1-7). Most follow-up sam-
ples (75%) were retrieved after two weeks of treatment (range 2-13 weeks of treatment). 
No resistance associated mutations were found in the UL97 gene in the 58 pre-treatment 
samples. Resistance at treatment failure was found in 1 of 23 patients (4%). In this previ-
ously described patient12 with recurrent treatment failure, CMV DNAemia first occurred 
at day 27 after transplantation, which was treated with vGCV (900 mg twice daily). Sub-
sequently, the patient was treated with vGCV prophylaxis (450 mg twice daily) because 
of persistent low levels of CMV DNA. However, from day 136 onward, CMV DNA loads 
steadily increased and eventually progression to CMV encephalitis occurred. Viral DNA 
with the resistance associated A594V mutation in the UL97 gene was found in plasma 
and cerebrospinal fluid samples from day 136 onwards, after 109 days of antiviral treat-
ment. In the other 22 patients with treatment failure, no resistance associated mutations 
were found in the UL97 gene (30 samples) or the UL54 gene (7 samples). 
discussion
In this study, the response to preemptive antiviral treatment of CMV infections after 
SCT and the role of antiviral resistance in treatment failure were studied. Based on regu-
lar monitoring of CMV DNA in plasma, CMV DNA levels during treatment were ana-
lyzed. Approximately half of the patients still had CMV DNAemia of at least 1000 cop-
ies/ml after a standard course of antiviral treatment of two weeks. Antiviral resistance 
played only a minor role in such persistent CMV DNAemia, with resistance-associated 
mutations found in only one patient with treatment failure and in none of the baseline 
samples. 
The definition of treatment failure as a CMV DNA load of at least 1000 copies/ ml after 
at least two weeks of treatment was chosen to include those patients in whom prolon-
gation of treatment is commonly considered. It appeared that patients with treatment 
failure according to our definition indeed had a longer duration of treatment for CMV 
than patients without treatment failure. Treatment failure can also be defined using 
viral dynamics and, for example, treatment failure defined as less then 2log decrease in 
viral load after 14 days of treatment would have resulted in a comparable prevalence of 
failure in 49% of the episodes (MTvdB et al., data not shown). Although the persistence 
of viral DNA in plasma is no direct proof of ongoing viral replication, it is likely that the 
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half-life of viral DNA is short and, therefore, that plasma DNAemia is a correlate for 
recent viral replication.13 This view is supported by the fact that viral loads decreased 
rapidly in many patients in our study.
The rate of treatment failure of 45% of all episodes was somewhat higher than ob-
served in an earlier study in our hospital (Leiden University Medical Center, Leiden, 
The Netherlands), which found failure in 20-25% of episodes, despite comparable 
patient and episode characteristics.3 This may be due to a longer duration of follow 
up in the current study. Our results are comparable to two other studies where rising 
antigenemia under treatment occurred in 45% of patients4 and PCR positivity was 
found in 39% of patients after treatment.14 A recent prospective cohort study showed 
persistent CMV infection after 21 days of antiviral treatment in only 4 of 59 (7%) SCT 
patients.15 The different definition of treatment failure (21 versus 14 days and inclu-
sion of DNAemia as well as antigenemia, viral culture and histopathology) probably 
contributed to this variation. Differences in antiviral treatment regimen, which was 
not further specified, may also play a role. A lack of association between treatment 
failure and CMV disease in our study may be explained by the small number of pa-
tients with CMV disease due to the effective preemptive treatment strategy.
 In our study, all patients treated for CMV DNAemia were tested for resistance, 
regardless of symptoms or clinical suspicion of resistance. Most previous publica-
tions on resistance comprised case reports or small case series of patients with CMV 
disease and did not assess the overall prevalence of resistant CMV. Only a few earlier 
studies are available in which resistance has been systematically studied in persistent 
CMV infections in SCT patients undergoing preemptive treatment.4;15;16 A prospec-
tive study found resistance in 1 of 4 SCT patients with persistent viral replication.15 
Low-level resistance (as determined by phenotypic methods) was found in 1 of 15 
patients with rising antigenemia levels under treatment4 and in none of 10 patients 
with positive PCR results after two weeks of antiviral treatment.16 In the setting of 
recurrent CMV after preemptive treatment, one study observed resistance in 1 of 
13 patients.17 These results are in accordance with the low prevalence of resistance 
found in our study, demonstrating that this does not provide a likely explanation for 
the majority of cases with treatment failure. There is a small chance that UL54 muta-
tions have been missed due to our strategy of only analyzing samples from patients 
harbouring UL97 mutants or from patients who had been treated with the antivi-
rals (foscarnet and cidofovir) that directly target the viral DNA polymerase UL54.18;19 
However, previous studies have shown that the majority of resistance-associated mu-
tations are found the UL97 gene.15;20
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Treatment failure was found most often during first treatment episodes. Probably, the 
development of CMV-specific immunity during CMV infection facilitates treatment re-
sponses in subsequent episodes. Furthermore, the use of immunosuppressive medication, 
mainly for GvHD or post-transplant lymphoproliferative disorder treatment, during an-
tiviral treatment increased the risk of treatment failure. Likewise, in previous studies, the 
use of high-dose corticosteroids was a significant risk factor for persistent or increasing 
pp65 antigenemia.4;21 Obviously, the time needed to clear DNAemia or antigenemia is re-
lated to the amount of virus at start of treatment22 and, indeed, in univariable analysis, a 
high viral load at start of treatment was associated with a higher risk of treatment failure. 
In multivariable analysis this effect was insignificant, however, suggesting a more complex 
relationship between viral load, treatment failure, failure of immunological recovery and, 
likely, viral resistance. A sustained lack of (CMV-specific) T-cells after transplantation, for 
example due to the use of immunosuppressive medication, probably allows for high viral 
loads and, hence, persistent or recurrent CMV infection.23 This necessitates repeated and 
prolonged antiviral treatment and may also lead to the development of antiviral resistance. 
Indeed, the prolonged treatment with a low dose of vGCV in the only patient with a UL97 
mutant, may have led to the development of resistance due to the erroneous use of sec-
ondary prophylaxis during an ongoing viral reactivation.12 Surprisingly, suboptimal dos-
ages of antiviral medication were not associated with treatment failure, but were admin-
istered more often during successful treatment episodes. This appears to be the confusing 
result of the off-protocol use of secondary prophylaxis with vGCV 900 mg once daily in 
certain patients. Those patients had a low viral load after a standard treatment course and 
then received secondary prophylaxis with low dose valganciclovir. Either spontaneously 
or due to the antiviral treatment, CMV DNAemia was rapidly cleared. This unexpected 
association was insignificant in multivariable analysis.
In conclusion, in SCT patients, CMV infections with a slow response to antiviral treatment 
occurred frequently. Antiviral resistance was observed but played a minor role in treat-
ment failure. 
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Background: Cytomegalovirus (CMV) infections after transplantation are commonly 
treated using a prophylactic or preemptive regimen with (val)ganciclovir. It remains 
unclear which approach is most effective in preventing CMV disease in D+R- patients. 
The aim of this retrospective study was to compare treatment response and antiviral 
resistance in CMV infections between two treatment regimens in D+R- renal transplant 
recipients.
Methods: Before 2006, a preemptive treatment regimen with valganciclovir was applied 
(42 patients). From 2006 onwards, patients first received prophylaxis with valganciclo-
vir for 90 days, followed by a preemptive regimen (29 patients). CMV infections were 
monitored by regular determination of the CMV-DNA load in plasma. Patient charts 
were reviewed for antiviral treatment data and resistance was analyzed by nucleotide 
sequence analysis of the UL97 and UL54 genes in CMV-DNA positive samples. 
Results: Treatment failure, defined as a CMV DNA load ≥ 1000 copies/ml after at least 
2 weeks of treatment, occurred less frequently in the prophylaxis cohort than in the 
preemptive cohort (14% versus 71%, p < 0.001). No CMV end-organ disease occurred in 
either cohort. Resistant viral isolates were found during treatment in one patient in the 
prophylaxis cohort versus in three patients in the preemptive group. All CMV infections 
with resistant virus were cleared without switch of (val)ganciclovir treatment. 
Conclusions: Treatment failure of CMV infections occurred less frequently in D+R- renal 
transplant patients on a sequential prophylaxis-preemptive regimen, than in patients 
on a purely preemptive regimen. Antiviral resistance was observed infrequently and 
apparently played a minor role in treatment failure.
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introduction
Prophylactic and preemptive regimens are widely applied in renal transplant recipients 
to reduce morbidity and mortality associated with cytomegalovirus (CMV) disease. Pa-
tients at high risk for CMV disease after transplantation are transplant recipients who 
are CMV-seronegative prior to transplantation and receive an organ from a CMV-sero-
positive donor (D+R-). Without preventive measures, CMV disease occurs in about 70% 
of D+R- patients.1;2 
 It remains unclear whether a prophylactic or a preemptive approach is most effec-
tive in preventing CMV disease in D+R- patients.3 In a direct comparison of prophylaxis 
versus preemptive treatment in renal transplant recipients using valganciclovir (vGCV), 
prophylaxis reduced the incidence of CMV infection in all transplant recipients, except 
for D+R- patients.4 Furthermore, no reduction in symptomatic episodes was observed.4 
In a trial using oral ganciclovir (GCV) for prophylaxis versus intravenous GCV for pre-
emptive treatment, prophylaxis also reduced the incidence of CMV infection and in-
creased long-term graft survival in all recipients5. No separate data were available for 
D+R- patients.5 After prophylaxis, late onset CMV disease still occurs in about 30% of 
D+R- transplant patients, necessitating follow up after prophylaxis.6-9 
 Treatment of CMV infections in D+R- patients does not always lead to a rapid and 
sustained viral response.4;10 Such treatment failure may be related to the type of treat-
ment regimen, to immunological factors or it may be caused by viral resistance. Resis-
tance of CMV to antiviral agents can occur after prolonged exposure to antiviral drugs,11 
both in prophylactic and preemptive treatment regimens. Yet, it is unknown if either 
type of CMV treatment regimen predisposes to the development of antiviral resistance.
 Our hospital has recently chosen to change its strategy for the prevention of CMV 
disease in D+R- renal transplant recipients. The purely preemptive strategy has been re-
placed by a three-month prophylaxis regimen followed by preemptive treatment. In this 
retrospective study, we compared the incidence and course of CMV infections, the fre-
quency of treatment failure of CMV infections and the role of antiviral resistance between 
the purely preemptive versus the prophylaxis followed by preemptive treatment regimen. 
Patients and metHods
Patients
Consecutive D+R- kidney and kidney-pancreas transplant recipients transplanted in 
the Leiden University Medical Center between 2004 and 2008 were included (n = 78). 
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Follow-up was one year after transplantation. The initial immunosuppressive regi-
men consisted of prophylaxis with either antibodies against the IL-2 receptor alpha-
chain (basiliximab/daclizumab) or anti-thymocyte globulin (ATG, Fresenius Kabi, 
Utrecht, The Netherlands) for kidney and kidney-pancreas transplant recipients, re-
spectively. Maintenance immunosuppression consisted of three immunosuppressive 
drugs including prednisolone, either tacrolimus or cyclosporine and either myco-
phenolate mofetil or mycophenolic acid (see Table 1). Exposition to tacrolimus and 
cyclosporine was monitored by area-under-the-curve (AUC) measurements. First 
acute rejection episodes were treated with methylprednisolone and second rejection 
episodes were treated with ATG (Merieux, Genzyme, Naarden, The Netherlands). 
The immunosuppressive regimen, target AUC ranges and rejection treatment were 
unchanged throughout the study period.
Table 1. Baseline characteristics of the included patients.
  regimen
  preemptive prophylaxis
  n = 42 n = 29
n (% of patients ) n (% of patients )
age at Tx age (years, mean) 46 49 n.s.
gender male 24 (57) 18 (62) n.s.
underlying disease PKD  7 (17)  3 (10) n.s.
diabetes mellitus  9 (21)  8 (28)
hypertension  4 (10)  3 (10)
other 22 (52) 15 (52)
type of Tx kidney 35 (83) 25 (86) n.s.
kidney-pancreas  7 (17)  4 (14)
type of donor living related 11 (26)  8 (28) n.s.
living unrelated  6 (14)  7 (24)
post mortal HB 12 (29) 10 (35)
post mortal non-HB 13 (31)  4 (14)
immunosuppressive 
regimen directly after Tx
prednisone 42 (100) 29 (100) n.s.
cyclosporine 32 (76) 27 (93)
tacrolimus 10 (24)  2 (7) n.s.
mycophenolate 42 (100) 29 (100)
Tx, transplantation; HB, heart beating; PKD, polycystic kidney disease; n.s., not significant (p >0.05).
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CMV treatment
During the study period, the protocols for CMV prevention and treatment were 
changed from a purely preemptive strategy to initial prophylaxis followed by a pre-
emptive regimen. In all regimens, (v)GCV dosing was adapted according to renal func-
tion (dose reduction if creatinin clearance was below 60 ml/min). Before 2006, a pre-
emptive treatment regimen with valganciclovir (900 mg twice daily for 14 days) was 
applied which was guided by the CMV DNA load. Treatment was initiated at the first 
detectable CMV DNA load after transplantation. Subsequent DNAemia episodes were 
treated if the load was above 100.000 copies/ml or above 10.000 copies/ml and increas-
ing at least tenfold in one week. From 2006 onwards, patients received prophylaxis 
with vGCV (900 mg once daily) for 90 days, followed by a preemptive regimen. CMV 
DNAemia occurring after prophylaxis was treated (900 mg twice daily for 10-14 days) if 
the load was above 100.000 copies/ml or above 10.000 copies/ml and increasing at least 
tenfold in one week. In both regimens, symptomatic CMV infection was treated with 
intravenous GCV (5 mg/kg twice daily for 14 days) and, if possible with regard to the 
risk of rejection, the use of mycophenolate mofetil or mycophenolic acid was reduced 
or temporarily discontinued. 
Data collection
Patient and treatment data were collected retrospectively from patient charts. Baseline 
data that were registered included age, sex, underlying renal disease, type of donor 
and transplantation, CMV serostatus of donor and recipient prior to transplantation 
and immunosuppressive medication directly after transplantation. Follow-up data that 
were collected were immunosuppressive medication at onset of each CMV DNAemia 
episode, rejection treatment episodes, signs and symptoms of CMV end-organ dis-
ease,12 renal function at six and twelve months after transplantation, patient survival 
and graft survival. Start and end date, and dosage of antiviral medication were docu-
mented. Creatinin clearance based on 24-hour urine collection and creatinin serum 
levels was registered at start of antiviral medication and subsequently monthly during 
antiviral medication to check for adequate dosing of antiviral medication in relation to 
renal function. 
CMV monitoring
CMV DNA loads in EDTA plasma had been determined prospectively by quantitative 
real-time PCR.13 CMV IgG (Vidas 30, Biomérieux, Zaltbommel, The Netherlands) was 
determined retrospectively in EDTA plasma samples. 




Analysis of resistance was performed by nucleotide sequence analysis on CMV DNA 
from plasma samples. Cycle sequencing reactions were performed after PCR and 
nucleotide sequence analysis was performed on an ABI Prism 3100 Genetic Analy-
ser (Applied Biosystems, Warrington, United Kingdom). For amplification and cycle 
sequencing forward primer GTGCTCACGGTCTGGATGT and reverse primer CG-
GTGGGTTTGTACCTTCTC were used. Additional cycle sequencing primers were for-
ward primer GATTACAGCCTCAGCGAG and reverse primer CGTCTCCTGAAAGAC-
GG. The detection limit of the assay was 1000 copies/ml of CMV DNA and the ampli-
fied region ranged from codon 370 to 708 of the UL97 gene, covering all previously 
described mutations.14;14 Sequences were compared to the sequence of the wild type 
AD169 strain and to pre-treatment samples from the patient.
 Baseline resistance was determined in the first sample from each patient contain-
ing at least 1000 copies/ml of CMV DNA. Resistance during treatment was determined 
by analysis of subsequent plasma samples containing at least 1000 copies/ml of CMV 
DNA after at least two weeks treatment of CMV infection. Sequence analysis of codon 
262 to 1169 of the UL54 gene was performed on DNA from samples from patients us-
ing foscarnet or cidofovir.
End points 
The two treatment regimens were compared for timing, incidence and course of CMV 
DNAemia and the occurrence of treatment failure and resistance. The course of CMV 
DNAemia was expressed as the AUC of the CMV loads of each patient. The AUC is 
a reflection of the total exposure of the patient to CMV and was calculated using the 
trapezoidal model as previously described.15 Since quantification of low plasma loads 
in the range below 250 copies/ml is less precise, the AUC above this threshold was 
calculated. Treatment failure was defined as the presence of at least 1000 copies/ml of 
CMV DNA in plasma after at least two weeks of treatment of CMV infection. Resis-
tance was defined as the presence of resistance-associated mutations in the UL97 or 
UL54 gene.14;14
Statistical analysis 
For statistical analysis of dichotomous variables the Pearson Chi-square test or Fisher’s 
exact test were used. Because for most continuous variables a normal distribution was 
not assumed, the Mann-Whitney-U-test was used.
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Plasma samples and treatment data were available from 78 transplanted D+R- patients. 
Baseline characteristics of the patients from the two regimens are shown in Table 1. Of 
the 71 included patients, 42 had been treated according to a purely preemptive regimen 
and 29 primarily with prophylaxis. Seven patients were excluded from the analysis for 
the following reasons; two patients died within one month after transplantation, two 
patients received prolonged courses of cidofovir for BK-virus and three patients were 
treated with delayed prophylaxis after rejection treatment. No significant differences 
were present in baseline characteristics between the two treatment regimens. 
Viral Monitoring
The number of plasma samples submitted for CMV DNA load determination during 
the first three months after transplantation was higher in the preemptive cohort than 
during prophylaxis (median of 10 versus 6 samples, p < 0.01), but was similar during 
the remainder of the year (median of 11 versus 10 samples, p 0.39). 
CMV DNAemia
Timing of CMV DNAemia differed significantly between the two treatment regimens; 
the first CMV DNA load was detected after a median of 33 days after transplantation in 
the preemptive cohort and after 138 days in the prophylaxis cohort (p < 0.01, Figure 1). 
Breakthrough CMV DNAemia occurred in one patient in the prophylaxis cohort, who 
already had a CMV infection at the start of prophylaxis (Figure 1).
 The incidence of CMV DNAemia was similar in both cohorts; 29 patients (69%) in the 
preemptive cohort and 15 patients (52%) in the prophylaxis cohort had CMV DNAemia in 
the first year after transplantation (p 0.14, Figure 2). The percentage of patients reaching a 
CMV DNAemia of at least 1000 copies/ml was significantly higher in the preemptive cohort 
than in the prophylaxis cohort; 69% of the patients in the preemptive cohort versus 45% of 
the patients in the prophylaxis cohort (p 0.04, Figure 2). The threshold of 10.000 copies/ml 
was reached by 55% and 24% of patients in each cohort respectively (p 0.01, Figure 2). 
 The course of CMV DNAemia was significantly different between the two regimens; 
the AUC above 250 copies/ml was significantly higher in the preemptive cohort than 
in the prophylaxis cohort (mean of 2.1·106 versus 0.9·106 copies·day/ml, Mann-Whitney 
U-test p 0.03). In the patients with CMV DNAemia, the period in which CMV DNA was 
present after transplantation was longer in the preemptive cohort than in the prophy-
laxis cohort (median of 203 versus 79 days, p < 0.01). 
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Figure 2 Incidence of CMV DNAemia. 
 
The percentage of patients having DNAemia, reaching 1000 copies/ml CMV DNA in plasma and 

























preemptive (n = 42)









The percentage of patients having DNAemia, reaching 1000 copies/ml CMV DNA in plasma and reaching 10.000 copies/ml 
CMV DNA i  plasma in he first year after transplantation. n.s., not significant.
The median time to first CMV DNAemia was 33 versus 138 days in the preemptive versus the prophylaxis cohort 
(p < 0.01).
Figure 1. Time to first CMV DNAemia. 
Figure 2. Incidence of CMV DNAemia. 
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 No CMV end-organ-disease occurred in the study cohort. One patient died and one 
graft was lost, but both events were unrelated to CMV infection. Seroconversion for 
CMV IgG occurred in the first three months after transplantation in 57% of the patients 
in the preemptive cohort and in 3% of the patients in the prophylaxis cohort (p <0.01). 
The two treatment regimens did not show a significant difference in the number of 
rejection episodes or the renal function at six and twelve months after transplantation. 
Rejection treatment was not associated with the occurrence of CMV DNAemia (data not 
shown).
Treatment failure 
The percentage of patients receiving preemptive treatment was not significantly differ-
ent between the two regimens; 67% of the patients (n = 28) in the preemptive cohort 
versus 48% of the patients (n = 14) in the prophylaxis cohort (p 0.12). Treatment failure 
was present in a significantly higher proportion of the treated patients in the preemp-
tive cohort than in the prophylaxis cohort; 71% (n = 20) versus 14% (n = 2) (p < 0.01, 
Figure 3a). The median duration of preemptive treatment was longer in the preemptive 
cohort than in the prophylaxis cohort (45 versus 29 days, p 0.02, Figure 3b). 
 The maximum CMV DNA load was significantly higher in the patients with treat-
ment failure compared to the patients without treatment failure (median of 10log 4.8 
versus 10log 4.0, p < 0.01). No significant differences were found regarding transplan-
tation characteristics, rejection episodes and immunosuppressive medication directly 
after transplantation or at the onset of the first antiviral treatment episode between 
patients with and without treatment failure. Suboptimal dosages of antiviral medica-
tion during infection, based on renal function, were administered to 30% of the patients 
with treatment failure and to 42% of the patients without treatment failure (p 0.43). 
CMV-specific IgG was present in 9% of the patients with treatment failure and in 35% of 
the patients without treatment failure at the start of the first treatment episode (p 0.06). 
Antiviral resistance
No antiviral resistance was found in 33 baseline samples from the 42 patients who had a 
CMV DNAemia of at least 1000 copies/ml. In nine of these 42 patients baseline resistance 
could not be determined. Resistance during treatment could be analyzed in 21 of 22 pa-
tients with treatment failure. Antiviral resistance was found in four of the 21 patients 
(19%). The four patients with resistant virus were recipients of kidney transplants and 
had various UL97 mutations (A594V, M460I/V, C603W). In one patient, resistance oc-
curred during prophylaxis that had been initiated at the moment when CMV DNAemia 
was already present at a very low level (Figure 4a). The three other patients belonged 
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to the preemptive cohort and developed resistance during preemptive treatment 
(Figure 4b-d). All these patients experienced episodes of rejection and bacterial urinary 
tract infections at the time of the occurrence of the resistant virus. This hindered a ret-
rospective conclusion regarding the contribution of their CMV infection to symptoms, 
such as fever or deterioration of renal function. In all four patients the CMV infection 
eventually disappeared without switching the (val)ganciclovir treatment (Figure 4a-d). 
Figure  Treatment failure.  
Treatment failure was defined as a CMV DNA load of at least 1000 copies/ml in plasma after at least 
two weeks of treatment. 
 
Figure  Duration of treatment. 
Antiviral treatment was defined as either preemptive or symptomatic treatment for CMV. Prophylaxis 
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Figure 3a Treatment failure.  
Treatment failure was defined as a CMV DNA load of at least 1000 copies/ml in plasma after at least 
two weeks of treatment. 
 
Figure 3b Duration of treatment. 
Antiviral treatment was defined as either preemptive or symptomatic treatment for CMV. Prophylaxis 
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Treatment failure was defined as a CMV DNA load of at least 1000 copies/ml in plasma after at least two weeks of treat-
ment.
Antiviral treatment was defined as either preemptive or symptomatic treatment for CMV. Prophylaxis was not included 
in the calculation of the treatment duration.
Figure 3a. Treatment failure.
Figure 3b. ration of treatment. 
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discussion
In this retrospective study the two most frequently applied regimens for the preven-
tion of CMV disease in D+R- renal transplant recipients were systematically com-
pared for the course of CMV DNAemia, treatment failure, and antiviral resistance. 
Due to a recent change in protocols, patients treated in a purely preemptive strat-
egy could be compared with patients who were treated initially with three months 
In patient A resistant virus was found during prophylaxis, whereas in patients B, C and D resistant virus was found 
during preemptive treatment. Meth.pred = methylprenisolone, ATG = anti-thymocyte globulin, myco.acid = my-
cophenolic acid, myco.mofe = mycophenolate mofetil, ciclospor = ciclosporine, tacrolim = tacrolimus, prednison = 
prednisolone, GCV = ganciclovir, vGCV = valganciclovir, vGCVprohp = valganciclovir prophylaxis. A594V, C603W, 
M460I, M460V: resistance associated mutations.
Figure 4a-d. Patients with resistant virus. 
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of prophylaxis followed by a preemptive regimen. CMV infections were effectively 
postponed by prophylaxis with valganciclovir, with only one CMV infection in the 
prophylaxis cohort occurring already before the start of prophylaxis. No CMV end-
organ disease occurred in either cohort. Prophylaxis followed by preemptive treat-
ment reduced the percentage of patients reaching high CMV loads, as well as the 
AUC of CMV DNAemia and the duration of subsequent preemptive treatment epi-
sodes. Therefore, the sequential prophylaxis-preemptive approach proved very prac-
tical in our outpatient setting. Furthermore, CMV infections with a slow response to 
preemptive antiviral treatment occurred less frequently in patients who had received 
prophylactic treatment than in patients on a strictly preemptive regimen. 
The relatively mild course of CMV DNAemia during a preemptive regimen after ini-
tial prophylaxis in our study and in studies by others7 demonstrates the effectiveness 
of regular CMV monitoring after prophylaxis to prevent CMV disease. The severe 
outcomes of late-onset CMV disease reported in previous studies may be explained 
by the fact that prophylaxis was not combined with a subsequent preemptive regi-
men.6;7 Apart from the early detection of the primary CMV-infection due to preemp-
tive monitoring, the decreased level of immune suppression at three months after 
transplantation probably facilitates the response to antiviral treatment as well. Firstly, 
the immunosuppressive effect of induction therapy lasts for six to twelve weeks after 
transplantation. In addition, the dosage of maintenance immunosuppressive medi-
cation is often reduced from six to twelve weeks after transplantation. Furthermore, 
reducing or temporarily stopping mycophenolate mofetil or mycophenolic acid at 
the occurrence of CMV infection harbors less risk of rejection at three months after 
transplantation. In accordance with previous findings, seroconversion for CMV dur-
ing prophylaxis was nearly absent in our patients.16;17 This renders preceding sero-
conversion an unlikely explanation for the milder course of CMV after prophylaxis.
In this study, patients with a higher CMV DNA load more often had a slower treat-
ment response. Obviously, the time needed to clear DNAemia is related to the 
amount of virus. Apart from the preemptive treatment regimen (i.e. without prior 
prophylaxis) and the height of the CMV load, no other risk factors were found to 
be associated with treatment failure. The type of immunosuppressive medication or 
preceding rejection treatment could not be identified as risk factors. Under-dosage of 
antiviral medication was systematically recorded and occurred frequently, probably 
due to the rapidly changing renal function in these patients. However, this did not 
predict treatment failure. Patients without CMV-specific IgG at the start of treatment 
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only showed a trend towards treatment failure. Based on our findings, the predic-
tive value of IgG in the management of CMV DNAemia remains unclear, as found 
earlier.16
 Our definition of treatment failure as a CMV DNA load of at least 1000 copies/ml 
after at least two weeks of treatment corresponds to those patients for whom exten-
sion of treatment is commonly considered. In previous studies, preemptive treatment 
resulted in a median time to clear DNAemia of 13 tot 20 days.4 In the setting of treat-
ment of symptomatic CMV infections, the median time to DNAemia eradication was 
reported to be 21 days.10
In this study, antiviral resistance was observed but apparently played a minor role in 
treatment failure. Baseline resistance was absent and resistance during treatment was 
found in a minority of patients (19%) with treatment failure. Furthermore, CMV infec-
tions with resistant virus were eventually cleared without switching antiviral therapy. 
Due to the retrospective nature of this study, it is unknown whether a switch of treat-
ment to UL97-independent antiviral medication, such as cidofovir or foscarnet, would 
have lead to a more rapid clearance of DNAemia. 
 Our findings are in contrast to those from studies in the setting of symptomatic CMV 
in which resistant CMV caused CMV disease often with an unfavorable outcome.18;19 
Explanations for this discrepancy may lie in the fact that CMV disease was effectively 
prevented in our cohort and that resistance was systematically studied, regardless of 
symptoms. The sensitivity of our PCR allowed us to study plasma samples from all 
patients who had a CMV load of at least 1000 copies/ml. Therefore, no selection bias 
was present towards patients with an extreme course of CMV. Previous studies address-
ing resistance after prophylaxis without selection for patients with symptomatic disease 
also reported resistance mutations in patients without CMV disease that were cleared 
spontaneously.20;21 
 There was no significant relation between the treatment regimen and the occur-
rence of resistance, but numbers were small in our study. However, since baseline re-
sistance was absent, resistance is mainly expected to occur during treatment failure. 
Treatment failure occurred less frequently after prophylaxis and, therefore, resistance 
is not expected to occur more often after prophylaxis. Indeed, in a previous trial with 
valganciclovir for prophylaxis in D+R- patients, no resistance was found at the end of 
prophylaxis nor during infections after prophylaxis.21 Based on our findings, the role of 
antiviral resistance testing in guiding preemptive therapy in case of treatment failure 
seems of limited significance, with the possible exception of patients with CMV disease 
and patients with CMV infections during prophylaxis.
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The cost-effectiveness of both regimens is a relevant aspect in decision making. Costs 
may vary locally, but depend among other things on the number of samples for CMV 
DNA load measurement, the amount of antiviral medication administered and the 
number of admissions for CMV infections. In our study, the total number of samples 
for CMV DNA load measurement in the first year after transplantation decreased by 
27% in the sequential prophylaxis-preemptive cohort compared to the purely pre-
emptive cohort. Because breakthrough CMV infections were very rare in our study, 
monitoring for CMV during prophylaxis may be very limited. In the study cohort, 
this would have decreased the number of samples for CMV monitoring further, up 
to 50%. The total number of antiviral treatment days including prophylaxis increased 
by 2,5 fold in the sequential prophylaxis-preemptive cohort. However, the number 
of hospital days for intravenous antiviral treatment decreased by 55%. Furthermore, 
based on pharmacokinetic studies, a lower dose of valganciclovir may be effective for 
prophylaxis.22;23 This may further reduce costs of prophylaxis and is an interesting 
topic for further study.
 
Some limitations to the present study apply. Firstly, it was small and due to its retrospec-
tive nature it was neither blinded nor randomized. Nevertheless, both cohorts were 
comparable with regard to baseline characteristics. Secondly, no clinical end points 
could be studied in view of the effective treatment strategies applied. Since both the 
CMV DNA load and the AUC have already been shown to predict the risk of CMV dis-
ease these parameters were used in our analysis.15;24 
In conclusion, in D+R- renal transplant recipients, prophylaxis with low dose valgan-
ciclovir for three months followed by a preemptive regimen not only effectively post-
poned CMV infections, but also made subsequent infections more manageable without 
increasing the occurrence of antiviral resistance. 
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Background & Aims: The lectin pathway of complement activation is a crucial effector 
cascade of the innate immune response to pathogens. Cytomegalovirus (CMV) infec-
tion occurs frequently in immunocompromised patients after orthotopic liver trans-
plantation (OLT). Single-nucleotide polymorphisms (SNPs) in the lectin pathway genes 
determine their, liver-derived, protein level and functional activity. We examined the 
association between these SNPs and the risk for CMV infection in OLT.
Methods: OLT patients (n=295) were genotyped for recipient and donor SNPs in man-
nose-binding lectin (MBL2), Ficolin-2 (FCN2) and MBL-associated serine protease 
(MASP2) genes.
Results: Combined analysis of independently associated variant MBL2 [HR 1.65, P<0.02] 
and wild-type FCN2 [1.85; P<0.02] SNPs in the donor liver showed an increased risk of 
CMV infection for either and both risk genotypes [HR 2.02 and HR 3.26, respectively, 
P=0.004], especially in CMV Donor-/Recipient+ patients [HR 4.7 and HR 10.0, respec-
tively, P=0.01]. A genetic donor-recipient mismatch for MBL2 and for FCN2 increased 
the CMV risk independently, also combined [HR 5.35; P<0.001], particularly in CMV 
D-/R+ patients [HR 16.6; P=0.009]. Multivariate Cox analysis showed a consistent step-
wise increase in CMV infection risk with the gene profile of the donor [up to HR 2.77; 
P<0.005] and the combined MBL2 and FCN2 donor-recipient mismatch profile [up to 
HR 4.57; P<0.001], independent from donor-recipient CMV serostatus, also at higher 
CMV (re)infection cut-off values.
Conclusions: MBL2 and FCN2 risk alleles of donor liver and recipient constitute inde-
pendent risk factors for CMV infection after OLT. Patients with these risk genes prob-
ably need intensified CMV monitoring and anti-viral therapy.
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introduction
Cytomegalovirus (CMV) is an important cause of opportunistic infection in immuno-
compromised individuals and can have severe manifestations.1 The administration 
of immunosuppressive drugs after orthotopic liver transplantation (OLT) has a broad 
range of inhibitory effects on the adaptive immune system which prevent graft rejection 
but increase the susceptibility to opportunistic infection, including CMV infection. After 
OLT the patient thus becomes critically dependent on the innate immunity and the 
complement system is a pivotal component of this innate defense against pathogens. 
The structurally similar pattern-recognition receptors mannose-binding lectin (MBL) 
and ficolin-2 bind carbohydrate ligands on pathogens and initiate the lectin pathway 
of complement activation via MBL-associated serine proteases (MASPs), predominantly 
through MASP-2. Common single nucleotide polymorphisms (SNPs) in the genes cod-
ing for these three members of the lectin complement pathway result in diverse protein 
variants and altered protein levels with potentially important functional implications, 
as recently shown by us for bacterial infections after OLT.2
Structural variations in the exon 1 region of the MBL gene (MBL2) interfere with the oligo-
merization of the protein and polymorphisms in the promoter regions alter the rate of syn-
thesis of the protein, leading to changes in avidity and protein level of the lectin, respective-
ly.3;4 Ficolin-2 (FCN2) gene polymorphisms within the carbohydrate-recognition domain 
encoding region of the FNC2 gene are associated with a decreased (FCN2-B) or increased 
(FCN2-C) ligand binding of Ficolin-2 compared to wild-type Ficolin-2 (FCN2-A).5 The rela-
tion between MBL and CMV in solid organ transplantation has been studied before, mainly 
in kidney transplantation6-8 and only in a small number of patients after liver transplan-
tation.9 Data concerning the relation between development of CMV infection and other 
components of the lectin pathway of complement, i.e., the ficolins and the MASPs, have not 
been reported before. The combination of an immunocompromised patient and a new do-
nor liver, as the major site where these proteins are synthesized, makes OLT a unique in vivo 
patient model to study the MBL-Ficolin-MASP gene profile in relation to CMV infection. 
metHods
Study population
Data were retrieved from the records of all patients undergoing orthotopic liver trans-
plantation (OLT) at the Leiden University Medical Center (LUMC, from 1992 to 2006) 
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and the University Medical Center Groningen (from 2000 to 2006) in The Netherlands. 
Follow-up data were collected until the end of December 2006. The study was per-
formed on prospectively collected data and samples obtained with informed consent 
from the patients according to the guidelines of both Medical Ethics Committees, in 
compliance with the Helsinki Declaration. 
 For the present study, 426 patients were identified who underwent OLT from whom 
we were able to unselectively include 310 patients of whom DNA was available from 
both donor and recipient, and who had at least 7 days of follow-up after transplanta-
tion, thus excluding patients with perioperative morbidity and mortality. From 248 cases 
blood CMV pp65 antigen follow-up within the first year after OLT was available. CMV-
DNA quantification data were available in 47 cases because of transition from pp65 in 
the LUMC from June 2002 onwards. Thus, a final cohort of 295 patients undergoing an 
OLT was used for the present study.
Covariates and definitions
Data on covariates of interest were indentified from the general patient database and 
from transplantation databases and included: age of recipient and donor at the time of 
OLT, gender, primary liver disease, donor and recipient CMV IgG antibody status, acute 
cellular rejection and date of death or last follow-up. Allograft rejection was diagnosed 
by liver allograft biopsy using the Banff classification scheme,10 and these patients re-
ceived additional immunosuppression (corticosteroids and other) which is known to 
increase the risk of CMV reactivation. Donor (D) and recipient (R) CMV serology was 
coded as a 4-level covariate (D-/R-, D-/R+, D+/R-, D+/R+).
Assessment of CMV infection and disease
CMV pp65 lower matrix protein had been detected routinely in leukocytes from eth-
ylenediaminetetraacetic acid (EDTA) blood samples. Laboratory evidence for CMV 
infection was defined as a result of one or more cells positive for CMV pp65 antigen 
per 50.000 leukocytes. CMV-DNA loads had been determined prospectively in EDTA 
plasma by a validated quantitative real-time polymerase chain reaction (PCR) using the 
I-Cycler IQ DNA detection system (Bio-Rad, Veenendaal, The Netherlands), as previ-
ously described11 with a detection limit of 0.90 log(10).
 Both CMV screenings were performed twice a week during the first 21 days post-
transplantation. Thereafter, the test was performed at each outpatient visit, at least ev-
ery other week until postoperative day 90. Subsequently screening was performed at 
least once every month until postoperative day 365. Since all patients had an unde-
tectable CMV load at the time of transplantation, any subsequent detection of pp65 or 
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CMV-DNA was considered CMV (re)infection in our study. Time to first positive CMV 
test result was calculated from the date of transplantation until the date of the first posi-
tive test. Those with persistently negative CMV assays were censored at day 365 and 
patients who died within 365 days after OLT were censored on the day of death. 
 Primary CMV infection was defined as the detection of CMV infection in an individ-
ual previously found to be CMV seronegative. Recurrent infection was defined as new 
detection of CMV infection resulting from either reactivation of latent virus (endog-
enous) or reinfection (exogenous) in a patient who has had previously a documented 
infection.12 CMV disease was defined as the presence of clinical signs and symptoms 
compatible with the diagnosis, i.e., presence of fever (temperature, >38°C), neutropenia 
(<1.5 x 109/L) or thrombocytopenia (<100,000/mm3), accompanied by the isolation of 
CMV from blood.12 Tissue invasive CMV disease was defined when tissue samples were 
found to be positively stained for CMV.  
Immunosuppression and antibiotic prophylaxis
Patients received routine immunosuppressive therapy consisting of corticosteroids, 
a calcineurin inhibitor (cyclosporine or tacrolimus) and either azathioprine or myco-
phenolate mofetil and/or basiliximab. With respect to the immunosuppressive therapy, 
azathioprine was used until 2001, and thereafter mycophenolate mofetil was given in 
case of impaired renal function. From 2001 on basiliximab was used on days 0 and 4. In 
addition, patients received 24 hours of prophylactic antibiotics intravenously (genta-
mycin, cefuroxim, penicillin G and metronidazol) and 3 weeks of selective digestive 
tract decontamination (polymyxin/neomycin, norfloxacin and amfotericin B) after OLT 
(131 patients) or amoxicillin-clavulanate and ciprofloxacin without selective digestive 
tract decontamination (164 patients). 
CMV prophylaxis
All patients transplanted before 2002 received anti-CMV prophylaxis irrespective of 
their CMV status: D+/R- received 3 weeks of intravenous ganciclovir (induction), fol-
lowed by oral acyclovir up to 3 months after OLT (maintenance). Patients with other 
serostatus combinations received oral acyclovir for 3 months. From 2002 onwards CMV 
prophylaxis was restricted to patients with a D+/R- serostatus combination: these re-
ceived prophylaxis with valganciclovir for 3 months, while the other D/R combinations 
did not receive prophylaxis. In both periods preemptive therapy was used, meaning 
that a primary infection was treated upon first positivity of CMVpp65 test or PCR, while 
reactivations were treated if a relevant increase in CMVpp65 or CMV-DNA occurred 
after first positivity. The use of acyclovir, ganciclovir and valganciclovir as prophylaxis 
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was included as one variable to consider the combined effects of these medications in 
the analyses.
Genotyping and MBL-deficiency single-nucleotide polymorphisms
Genomic DNA was from peripheral blood and/or tissue samples. SNPs in the MBL2, 
FCN2 and MASP2 gene were determined with the use of high resolution DNA melting 
assays (HRMA) with the oligonucleotide primers as indicated in Table S1.2;13;14 Briefly, 
HRMA of PCR products amplified in the presence of a saturating double-stranded DNA 
dye (LCGreenPlus, Idaho Technology) and a 3’-blocked probe, identifies both heterozy-
gous and homozygous sequence variants by a change in melting temperature curves, 
verified by DNA sequenced controls.
 Genotypic MBL studies have shown that different SNPs in the promoter and exon 1 
of the MBL gene (B, C and D collectively called O, whereas the wild-type allele for each 
position is called A) are in strong linkage disequilibrium. The association between MBL 
genotype and phenotype is very strong: sufficient functional MBL concentration is as-
sociated with YA/YA, YA/XA, XA/XA and YA/O genotypes, whereas relatively deficient 
functional MBL concentration is associated with XA/O and O/O genotypes.15;16
Statistical analysis
In the univariate analysis, pretransplantation and post-transplantation covariates were 
analyzed for their association with CMV infection. Cox proportional-hazards survival 
analysis was used for both discrete categorical variables and continuous variables. For 
survival analysis, cases were censored at the date of the last follow-up, death or liver re-
transplantation. The multivariate Cox proportional hazards regression analysis was used 
to evaluate the independence of covariates with a P value <0.15 in the univariate analy-
ses. Results were considered statistically significant when P values were <0.05. Bonfer-
roni correction for multiple comparison tests was not performed because SNPs were se-
lected on the basis of a deducible hypothesis, i.e., the reported associations with bacterial 
infections2 and preliminary studies on CMV in OLT9 consequence of the SNP on the func-
tion of the respective proteins and the liver as their production organ. All analyses were 
performed with SPSS Statistical Software Package (version 16.02, SPSS Inc., Chicago, IL).
results
We evaluated 295 orthotopic liver transplantation recipient-donor pairs. Pre- and post-
transplantation clinicopathological features of the patients are shown in Table 1. In 120 
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out of the 295 patients (35%) there was laboratory evidence of CMV infection within 
the first year after OLT, of which 90 (75%) were recurrent infections and 30 (25%) were 
primary infections. The median time to infection was 36 days (range 1-348 days) after 
transplantation. Out of these 120 patients 37 (31%) [13% (37/295) of all patients] had 
Table 1.  Characteristics of Orthotopic Liver Transplant Re-





Gender   
Male recipient 181 (61.4)





Other disease§ 116 (39.3)
Immunosuppressive regimen
Prednisone / CNI (+ azathioprine) 94 (31.9)




Ganciclovir+ Acyclovir 8 (2.7)
Valganciclovir 34 (11.5)











§ Other diseases included predominately autoimmune hepatitis, crypto-
genic cirrhosis and metabolic disorders.
CNI denotes calcineurin inhibitors, MMF mycophenolate mofetil, MELD 
Model for End-Stage Liver Disease, CMV cytomegalovirus, D donor, R 
recipient.
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CMV disease. All 295 recipients and their donor liver were tested for 9 functional poly-
morphisms in the MBL2, FCN2 and MASP2 genes (Table S2).
MBL2 and FCN2 polymorphisms of the donor are associated with CMV infection.
The MBL2, FCN2 and MASP2 genotype distributions of the donor livers were analyzed 
in relation to the cumulative incidence of CMV infection within the first year post-OLT. 
In a univariate Cox proportional hazards model, patients receiving a liver from an MBL 
deficient donor (XA/O or O/O) were found to have a significantly increased risk of CMV 
infection compared to those receiving a wild-type liver [54% (27/50) versus 38% (93/245) 
HR 1.65; CI, 1.07-2.54 P=0.02] (Fig.1A). In addition, there was a significant association 
with increased CMV infection in patients receiving a donor liver with an absence of the 
minor T-allele of FCN2 SNP rs7851696 (FCN2-A) compared to a donor liver with at least 
one copy of the minor T-allele (FCN2-C) [44% (103/232) versus 27% (17/63) [HR 1.85; 
CI, 1.11-3.13 P<0.02] (Fig.1B). Particularly the recurrent CMV infection in seropositive 
recipients was increased with an MBL deficient compared to a wild type donor liver 
[75% (24/37) versus 40% (66/167), respectively, P=0.005], and it was again found to be 
increased when receiving a FCN2-A donor liver compared to FCN2-C donor liver [49% 
(78/159) versus 29% (12/42), P=0.02].
The FCN2-B (rs17549193) and MASP2 donor gene polymorphisms showed no signifi-
cant association with CMV infection. Moreover, none of the gene polymorphisms re-
lated with CMV infection in the donor showed a direct association in the recipients 
(Table S2). However, the genotype of the recipient in relation to the donor genotype was 
found to be a major determinant regarding the occurrence of CMV infection after OLT. 
Recipients with a sufficient (wild type) MBL genotype (A/A and YA/O) receiving a do-
nor liver with a deficient MBL genotype (XA/O and O/O) developed significantly more 
frequently an CMV infection than the other patients [58% (26/45) versus 38% (94/250), 
respectively, P=0.006]. Conversely, CMV infection was less frequent in low-binding 
FCN2-A recipients who received a high-binding FCN2-C donor liver compared to the 
other genotype combinations [22% (10/46) versus 44% (110/249) P=0.009].
Combined analysis of MBL2 and FCN2-C SNP in the risk of CMV infection
The combination of MBL deficiency genotypes (XA/O or O/O) and presence of FCN2-A 
in the donor liver revealed a significant relation with CMV infection (Table 2). To extend 
the findings of the univariate model, the combined impact of donor MBL2 and FCN2-
A genotype on the cumulative probability of CMV infection was assessed as shown in 
Figure 1C. 
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Figure 1.  Kaplan-Meier estimation of cytomegalovirus (CMV) infection in liver transplant re-
cipients with functional lectin pathway polymorphisms. 
In the donor liver: A MBL2 variant carriers (VC) compared to MBL2 wild types (WT). B minor T-allele of FCN2-C SNP 
compared to absence of the minor T-allele (FCN2-A). C combination of donor MBL2 (XA/O or O/O) and FCN2 (FCN2-A 
or FCN2-C). In donor-recipient: D combined MBL2 and FCN2 donor-recipient mismatch profile. P values were calcu-
lated with the use of the log-rank test.
Figure 1. Kaplan-Meier estimation of cytomegalovirus (CMV) infection in liver transplant 
recipients with functional lectin pathway polymorphisms.  
In the donor liver: A MBL2 variant carriers (VC) compared to MBL2 wild types (WT). B minor T-
allele of FCN2-C SNP compared to absence of the minor T-allele (FCN2-A). C combination of 
donor MBL2 (XA/O or O/O) and FCN2 (FCN2-A or FCN2-C). In donor-recipient: D combined 
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 In order to determine the risk of true CMV reactivation we additionally analyzed the 
rates of CMV infection in the subgroup of seropositive recipients who received a liver 
from a seronegative donor, i.e., the D-/R+ subgroup. In this particular group cumulative 
CMV infection occurred significantly more often in recipients who received a liver from 
an MBL deficient (XA/O or O/O) and FCN2-A (54%, HR 10.0, P=0.004) donor or in those 
with either one of these genotypes in the donor liver (35%, HR 4.7, P=0.04) compared to 
those with the MBL2 wild type and the presence of FCN2-C (9%, reference) (Figure S1). 
 Furthermore, in these D-/R+ patients an MBL2 mismatch, i.e., a sufficient recipient 
with a deficient donor liver, conferred a significantly increased risk for developing CMV 
reactivation compared to the other MBL2 combinations [59% (10/17) versus 27% (26/97) 
respectively, P=0.003]. The FCN2 mismatch, i.e., a FCN2-A recipient and a FCN2-C do-
nor liver showed a trend towards less frequent CMV reactivation when compared to 
the other combinations [17% (4/23) versus 35% (32/91) respectively, P=0.09].
 The combined MBL2 and FCN2 mismatch profile showed a notably higher risk for 
developing CMV infection when compared to the combined donor SNPs alone (5.35 
versus 3.26, see Table 3 and Table 2, respectively). Particularly the rates of reactivation 
in the CMV D-/R+ subgroup increased with the number of mismatches compared to 
no mismatches (mismatch in both MBL2 and FCN2 58%, HR 16.6, P=0.009; mismatch in 
MBL2 or FCN2  33%, HR 7.3, P=0.05). 
CMV disease in all OLT patients showed no significant relation with the number of vari-
ants present in the donor liver [10% (5/51) with no genetic variant; 13% (27/206) in those 
with one and 13% (5/38) in those with two variants] or the combined mismatch profile 
[8% (3/36) with no mismatch; 13% (29/224) in those with one and 14% (5/35) in those 
with two mismatches]. Occurrence of CMV disease in the D-/R+ subgroup showed 
a trend to increase with the number of variants present in the donor liver but this did 
not reach statistical significance [9% (2/23) with no genetic variant; 12% (9/78) in those 
with one and 23% (3/13) in those with two variants]. The mismatch profile showed an 
increase of CMV disease in case of an MBL2 mismatch [29% (5/17) versus 9% (9/97) re-
spectively, P=0.02] but no relation with FCN2 mismatches (data not shown). The com-
bined mismatch profile also showed a trend to increase with the number of mismatches 
but this did not reach statistical significance [6% (1/18) with no mismatch; 12% (10/84) in 
those with one and 25% (3/12) in those with two mismatches]. 
Covariates
Analysis of other factors associated with development of CMV infection using the uni-
variate Cox proportional hazards model is shown in Table 2. In this model the four strata 
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based on the CMV serostatus of donor and recipient showed a strong association with 
infection. Patients who were CMV D+/R- had the highest cumulative incidence of CMV 
infection (64%), followed by CMV D+/R+ (60%), CMV D-/R+ (32%) and CMV D-/R- 
(6%). CMV disease was most frequently observed in the CMV D+/R+ patients with a 
cumulative incidence of 17% (15/90), and 17% (7/42, 1 with suspected CMV hepatitis) 
in CMV D+/R-, followed by 12% (14/114, 1 with CMV gastritis) in CMV D-/R+, and 
2% (1/49) in CMV D-/R- patients. Male gender of the recipient was significantly associ-
ated with more frequent CMV infection. Furthermore, a (non-significant) trend was 
observed concerning the type of primary liver disease in relation to the risk of CMV 
infection. 
Multivariate analysis
In the multivariate Cox proportional hazards model, adjusting for risk factors associated 
with CMV infection (P<0.15), both donor MBL2 (XA/O or O/O) genotypes [HR 1.56 
(CI 1.01-2.42), P<0.05] and FCN2-A [HR 1.69 (CI 1.01-2.86), P<0.05] showed an indepen-
dent relation with CMV infection. In the multivariate Cox proportional hazards model, 
adjusting for risk factors associated with CMV infection, the gene-dose related combi-
nations of genetic variations in MBL2 and FCN2 in the donor liver [either gene HR 2.03, 
P<0.02; both genes HR 2.77, P<0.005], donor-recipient CMV serostatus pairs [HR ≥ 6.47, 
P<0.002] and antiviral treatment [HR 0.62, P<0.02] remained the only significant inde-
pendent predictors of an CMV infection after OLT (Table 2). All other clinicopathologi-
cal factors lost their predictive impact on the incidence of CMV. Despite the fact that 
antiviral prophylaxis was not associated with CMV infection in the univariate analysis 
(P=0.59) it was included in the multivariate analysis as a possible confounder. Since the 
multivariate model showed that the individual mismatches in MBL2 and FCN2 were 
independently associated with an increased CMV infection risk (Table 3) both donor-
recipient mismatch genotypes were included in the final multivariate model. An even 
higher CMV infection risk profile, compared to the donor gene profile alone (Table 2), 
was found for one or two mismatches as compared to no mismatch, with adjusted haz-
ard ratios of 3.09 [CI 1.34-7.11] and 4.57 [CI 1.83-11.40], respectively. To substantiate these 
observations we performed similar analyses at increasing cut-off values of pp65 and 
CMV-DNA for CMV positivity. The univariate and multivariate analysis results, broken 
down by extent of CMV positivity showed a consistent association between MBL2 and 
FCN2 genotype combinations, particularly the donor-recipient mismatches, and CMV 
infection.
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discussion
The present study revealed the association of polymorphisms in liver-derived members 
of the lectin pathway of complement activation with the occurrence of CMV infection 
after liver transplantation. In particular, liver transplant patients with single-nucleotide 
MBL2 polymorphisms (XA/O or O/O) in the donor liver had significantly increased rates 
of CMV infection compared to recipients of MBL2 wild type donor livers. Furthermore, 
the major allele of the FCN2 SNP rs7851696 (FCN2-A) of the donor liver increased the 
chance of CMV infection compared to the minor allele (FCN2-C). The joint genetic ef-
fect of these MBL2 and FCN2 genotypes in the donor liver and donor-recipient mis-
matches were even stronger. The involvement of mannose-binding lectin in the im-
mune response against CMV after solid organ transplantation was suggested earlier.6-9 
For example, the study from Cervera et al.7 reported that low-MBL genotypes of the 
pretransplant CMV positive recipient were associated with a higher proportion of CMV 
disease in renal transplantation, Despite the small number of patients (13%) who devel-
oped CMV disease in our OLT group we also found a trend between genotypically vari-
ant donor livers or donor-recipient mismatches and the development of CMV disease 
in pretransplant CMV positive recipients.
Our results indicate there is a pathogenetic link between several components of the 
lectin pathway of complement activation and the initial immune response against CMV 
after OLT, as we recently also reported for bacterial infections.2 Both lectins i.e., MBL 
and Ficolin-2 are known to exert their effects via binding of specific carbohydrates pre-
sented on the surface of pathogens leading to activation of the complement cascade and 
enhanced phagocytosis in the host. CMV glycoproteins consist of proteins which are 
covalently linked to carbohydrates, like mannose and N-acetylglucosamine. The single 
nucleotide polymorphisms in the MBL2-gene are associated with changes in avidity 
and production level of this lectin.4 The FCN2-C genotype was previously reported to 
be associated with stronger N-acetylglucosamine binding capacity compared to the 
wild type (FCN2-A).5 Therefore, gene polymorphisms of both lectins of the donor liver 
may very well contribute to their functional activity in the innate immune response 
against CMV after OLT.
The lectin complement pathway genes of the OLT recipients were not found to be in-
trinsically related to the risk of CMV infection but a major indirect contribution related 
to the genetic constitution of the donor liver was observed. Particularly, MBL sufficient 
recipients receiving an MBL deficient donor liver were found to be at high risk for CMV 
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infections, especially for CMV reactivation in the D-/R+ subgroup. In addition, a FCN2-
C donor liver reduced the chance for CMV infection in a FCN2-A recipient as opposed 
to the other FCN2 genotype combinations. These finding are to some extent similar to 
the observations we made previously with bacterial infections2, i.e., an association with 
the variant MBL2 genotype and the donor recipient mismatch. In contrast, however, 
with bacterial infections an association with FCN2-B and with MASP2 was found which 
was not observed with the CMV infection. These observations illustrate intrinsic dif-
ferences in the involvement of the lectin complement pathway in bacterial versus viral 
(CMV) infections after OLT.  
Viruses have developed different strategies to evade complement-mediated destruc-
tion. Modulation of host immune responses is a common strategy for promoting vi-
rus persistence and avoiding clearance. CMV is known to encode numerous immuno-
modulatory genes and is capable of altering several innate immune responses in favor 
of its own survival, for instance cytotoxicity, inhibition of NF-kB, etc.17-19 Complement 
activation is potentially harmful to the host by inducing tissue damage and is therefore 
carefully kept in place by regulators of complement activation. Inhibition of comple-
ment activation is important for CMV replication. So far no virus-encoded complement 
inhibitors have been identified for CMV, but several studies show that CMV upregu-
lates the expression of host-encoded (surface) complement inhibitors20 and counteracts 
complement activation by incorporation of host cell-derived complement regulatory 
proteins CD55 and CD59.21 Previous research also showed that the Toll-like receptor 2 
(TLR2) Arg753Gln gene polymorphism seems to be associated with CMV replication af-
ter liver transplantation.22 Interestingly, MBL is able to interact with TLR 2 in the phago-
some to initiate proinflammatory signaling23 and, although speculative, this might also 
play a role in CMV infection after OLT.
 In addition, there may be a subsequent mechanism by which MBL could be involved 
in CMV replication. MBL naturally occurs in two forms, S-MBL and I-MBL, which are 
synthesized mainly in the liver and translated from a single form of mRNA. S-MBL acti-
vates complement via the lectin pathway, whereas I-MBL acts as a putative intracellular 
cargo lectin for glycoprotein transport between the endoplasmic reticulum and Golgi ap-
paratus.24 The intracellular interaction of I-MBL with HMCV glycoproteins may thereby 
disrupt CMV virion assembly or formation, restricting CMV replication and transmission.
Liver transplant recipients who were initially seronegative for CMV, but received a graft 
from a CMV positive donor are at greatest risk for CMV infection, similar to the ob-
servations with other organ transplants.25 These D+/R- OLT patients always receive 
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CMV prophylaxis and constitute only a small percentage (14% 42/295) of our patients. 
Probably, therefore no association with the lectin and pathway genes was found in this 
group. Of the CMV seropositive recipients only some will develop CMV reactivation 
and the optimal strategy for prevention of CMV infection in this subgroup has not yet 
been established. In our study, in CMV seropositive recipients who received a liver from 
a CMV negative donor, reactivation of CMV occurred significantly more often when the 
donor liver was MBL-deficient. The presence of the minor allele of the FCN2-C SNP of 
the donor liver limited CMV infection compared to the presence of the major A-allele.
 The impact of the lectin pathway genes in the CMV (re)infection process was rein-
forced by our observation that their contribution remained impressive even at higher 
cut-off values in the CMV seropositive recipients. In the CMV seronegative recipients 
any CMV detection is already indicative for infection and necessitates treatment. Al-
though the associations we found are observational findings, it is tempting to speculate 
that in CMV negative donors, due to the primary exposure of the liver to CMV from the 
recipient, the mentioned CMV-induced immune evasion responses have not yet been 
modulated by the virus, and therefore functional MBL and FCN2-C from the donor 
might still exert their initial protective effect.  
 At present genetic risk factors for CMV infections are insufficiently understood, but 
a possible clinical application of our findings would be to screen for presence of MBL2-
FCN2 risk alleles in the donors for the CMV serostatus D-/R+ patients and subsequently 
intensify viral load or antigenemia monitoring in high risk patients.
There are some theoretical limitations to our study. Firstly, it is a retrospective study; 
nevertheless, frequencies of the studied SNPs associated with MBL deficiency and of the 
FCN2-C SNP in both donors and recipients were comparable to the frequency reported 
by others in healthy Caucasian populations.26-29 Furthermore, the two independent co-
horts showed a consistent association and were comparable with regard to the genetic 
profile and the occurrence of CMV infection/reactivation (Figure S2) but separately did 
not have enough power, i.e., numbers to be conclusive. Secondly, despite a relatively 
large combined patient cohort, only a small number of patients (13%) developed CMV 
disease or tissue invasive disease (2 patients). These numbers were too small to perform 
robust statistical analyses on CMV disease in the different subgroups. Therefore we 
limit our interpretation to the observation that donor and recipient MBL2 and FCN2 
polymorphisms contribute to the CMV infection and /or reactivation in OLT recipients.
In conclusion, the present study strongly suggests an association between the occur-
rence of CMV infection and donor/recipient MBL2 and FCN2 gene polymorphisms in 
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liver transplant patients, independent from other risk factors. These observations may 
have potential clinical implications, as recently discussed regarding this component of 
the innate immune system and infections after liver transplantation in general.30 There-
fore, further studies on these genetic risk factors in liver transplantation, including lon-
ger follow-up, more patient cohorts, and patients with invasive CMV disease, could 
contribute to novel CMV infection prevention strategies in these patients.
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Table S2.  Frequencies of Lectin Pathway Gene Polymorphisms in Orthotopic Liver Transplant 
Recipients and Donors.
Genotype Donor Recipient








secretor haplotype a, b A/A and YA/O 38 (93)* 62 (152) 43 (107) 57 (144)
XA/O and O/O 54 (27)* 46 (23) 30 (13) 70 (31)
FCN2
rs17549193 +6359 (B) C"T T236M CC 40 (55) 60 (84)
CT 41 (52) 59 (75)
TT 45 (13) 55 (16)
rs7851696 b +6424 (C) G"T A258S GG 44 (103)* 56 (129) 41 (96) 59 (136)
GT 28 (17)* 72 (43) 38 (23) 62 (37)
TT 0 (0)* 100 (3) 33 (1) 67 (2)
MASP2
rs72550870 +105 A"G D105G AA 41 (114) 59 (164)
AG 35 (6) 65 (11)
GG 0 (0) 0 (0)
rs12711521 +371 G"T D371Y AA 39 (74) 61 (117)
AC 44 (41) 56 (53)
CC 50 (5) 50 (5)
CMV denotes cytomegalovirus, *P Values <0.05, calculated with the use of the univariate Cox proportional-hazards 
survival analysis
a Five single nucleotide polymorphisms in MBL2 were genotyped: MBL2 -550 (H/L), rs11003125; MBL2 -221 (X/Y), 
rs7096206; MBL2 codon 52 (D), rs5030737; MBL2 codon 54 (B), rs1800450 and MBL2 codon 57 (C), rs1800451. Structural 
variants D, B and C are collectively called O; where A is considered wild type; Secretor haplotypes were constructed: 
A/A and YA/O versus XA/O and O/O.
b SNP distribution (%) of the donors and recipients were comparable to the frequency reported by others in healthy 
Caucasian populations.
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Figure S1.  Kaplan-Meier estimation of cytomegalovirus (CMV) infection in liver transplant re-
cipients with functional lectin pathway polymorphisms in the donor liver according to 
the four strata based on the CMV serostatus of donor (D) and recipient (R). 
MBL2 wild types (WT): A/A or YA/O; MBL2 variant carriers (VC): XA/O or O/O; FCN2-A: absence of the minor T-allele; 
FCN2-C: presence of minor T-allele. P values were calculated with the use of the log-rank test.
 
Supplem ntal Figure 1. Kaplan-Meier estimation f cytomegalovirus (CMV) infection in liver tr splant recipients 
with functional lectin pathway polym rphisms the donor liver according to the four strata based on the CMV 
serostatus of donor (D) and recipient (R).  
 
MBL2 wild types (WT): A/A or YA/O; MBL2 variant carriers (VC): XA/O or O/O; FCN2-A: absence of the minor 
T-allele; FCN2-C: presence of minor T-allele. P values were calculated with the use of the log-rank test. 
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Figure S2.  Kaplan-Meier estimation of cytomegalovirus (CMV) infection in liver transplant re-
cipients with functional lectin pathway polymorphisms in the donor liver for both 
independent centers. 
 
Supplemental Figure 2. Kaplan-Meier estimation of cytomegalovirus (CMV) i fection in liver transplant recipients 
with functional lectin pathway polymorphisms in the donor liver for both independent centers.  
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Figure S2.  Continued
P values were calculated with the use of the log-rank test.
A MBL2 variant carriers (VC) compared to MBL2 wild types (WT). 
B minor T-allele of FCN2-C SNP compared to absence of the minor T-allele (FCN2-A). 
C combination of donor MBL2 (XA/O or O/O) and FCN2 (FCN2-A or FCN2-C).
D combined MBL2 and FCN2 mismatch profile.
 
Supplemental Figure 2. Kaplan-Meier estimation of cytomegalovirus (CMV) infection in liver transplant recipients 
with functional lectin pathway polymorphisms in the donor liver for both independent centers.  
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HerPes simPlex virus tyPe-1
Role in oral ulcerations
Based on our knowledge of the pathogenesis of HSV-1 infections a causative role for 
HSV-1 in oral ulcerations in hematopoietic stem cell transplant (HSCT) recipients is very 
plausible. However, the contribution of herpesviruses to oral ulcerations in this setting 
has never been studied systematically, by sampling all cases regardless of the presence 
of ulcerations. The multifactorial etiology of oral ulcerations during and after HSCT and 
the fact that asymptomatic oral shedding of serveral viruses has been described during 
immunesuppression warrant this type of study, as described in chapter three. 
Hence, the relative contribution of chemoradiation and different herpesvirus infections 
to oral ulceration after HSCT was studied. In the study in chapter three the presence of 
HSV-1 was a significant positive predictor for both ulcerative mucositis and ulcerations 
of the keratinized mucosa. Truly asymptomatic oral HSV-1 shedding occurred rarely. 
Since conditioning regimen and donortype were no predictors of oral ulcerations and 
since the rate of HSV-1 shedding was high, the relative contribution of HSV-1 to oral 
ulcerations after HSCT should be considered large. These findings support the use of 
antiviral prophylaxis with (val)aciclovir ((v)ACV) in this patient group.1-6 Without pro-
phylaxis, prompt administration of antivirals upon the development of oral ulcerations 
awaiting viral diagnostics should certainly be considered. 
Interestingly, also the presence of EBV in oral washing samples was an independent 
predictor of oral ulcerations on the keratinized mucosa, but not of ulcerative mucositis. 
The pathogenetic role of EBV in oral ulcerations is not well-known. EBV has clearly been 
associated with oral hairy leukoplakia in various categories of immunocompromised 
patients.7 EBV-associated oral ulcerations have also sporadically been described.8,9 
However, a causative role of EBV in oral ulcerations shortly after HSCT has not been 
proven by our study nor by others. Its presence may rather be the consequence of in-
creased shedding in the presence of (HSV-1-induced) ulcers rather than being the cause 
of ulceration. Prophylaxis of HSV-1 with (v)ACV may decrease oral shedding of EBV, 
because EBV is susceptible to ACV during lytic infection.10-15 Still, it is unclear whether 
EBV in oral ulcerations represents lytic infection, comparable to mononucleosis and oral 
hairy leukoplakia, or expansion of latently EBV infected cells, comparable to EBV re-
lated lymphoproliferative disorders, and the response to antiviral prophylaxis is there-
fore uncertain.16-21 Certainly, the possible role of EBV in oral lesions in HSCT recipients 
merits further study.




In clinical diagnostics, viral sequence analysis to detect resistance-associated mutations 
has the advantages of speed and technical ease. Nevertheless, as shown previously22;23 
and in chapter two and three, mutations of unknown significance are commonly found 
in HSV-1 clinical isolates. This demonstrates the need for a phenotypical susceptibility 
test to establish the significance of such mutations. The classical plaque reduction assay 
(PRA) can be used for this purpose, but because of its long assay time, a faster assay is 
needed.
 In the study described in chapter two a faster and more easily applied protocol for 
phenotypical susceptibility testing of HSV-1 was developed. Results of the DNA reduc-
tion assay (DRA) compared very well to results obtained by genotypic tests and by PRA. 
Moreover, low level resistance to ACV and FOS was more accurately detected by DRA 
than by PRA. However, low-level resistance or intermediate susceptibility is not defined 
in the CLSI protocol24 or by breakpoints suggested previously25 and it remains to be 
investigated if infections with such isolates should be treated differently from high-level 
resistant isolates.
A two-step approach is likely to be most practical in the clinical setting, starting with 
target gene sequencing of, preferably, a pre- and on-treatment sample and subsequent 
phenotypical confirmation of resistance if mutations of unclear significance are encoun-
tered. As described in chapter two, DRA was successfully applied to confirm susceptibil-
ity to ACV in an isolate with a previously not well characterized mutation.22;26 Also, in 
chapter three DRA demonstrated ACV resistance in an isolate with a novel mutation. 
This demonstrates the utility of a two-step approach for HSV-1 resistance analysis.
Treatment failure and antiviral resistance
In chapter three, HSCT recipients were systematically monitored for persistent oral 
replication of HSV-1. Oral shedding after a standard course of antiviral therapy for 
five days occurred in 43% of the patients and was due to resistance in 18% of treated pa-
tients. Of course, sensitive detection of HSV-1 DNA by real-time PCR after ulcerations 
have (almost) healed may account for part of the persistence. However, given the very 
short half-life of DNA,27-31 such detection must represent at least recent viral replication 
rather than being a remnant of past replication. 
The retrospective analysis of resistance in our study hampers establishing the clinical 
significance of the infections with resistant HSV-1. Probably, resistant isolates have re-
duced fitness and virulence32;33 or are rapidly cleared as soon as immunological recov-
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ery occurs. Nevertheless, a protracted course with severe ulceration occurred in sev-
eral patients in our study and as patients have reported that oral mucositis was the 
single most debilitating side effect of HSCT conditioning,34 its possible clinical relevance 
should not be ignored. Therefore, persistent oral ulcerations despite antiviral treatment 
demand viral diagnostics and antiviral resistance testing, to optimize treatment, both 
for patients with and without resistant HSV-1. 
varicella-zoster virus
Antiviral resistance
Because VZV is a rather slow growing and highly cell-associated virus and is often pres-
ent in samples from which it cannot be cultured (plasma, CSF), resistance analysis is 
usually performed by sequence analysis of the genes involved in antiviral resistance.35-40 
As described previously41 compartmentalization of antiviral resistance in sanctuary sites 
such as CSF and eye was found in a relevant proportion of the patients with resistant 
virus in our study in chapter four. In addition, amplification of full length viral genes 
from CSF and eye samples was often problematic necessitating us to adapt the protocol 
for such samples (using smaller amplicons). This may be related to the viral loads in the 
samples, but may also be due to the presence of fragmented viral DNA.42
Using sequence analysis as a resistance assay, the significance of mutations that have 
not been described before, which were found in half of the patients with resistant virus 
in chapter four, cannot be determined with certainty. Comparing sequences between 
pre-treatment and on-treatment samples from a patient can partly overcome this limita-
tion. Nevertheless, phenotypical confirmation assays43;44 that can be performed without 
the need for a viral isolate will be a useful addition to the diagnostics of antiviral resis-
tance of VZV.
Treatment failure and antiviral resistance
The study in chapter four aimed to investigate the occurrence and significance of per-
sistence and antiviral resistance systematically by analyzing all episodes of VZV in he-
matological patients between 2007 and 2010. VZV episodes with a duration of at least 
7 days were demonstrated in 59% of the episodes and were associated with complica-
tions in 50% of the episodes. Persistence was accompanied by antiviral resistance in 27% 
of the cases and some cases of resistant VZV concerned very complicated cases with 
unfavorable outcome. 
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Due to the retrospective and biased nature of the study, the significance of virological 
persistence without clinical persistence is unclear. However, it was shown that com-
bined clinical and virological persistence may predict complications. Therefore, routine 
follow up after a VZV episode by PCR on blood samples has no proven additional pre-
dictive value, also because the consequence of asymptomatic persistence for antiviral 
treatment is unclear. Since antiviral resistance explained a relevant part of the persistent 
episodes, antiviral susceptibility testing should be performed timely and comprehen-
sively (i.e. studying all affected body sites), to optimize patient management. 
cytomegalovirus
Predictors of infection
Immunological determinants of the occurrence and outcome of CMV infection in trans-
plant recipients have been studied widely.45-67 Improved prediction on the basis of these 
immunological determinants of patients at risk for (complicated) CMV infections after 
transplantation could individualize prevention strategies. 
As described in chapter eight, orthotopic liver transplant recipients were shown to 
have significantly increased rates of CMV infection if single-nucleotide polymorphisms 
(SNPs) were present in the gene for mannose-binding lectin 2 (MBL2) in the donor liver 
that are associated with decreased synthesis of MBL2. Furthermore, the risk of CMV in-
fection was decreased in the presence of the minor allele of the Ficolin-2 (FCN2) gene in 
the donor liver that is associated with improved ligand binding. The joint genetic effect 
of these MBL2 and FCN2 genotypes in the donor liver was even stronger. 
 Interestingly, especially patients with the favorable genotype combination who re-
ceived a liver with the unfavorable genotype combination had an increased risk for 
developing CMV reactivation compared to all other recipient-donor combinations. In 
contrast, recipients with an unfavorable genotype were not at increased risk of CMV. 
This suggests that some adaptation to or compensation for the potentially unfavorable 
genotypes of MBL2 and FCN2 occurs normally that is not transferred with the donor 
liver. The absence of this compensation in recipients with a favorable genotype com-
bination, increases the risk of infection when receiving a liver from a donor with the 
unfavorable genotype combination.
 The effects of MBL2 and FCN2 SNPs were most clear in CMV seropositive recipients 
of a liver from a CMV seronegative donor, who constitute a relevant proportion of liver 
transplant recipients. For this group, the optimal CMV prevention strategy has not been 
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defined and identifying immunological correlates of protection against severe CMV 
may aid in choosing the optimal strategy. However, as shown in our study the effect 
of SNPs in innate immunity genes is complex and their predictive potential should be 
studied in clinical trials before their use can be implemented in routine clinical practice.
Treatment 
The optimal prevention strategy for CMV disease in renal transplant recipients has not 
been established yet.68-71 In chapter seven the two most frequently applied regimens 
for the prevention of CMV disease in D+R- renal transplant recipients were systemati-
cally compared retrospectively. Patients treated in a purely preemptive strategy were 
compared with patients who were treated initially with three months of valganciclovir 
(vGCV) prophylaxis followed by a preemptive regimen. Prophylaxis effectively post-
poned CMV infections and reduced the percentage of patients reaching high CMV 
loads, as well as the AUC of CMV DNAemia, the duration of subsequent preemptive 
treatment episodes and the occurrence of treatment failure. No CMV end-organ disease 
occurred in either cohort. 
The relatively mild course of CMV DNAemia during a preemptive regimen after initial 
prophylaxis in our study and in studies by others72 demonstrated the effectiveness of 
regular CMV monitoring to prevent CMV disease. The severe outcomes of late-onset 
CMV disease reported in previous studies in which prophylaxis was not combined with 
a subsequent preemptive regimen emphasize the importance of regular monitoring af-
ter the end of prophylaxis in preventing late-onset CMV disease.72;73 The optimal fre-
quency and duration for monitoring remain to be studied.74 Reluctance to include CMV 
monitoring is probably explained by the presumed costs of continued CMV monitoring 
after transplantation.68-71 However, timely and thus more effective CMV treatment re-
duces the number of expensive hospital days for intravenous antiviral treatment and 
reduces long-term morbidity, including graft loss.75-78 
Antiviral resistance
In case of treatment failure a rapid diagnosis of resistance is valuable. GCV resistance as-
sociated mutations in clinical isolates mainly map to the viral kinase gene UL97.79-83 Se-
quence analysis is the fastest method for susceptibility testing of CMV. Novel techniques 
such as mass-spectrometry based comparative sequence analysis (MSCSA) combine the 
possibility of detection of all nucleotide variations within a target gene with reduced 
hands on time due to the automation of post-PCR processing and analysis.84-86 
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In chapter five, we investigated the applicability of an MSCSA method for automat-
ed high-throughput DNA sequence analysis for the detection of mutations in the 
UL97 gene. MSCSA was found to be equally accurate compared to conventional se-
quencing techniques and the sensitivity of mutation detection in a mixture was com-
parable as well. The accuracy of SNP detection by MSCSA was largely dependent on 
the quality (and quantity) of the sequences in the reference database, as performance 
improved considerably when the databases were supplemented with new sequences. 
Since MSCSA did not improve mutation (mixture) detection, its benefit lies mainly in 
its suitability for high-throughput analysis. With the relatively rare occurrence of GCV 
resistant CMV there is no such requirement. However, its ability to accurately detect 
resistance associated mutations in CMV is a proof of principle for its applicability in set-
tings where larger amounts of samples can be expected, such as detection of resistance 
mutations in human immunodeficiency virus or influenza. 
Currently, CMV resistance testing can be rapidly and easily performed by routine se-
quencing techniques. As shown in chapter six and seven, phenotypical confirmation 
of mutations is seldom required, since the number of mutations is rather limited and 
knowledge on the significance of these mutations is sufficiently available.
Treatment failure and antiviral resistance
The occurrence and possible causes of persistent CMV infection despite antiviral treat-
ment were studied in two different cohorts of transplant recipients in chapter six and 
seven. In both studies, treatment failure was defined as the presence of at least 1000 cop-
ies/ ml of CMV DNA in plasma after a standard course of two weeks of treatment of 
CMV infection. Because the half-life of viral DNA in blood is probably very short,27-31 
plasma DNAemia is a correlate for recent viral replication.87 This view is supported by 
the fact that viral loads decreased rapidly, with or without antiviral treatment, in many 
patients in our studies.
In D+R- renal transplant recipients treatment failure occurred in 52% of the treated pa-
tients (chapter seven). Undergoing a preemptive treatment regimen (i.e. without prior 
prophylaxis) and a high peak CMV load were found to be associated with treatment 
failure. In recipients of an allogeneic T-cell depleted HSCT who were at risk for CMV 
(donor and/or recipient CMV seropositive) treatment failure occurred in 55% of the 
treated patients (chapter six). The risk of treatment failure was increased during first 
treatment episodes and during the use of immunosuppressive medication. A high CMV 
load at the start of treatment was a predictor in univariable analysis only. 
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In both patient groups a comparable incidence of treatment failure of approximately 
50% was found. This number is in accordance with previous studies in renal trans-
plant recipients in which preemptive treatment resulted in a median time to clear 
DNAemia of 14-15 days and between 13 to 20 days, respectively.88;89 For HSCT recip-
ients varying rates of treatment failure have been reported from 7% up to 45%.90-93 
Different definitions of failure as well as differences in antiviral treatment regimens 
probably play a role in these variations. The similarity in the rates of treatment fail-
ure in the two very different patient groups studied in this thesis at least demon-
strates that CMV replication often persist during antiviral treatment in transplant 
recipients.69-71 
Predictors of treatment failure were different between the two types of transplant recip-
ients. Apart from differences of patient characteristics and types of immune deficiencies 
between the two groups, variations in the analysis may account for some of the differ-
ences. In chapter seven, predictors were analyzed on a patient level, whereas in chapter 
six predictors were studied for each CMV episode. The latter method takes into account 
the effects of repeated measures per patients and increases statistical power and, in 
retrospect, would have been the preferred method in the study described in chapter 
seven. Nevertheless, as expected,89;94;95 the height of the viral load at the beginning of 
antiviral treatment was a predictor (albeit univariable) in both studies. The relation with 
immunosuppressive medication and first episodes in HSCT recipients is logical, since 
lack of antiviral immunity allows for higher levels of viral replication hence increasing 
the time to clear CMV DNAemia. 
The contribution of antiviral resistance to persistence was studied in both cohorts as 
well. Resistance was found in only one of 47 HSCT patients (2%) with CMV treatment. 
In D+R- renal transplant recipients resistance was found in four of 42 patients (9.5%) 
with CMV treatment. Hence, in both patient groups low although different rates of 
GCV resistance were found and four of five CMV infections with resistant virus were 
eventually cleared without switching antiviral therapy. 
This implicated that in the majority of the cases persistent infection despite treatment is 
not due to antiviral resistance and that switching antiviral treatment to more toxic sec-
ond line agents was often not necessary. Also, it demonstrated that antiviral resistance 
does not appear to be a negative consequence of a sequential prophylaxis-preemptive 
treatment regimen.96 Our findings are in accordance with previous studies systemati-
cally addressing resistance,91;92;96-98 but in contrast to studies on symptomatic CMV, in 
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which resistant CMV was found more frequently and more often caused CMV disease 
with an unfavorable outcome.99;100 Explanations for this discrepancy may lie in the 
fact that in our studies resistance was studied regardless of symptoms and that CMV 
disease was effectively prevented in our patients. This emphasizes, again, the need 
for CMV monitoring to prevent disease. The results from both studies show that the 
role of antiviral resistance testing lies merely in reassuring clinicians to continue first 
line treatment awaiting viral clearance by the immune system. In addition, cessation 
of treatment in some cases of persistent infection may be safe as well and should be 
further studied. 
future directions
The aim of this research was to develop and improve diagnostic tools in order to rapidly 
diagnose HSV-1, VZV and CMV resistance to antiviral agents. Subsequently, the contri-
bution of antiviral resistance and other predictors to persistent infections with HSV-1, 
VZV and CMV were studied. 
Treatment failure
As shown in various chapters, persistence of herpesvirus DNA after a standard course 
of treatment is detected in about 50% of immunocompromised patients. If persistence 
is accompanied by clinical disease it is evident that additional antiviral treatment is re-
quired. However, the treatment of virological persistence without signs or symptoms 
of infections is a matter of debate. Of course, one should treat the patient and not the 
laboratory results, but in a preemptive setting this distinction is absent by definition. 
In addition, prolonged treatment of ongoing viral replication harbors the risk of select-
ing resistant virus. This emphasizes the limitations of our knowledge of the required 
treatment duration for herpesvirus infections after transplantation. In our studies the 
treating physicians usually have chosen to prolong treatment in patients with treatment 
failure. However, the duration of treatment of herpesvirus infections after transplan-
tation is not based on controlled clinical trials and it is unknown whether treatment 
should be continued if viral replication persists after a course of treatment. Possibly, 
immune monitoring and viral dynamics may aid not only in deciding in whom to start 
antiviral treatment, but also in whom to safely end treatment.94;101 At least one clinical 
trial is currently being performed on this topic.101 Such studies may tailor the duration 
of antiviral treatment. For a flow chart on the suggested treatment of persistent herpes-
virus infections, see Figure 1.
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It appears from the presented observations that antiviral immunity is the main determi-
nant of treatment response. Interesting and promising in this regard are the current tri-
als (http://clinicaltrials.gov/) on the effectiveness of pre-transplantation CMV and VZV 
vaccination strategies in preventing the occurrence or changing the course of these her-
pesvirus infections after transplantation.102 
Antiviral resistance
Also shown in various chapters is the fact that persistent herpesvirus infection is ex-
plained by resistance in only a minority of the cases. Often, resistance was associat-
ed with a severe clinical course of the infection, but sometimes resistant viral isolates 
cleared spontaneously without appreciable clinical problems. These findings emphasize 
the need for rapid and adequate diagnostics of antiviral resistance in cases of persistent 
clinical and virological infection. Susceptibility testing will rule out resistance in most 
cases thus avoiding the need for second line agents with their associated toxicity and 
need for intravenous administration. In addition, it will optimize treatment in patients 
with resistant virus who not seldomly have serious organ manifestations.
Diagnosing antiviral resistance was found to be most straightforward in CMV where 
simple sequencing analysis suffices in most instances. Web based software tools, such as 
ReCall (RECall beta v2.6, http://pssm.cfenet.ubc.ca/home/index) can be applied for her-
pesvirus sequence analysis and may facilitate sequence analysis in routine diagnostics. 
For HSV and VZV, a two step approach is required, starting with sequence analysis and 
followed by phenotypical confirmation if mutations of unclear significance are found. 
An additional difficulty for VZV is the fact that usually viral isolates cannot be obtained. 
The latter point deserves further assay development. Possible compartmentalization 
demands investigation of virus in all affected body sites. For a flow chart on suggested 
diagnostics in case of persistent herpesvirus infections, see Figure 1.
There is a relevant need for less toxic and oral alternatives for antiviral treatment in case 
of antiviral resistance. For HSV several trials exploring novel antiviral drugs have been 
done (e.g. helicase-primase inhibitors) and are ongoing (e.g. NB-001, BTL TML HSV, 
http://clinicaltrials.gov/) and pre-clinical studies have been performed for other new 
drugs.103;104 For CMV novel agents for treatment including CMX001 are being investi-
gated.105-107 For VZV an as yet unpublished clinical trial on the effectiveness of FV-100 
has been performed (http://clinicaltrials.gov/). This increases the number of options for 
antiviral treatment in case of resistance. As a consequence, susceptibility testing needs 
to be adapted continuously to include novel antivirals.
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The research described in this thesis aimed to study determinants of the course and 
outcome of treatment of herpesvirus infections in immunocompromised patients. 
Both viral factors, such as antiviral resistance, but also patient factors, including im-
munological parameters, were investigated. Techniques to study antiviral resistance 
were optimized for use in a clinical diagnostic setting. The aim of this research was 
to improve and facilitate management of herpesvirus infections in immunocompro-
mised patients.
In chapter two the development and validation of a real-time pcr based phenotypical 
technique to study susceptibility of HSV-1 to antiviral drugs in a routine diagnostic 
setting is described. This assay was designed to be faster and less labor intensive than 
classical culture based phenotypical susceptibility tests for HSV-1, such as the plaque 
reduction assay.
 The results from our DNA reduction assay (DRA) were in accordance with plaque 
reduction assay results and with sequence analysis. DRA appeared to have a better 
discriminative value for low-level resistance. Although the direct application of DRA 
in clinical samples appeared not possible, short pre-culture of 48 hours was sufficient 
and ensured results within a clinically relevant time frame of 5 days. 
Oral ulcerations are frequent and debilitating complications after hematopoietic stem 
cell transplantation (HSCT). In chapter three the role of HSV-1, EBV and CMV in oral 
ulcerations in HSCT recipients was investigated. Insight on the precise role of herpes-
viruses in this setting may improve management.
 In a prospective observational cohort study in 49 adult patients that underwent 
allogeneic HSCT, the occurrence and localization of oral ulcerations and the presence 
and quantity of HSV-1, EBV and CMV in oral washing samples were systematically 
documented. Persistent HSV-1 infection was defined as an infection that lasted at 
least 5 days despite antiviral treatment. Antiviral resistance was studied in all persis-
tent HSV-1 infections by viral sequence analysis.
 Having an HSV-1 or EBV DNA positive sample was found to be a significant pre-
dictor for ulceration of keratinized mucosa. HSV-1 was a significant predictor for 
ulcerations on non-keratinized mucosa as well. Furthermore, persistent HSV-1 in-
fection occurred in 12 of 28 patients treated with antiviral medication and aciclovir 
resistant HSV-1 was found in 5 persistent infections. In conclusion, given the impor-
tant role of HSV in oral ulcerations after HSCT, prophylaxis or rapid treatment of oral 
HSV-1 infection and timely resistance diagnosis are warranted after HSCT.
proefschrift.indd   165 8-10-2012   19:21:05
Summary
166
VZV infections are a relevant cause of morbidity and mortality in hematological pa-
tients and especially in HSCT recipients. However, little is known on the course and 
on the occurrence of antiviral resistance of VZV in this setting. In chapter four the 
course of VZV infections in hematological patients was studied including the role of 
antiviral resistance in persistent infections.
 In a retrospective study including all 87 pediatric and adult hematological pa-
tients diagnosed with VZV in our laboratory between 2007 and 2010, the clinical and 
virological course of VZV infections was studied. Persistent infection was defined as 
an infection that lasted at least 7 days. Antiviral resistance was studied in all persis-
tent infections by viral sequence analysis.
 Persistent VZV was demonstrated in 59% of the 54 episodes with follow-up avail-
able. Complications occurred in 50% of the persistent episodes and possible resis-
tance associated mutations were found in 27% of the patients with persistent VZV, 
including patients with treatment unresponsive dermatomal zoster that progressed 
to severe retinal or cerebral infection. Therefore, antiviral resistance of VZV needs to 
be investigated timely and in all affected body sites in persistent infections.
In chapter five the application of a novel technique using mass spectrometry-based 
comparative sequencing to detect ganciclovir resistance in CMV is addressed. Mass 
spectrometry-based comparative sequence analysis (MSCSA) might be advantageous 
for this purpose because of its suitability for semi-automation. 
 Comparison of results from MSCSA with conventional cycle sequencing showed 
94.1% concordance. The threshold to detect mutant sequences in a mixture with 
wild-type material was 20% using either technique. Thus, MSCSA was found to be 
equally accurate compared to conventional cycle sequencing in the analysis of the 
UL97 gene of HCMV
Pre-emptive treatment of CMV infections does not always lead to a rapid viral response. 
The causes of this type of treatment failure can be diverse and include antiviral resis-
tance, pharmacological aspects and immunological factors. In chapter six various de-
terminants of the response to antiviral treatment of CMV infections in HSCT recipients 
were studied, including resistance to antivirals. 
 Consecutive adult recipients of allogeneic T-cell depleted SCT were studied retro-
spectively (n=92). Treatment failure was defined as a CMV DNA load of 1000 copies/
ml or more after at least 2 weeks of treatment. Resistance was analyzed in all failure 
episodes by viral sequence analysis. 
 Treatment failure occurred in 45% of pre-emptive treatment episodes and occurred 
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more often during first treatment episodes and during the use of immunosuppressive 
medication. Antiviral resistance was found in only 1 patient with treatment failure. 
Hence this study showed that a slow response to pre-emptive antiviral treatment oc-
curred frequently in this setting and that antiviral resistance played a minor role.
In chapter seven the response to treatment and the occurrence of antiviral resistance 
are compared between a preemptive and a sequential prophylactic-preemptive treat-
ment regimen for CMV in D+R- renal transplant recipients. 
 Consecutive adult D+R- recipients of a renal transplant were studied retrospec-
tively. Before 2006, a preemptive treatment regimen with valganciclovir was applied 
(42 patients). From 2006 onwards, patients first received prophylaxis with valganci-
clovir for 90 days, followed by a preemptive regimen (29 patients). Treatment failure 
was defined as a CMV DNA load of 1000 copies/ml or more after at least 2 weeks of 
treatment. Resistance was analyzed in all failure episodes by viral sequence analysis. 
 Treatment failure occurred less frequently in the prophylaxis cohort than in the 
preemptive cohort (14% vs. 71%). Resistant viral isolates were found during treat-
ment in one patient in the prophylaxis cohort versus in three patients in the preemp-
tive group. All CMV infections with resistant virus were cleared without switch of 
(val)ganciclovir treatment. In conclusion, treatment failure occurred not frequently 
in the sequential prophylaxis-preemptive cohort and antiviral resistance played a mi-
nor role in treatment failure.
The lectin pathway of complement activation, component of the innate immunity, is 
a crucial effector cascade of the innate immune response to pathogens. Because many 
effector proteins from this pathway are synthesized in the liver, after liver transplan-
tation a unique situation exists in which a recipient acquires the donor derived geno-
type en phenotype. In chapter eight the role of gene polymorphisms influencing 
mannose-binding lectin (MBL2), ficolin-2 (FCN2) and MBL-associated serine protease 
(MASP2) on CMV infection after orthotopic liver transplantation was investigated. 
 Transplant recipients (n=295) and donors were genotyped for polymorphisms 
in MBL2, FCN2 and MASP2 genes. Combined analysis of independently associated 
variant MBL2 and wild-type FCN2 SNPs in the donor liver showed an increased risk 
of CMV infection for either and both risk genotypes, especially in D-R+ patients. A 
genetic donor–recipient mismatch for MBL2 and FCN2 increased the CMV risk inde-
pendently, also combined, particularly in CMV D-/R+ patients. In conclusion, MBL2 
and FCN2 risk alleles of donor liver and recipient constitute independent risk factors 
for CMV infection after OLT. 
proefschrift.indd   167 8-10-2012   19:21:05
Summary
168
In the discussion, implications for management of herpesvirus infections in immu-
nocompromised patients as well as suggestions for further research are described.
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Inleiding
Het onderzoek zoals beschreven in dit proefschrift betreft het beloop en de gevolgen 
van infecties met herpesvirussen bij immuungestoorde patiënten. Herpesvirussen ko-
men veel voor en leiden na besmetting tot een levenslange, zogenoemd latente, infectie. 
Doorgaans verlopen deze latente infecties onopgemerkt, maar wanneer sprake is van 
een verminderde afweer kunnen zij opvlammen, reactiveren genoemd, en tot ernstige 
ziektebeelden leiden. De herpesvirussen die behandeld worden in dit proefschrift staan 
weergegeven in Tabel 1. 
Tabel 1. Humane herpesvirussen behandeld in dit proefschrift.
virus ziektebeeld bij eerste besmetting ziektebeeld bij reactivatie
Herpes simplex virus type 1 blaasjes in de mond koortslip, zweren in mond/keel
Varicella-zoster virus waterpokken gordelroos
Epstein-Barr virus ziekte van Pfeiffer tumoren, slijmvliesafwijking mond
Cytomegalovirus ziekte van Pfeiffer koorts, ontsteking van inwendige 
organen, ogen, hersenen
Zo kan een infectie met het herpes simplex virus type 1 (HSV-1) bij reactivatie leiden 
tot een koortslip en bij ernstig gestoorde afweer tot uitgebreide pijnlijke afwijkingen in 
en om de mond. Wanneer een latente infectie met varicella zoster virus (VZV) opvlamt 
kan dit leiden tot een lokale ophoping van pijnlijke blaasjes, beter bekend als gordel-
roos, maar uitgebreidere huidafwijkingen en aantasting van interne organen, ogen en 
hersenen kan ook voorkomen. Tenslotte kan reactivatie van een latente infectie met 
cytomegalovirus (CMV) koorts veroorzaken, evenals infectie van bijna alle interne or-
ganen, ogen en hersenen.
 Bij immuungestoorde patiënten wordt daarom behandeling met antivirale midde-
len toegepast om symptomen te voorkomen of verminderen. In dit proefschrift is bij 
patiënten met een verminderde afweer onderzocht hoe deze drie herpesvirussen rea-
geren op behandeling met antivirale middelen en of er sprake is van resistentie tegen 
antivirale middelen, wanneer de infectie niet vlot herstelt. Daarnaast zijn technieken 
opgezet om resistentie te kunnen aantonen bij de verschillende virussen.
Hoofdstuk 2
In hoofdstuk 2 wordt de opzet beschreven van een nieuwe techniek om de gevoelig-
heid van HSV-1 voor antivirale middelen te bepalen. Bij de zogenaamde fenotypische 
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gevoeligheidstesten wordt bepaald in welke mate antivirale middelen de vermenig-
vuldiging van een virus remmen (zie figuur 1). Door de hoeveelheid virus na kweek 
in aan- en afwezigheid van antiviraal middel te vergelijken kan nagegaan worden in 
hoeverre er remming is door het antivirale middel. Afwezigheid van remming duidt op 
resistentie tegen het betreffende middel. 
Figuur 1. Fenotypische gevoeligheidsbepaling HSV-1.
HSV-1 wordt gekweekt in een laag cellen in een kweekplaat. Daar waar het virus zich vermenigvuldigt worden de cel-
len vernietigd door het virus en dat zorgt voor de ophelderingen (plaques) in de blauwe cellaag (linker foto voor beide 
virussen). Elke plaque staat voor 1 virusdeeltje dat zich vermenigvuldigt. Wanneer antiviraal middel de vermenigvul-
diging van een virus remt, ontstaan er geen plaques (rechter foto gevoelig virus). Wanneer virus resistent is tegen het 
antivirale middel, zal er ondanks de aanwezigheid van antiviraal middel vermenigvuldiging optreden en ontstaan er 
plaques (rechter foto resistent virus).
Eerder ontworpen methodes zijn afhankelijk van zichtbare en voldoende groei van 
het virus, waardoor deze testen lang duren en veel handwerk vergen. De nieuwe 
methode die is opgezet ondervangt deze nadelen door gebruik te maken van snelle 
en gevoelige detectie van DNA van HSV-1. Vergeleken met de traditionele testen, 
voldeed de methode goed in een testpanel van opgekweekt HSV-1 en in bepaalde 
gevallen (bij een geringe mate van resistentie) zelfs beter. Met het nieuwe protocol 
werd bovendien vlot een resultaat verkregen. 
 Bij patiënten die een stamceltransplantatie ondergaan worden de eigen bloed- 
en afweervormende cellen vernietigd om ziektes die hierin aanwezig zijn te gene-
zen. Vervolgens krijgen deze patiënten stamcellen uit het beenmerg of bloed van 
een donor die weer kunnen uitgroeien tot effectieve bloed- en afweercellen. In de 
fase waarin de donorcellen nog niet volledig zijn uitgegroeid zijn deze zogenoemde 
stamcel transplantatie (SCT) ontvangers zeer ernstig immuungestoord. Een frequen-
te en vervelende bijwerking van SCT is het ontstaan van pijnlijke zweren in en om de 
mond. Deze kunnen veroorzaakt worden door de chemotherapie die gegeven wordt 
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om de eigen cellen van de patiënt te vernietigen, maar het reactiveren van HSV-1 of 
andere herpesvirussen zoals Epstein-Barr virus (EBV) kan hierbij ook een rol spelen.
Hoofdstuk 3
In hoofdstuk 3 is een groep patiënten tijdens het SCT traject gevolgd. Geregistreerd 
werd of zij last kregen van afwijkingen in de mond en of er HSV-1, CMV of EBV 
in hun mond aanwezig was. Daarnaast werd bij de patiënten die HSV-1 bleken te 
hebben onderzocht hoe vaak er sprake was van een blijvende infectie in de mond 
ondanks behandeling. Bij de patiënten met een blijvende infectie werd tenslotte 
bekeken of er sprake was van een resistent virus.
 De aanwezigheid van HSV-1 bleek verband te houden met zweren in de gehele 
mond. EBV leek verband te houden met het optreden van zweren in specifieke ge-
deelten van de mond. Een blijvende HSV-1 infectie ondanks behandeling trad op bij 
43% van de behandelde patiënten en ging gepaard met een resistent virus bij 42% van 
de blijvende infecties. Dit betekent dat preventie, diagnose en behandeling van HSV-
1 infecties na SCT van belang zijn evenals resistentie onderzoek, wanneer de infectie 
niet reageert op behandeling. De rol van EBV verdient nog nader onderzoek.
Figuur 2. Werkings- en resistentiemechanismen antivirale middelen tegen herpesvirussen.
Vereenvoudigde weergave van het werkingsmechanisme van anti-herpesvirus middelen in een virus geïnfecteerde 
cel. Deze middelen kunnen in 2 typen verdeeld worden op grond van hun aangrijpingspunt in het virus. Middelen 
van type 1 dienen voordat zij werkzaam zijn geactiveerd te worden door het virale enzym proteïne kinase. Daarna 
blokkeren zij de werking van het virale enzym DNA polymerase waardoor het virus zich niet meer kan vermenig-
vuldigen. Middelen van type 2 zijn direct actief tegen het virale DNA polymerase. Hieruit volgt dat mutaties in het 
virale proteïne kinase de werking van type 1 middelen teniet doen. Mutaties in het virale DNA polymerase kunnen de 
werken van beide typen antivirale middelen blokkeren.




In hoofdstuk 4 zijn het beloop, het effect van antivirale behandeling en het vóórkomen 
van resistent virus onderzocht bij hematologische patiënten met een VZV infectie. 
Hoewel VZV veel voorkomt in deze patiëntengroep, is over het voorkomen van lang-
durige VZV infecties en de rol van resistent virus hierbij weinig bekend. Daarom is dit 
terugkijkend onderzocht bij een groep volwassenen en kinderen die ofwel chemothe-
rapie voor bloed- of lymfeklierkanker ofwel een SCT hadden ondergaan in het recente 
verleden en daarna een VZV infectie ontwikkelden. Van deze patiënten is nagezocht 
hoe lang zij symptomen hadden en wat voor soort symptomen dat waren. Ook is bij 
hen achteraf bepaald in opgeslagen monsters hoeveel en hoe lang VZV aantoonbaar 
was. Tenslotte is bij langdurige infecties gekeken of er sprake was van resistent virus.
 Van de patiënten bij wie dit achteraf onderzocht kon worden had 59% een lang-
durige infectie en dit ging bij de helft van de patiënten gepaard met complicaties. 
Resistent virus werd gevonden in 27% van de patiënten en ging in een aantal geval-
len gepaard met zeer ernstige infecties met resistent virus in ogen of hersenen. Dit 
betekent dat bij langdurige VZV infectie tijdig en uitgebreid resistentie onderzoek 
van virus uit alle mogelijk aangedane organen noodzakelijk is.
Hoofdstuk 5
Antivirale middelen die CMV en andere herpesvirussen remmen hebben twee aangrij-
pingspunten in het virus (zie figuur 2). De eerste is het virale enzym proteïne kinase 
dat door het antivirale middel benut wordt om zich te laten omzetten tot actieve rem-
mende stof. De tweede is het enzym DNA polymerase waarvan de werking door de 
antivirale middelen geblokkeerd wordt, waardoor het virus zich niet meer kan verme-
nigvuldigen. 
 In het DNA van CMV liggen de twee genen die, wanneer zij afgelezen en vertaald 
worden, leiden tot de productie van deze twee enzymen. Resistentie ontstaat in een 
virus zoals CMV bij toeval, omdat tijdens de vermenigvuldiging van een virus het 
DNA ervan wordt gekopieerd voor het nieuwe virusdeeltje en hierbij wel eens fouten, 
mutaties genoemd, ontstaan. Wanneer zo’n mutatie gelokaliseerd is in een stuk viraal 
DNA waarin zich de genen voor proteïne kinase of DNA polymerase bevinden is het 
mogelijk dat deze enzymen niet meer of anders gaan werken. Daardoor kan het virus 
het aangrijpingspunt van een antiviraal middel verliezen. Het virus is dan resistent 
geworden tegen het middel.
Resistentie kan bij een virus daarom gedetecteerd worden door op zoek te gaan naar 
mutaties in de genen van de enzymen proteïne kinase en DNA polymerase. De gebrui-
proefschrift.indd   174 8-10-2012   19:21:05
Samenvatting
175
kelijke techniek hiervoor bestaat uit het volledig aflezen van de betreffende genen. Dit 
behelst vrij veel handwerk en veel analysetijd. Massa spectrometrie gebaseerde verge-
lijkende sequentie analyse (mass spectrometry-based comparative sequence analysis, 
MSCSA) is een nieuwe techniek waarbij het niet nodig is een heel gen af te lezen. Met 
massa spectrometrie worden het gewicht en de lading van een molecuul bepaald. Dit 
kan gebruikt worden voor het analyseren van DNA door een gen in ontelbare kleine 
fragmentjes te knippen en daarvan de lading en massa te bepalen. Software kan de 
gegevens van alle kleine fragmentjes vergelijken met gegevens over hoe het gen sa-
mengesteld zou moeten zijn en zo herleiden op welke volgorde de fragmenten zich 
in het oorspronkelijke gen bevonden. Als het gewicht van een fragment veranderd is 
betekent dit dat er iets veranderd is in het gen en zo kan bepaald worden of er mutaties 
in aanwezig zijn. De bewerking van het virus monster en de analyse kunnen beide 
halfautomatisch verricht worden en dat bespaart dus tijd. 
 In hoofdstuk 5 is deze nieuwe techniek om resistentie veroorzakende mutaties op te 
sporen onderzocht voor het proteïne kinase gen van CMV. In een testpanel van gevoe-
lige en resistente CMV monsters werkte de nieuwe techniek net zo goed als de gebrui-
kelijke voor het opsporen van mutaties in het proteïne kinase gen. Wanneer er een groot 
aanbod is van monsters voor resistentie analyse zou deze techniek dus ingezet kunnen 
worden.
Hoofdstuk 6
CMV infecties kunnen bij SCT patiënten ernstig verlopen in de fase waarin hun donor 
stamcellen nog onvoldoende zijn uitgegroeid. Om dit te voorkomen worden deze in-
fecties al behandeld voordat de patiënt er symptomen van heeft door regelmatig in het 
bloed van de patiënten te kijken of er CMV aantoonbaar is. Het monitoren van het ont-
staan van een infectie en het starten met behandelen voordat deze klinisch merkbaar 
is heet pre-emptieve therapie (zie Figuur 3). Soms is na een pre-emptieve behandeling 
toch nog virus meetbaar in het bloed van patiënten. Het is onduidelijk hoe dit komt.
In hoofdstuk 6 is bij SCT patiënten terugkijkend onderzocht hoe vaak er ondanks pre-
emptieve behandeling van CMV sprake was van een aanhoudende infectie in het bloed. 
De risicofactoren hiervoor en de rol van resistent virus zijn bestudeerd. Bij 45% van de 
ziekte episodes bleek sprake van een aanhoudende infectie ondanks behandeling. Dit 
kwam vooral voor tijdens de eerste CMV infectie sinds de SCT en bij patiënten die veel 
afweer onderdrukkende medicijnen gebruiken. Resistent virus kwam slechts bij één pati-
ent voor. Dit betekent dat een langdurige CMV infectie na SCT vooral verband houdt met 
een slechte afweer en dat het meestal niet nodig is een ander antiviraal middel te geven.
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 Na een orgaan transplantatie komen CMV infecties ook veelvuldig voor. Dit komt 
enerzijds doordat patiënten sterke afweer onderdrukkende medicatie gebruiken na 
transplantatie om afstoting van het donor orgaan te voorkomen. Anderzijds komt dit 
doordat ontvangers van een orgaan geïnfecteerd kunnen worden doordat CMV zich 
in het donor orgaan bevindt. Vooral wanneer de ontvanger zelf nog nooit CMV heeft 
opgelopen en hiertegen dus geen afweer heeft opgebouwd is dit gevaarlijk, omdat de 
patiënt dan een eerste CMV infectie oploopt op een moment waarop er sprake is van 
een sterk onderdrukte afweer. Om ernstige ziekteverschijnselen te voorkomen krijgen 
patiënten zonder afweer tegen CMV daarom soms preventief antivirale middelen toe-
gediend na transplantatie van een orgaan dat CMV bevat (profylaxe, zie Figuur 3). Een 
pre-emptieve strategie, zoals in de vorige paragraaf beschreven kan ook worden toe-
gepast. Het is onbekend welke van deze twee strategieën het meest effectief is en het 
laagste risico op resistentie geeft.
Hoofdstuk 7
In het LUMC is men recent van een pre-emptieve strategie overgegaan op een strategie 
van 3 maanden profylaxe gevolgd door een pre-emptieve strategie ter voorkoming van 
CMV infecties bij niertransplantatie patiënten uit de genoemde hoog risico categorie. In 
hoofdstuk 7 is terugkijkend een vergelijking gemaakt van het vóórkomen van langduri-
ge infecties en het vóórkomen van resistent virus tussen beide behandelingsstrategieën. 
Blijvende CMV infecties ondanks behandeling kwam voor bij 71% van de patiënten uit 
Figuur 3 Preventie- en behandelingsstrategieën van herpesvirus infecties na transplantatie.
Om een ernstig verloop van infecties met herpevirussen bij transplantatiepatiënten te voorkómen kunnen verschillen-
de strategieën worden toegepast. Profylaxe bestaat uit het geven van antivirale middelen vanaf het moment van trans-
plantatie. Pre-emptieve behandeling omvat het regelmatig monitoren van virus in het bloed om therapie te kunnen 
starten zodra virus aantoonbaar is nog voordat de patiënt hier verschijnselen van heeft. Tenslotte kunnen infecties ook 
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het pre-emptieve cohort en slechts 14% van de patiënten in het profylaxe gevolgd door 
pre-emptieve behandeling cohort. Resistentie kwam voor bij respectievelijk 3 en 1 pati-
ent uit de beide groepen en deze infecties verdwenen zonder behandeling. Dit betekent 
dat profylaxe leidt tot minder langdurige infecties en dat, wanneer profylaxe gevolgd 
wordt door pre-emptieve therapie, er geen grotere kans op resistentie is en misschien 
zelfs een kleinere kans.
Hoofdstuk 8
Omdat bepaalde delen van de afweer na orgaantransplantatie sterk onderdrukt wor-
den met medicatie, spelen de minder onderdrukte componenten zoals de aangeboren 
afweer waarschijnlijk een belangrijke rol in de afweer tegen infecties. De zogenoemde 
aangeboren afweer bestaat onder andere uit verschillende eiwitten die ziekteverwek-
kers zoals CMV kunnen herkennen en onschadelijk kunnen maken. Voorbeelden van 
deze eiwitten zijn mannose-bindend lectine (MBL), ficoline-2 (FCN2) en MBL-geasso-
cieerd serine protease (MASP2). Door verschillen in de genen die voor deze eiwitten 
coderen, zijn er verschillen tussen mensen wat betreft de hoeveelheid en de werking 
van deze eiwitten. Mogelijk leidt dit ook tot verschillen in de effectiviteit van de aan-
geboren afweer tegen infecties zoals CMV. De eiwitten MBL, FCN2 en MASP2 worden 
geproduceerd door de lever. Na een levertransplantatie erft de ontvanger daarmee de 
genen van de leverdonor en gaat voortaan eiwitten produceren in de hoeveelheid en 
werking zoals voorgeschreven door die genen. 
In hoofdstuk 8 is onderzocht of dit gevolgen heeft voor de kans op CMV infecties 
na levertransplantatie. Terugkijkend is van ontvangers van een levertransplantaat 
gekeken naar hun MBL, FCN2 en MASP2 genen en die van de leverdonor. Van alle 
patiënten is vervolgens terugkijkend geregistreerd of zij een CMV infectie opliepen 
na transplantatie. 
 Ontvangers van een levertransplantaat met genen die zorgden voor verminderde 
productie van MBL2 of een minder effectief FCN2 hadden inderdaad een grotere kans 
op CMV infecties, vooral wanneer zij beide ongunstige genvarianten hadden. Dit risico 
was het grootst bij patiënten die zelf vóór transplantatie gunstige genvarianten hadden. 
Bij de patiënten die zelf al ongunstige genvarianten hadden was dit risico minder groot. 
Misschien komt dit door het feit dat deze patiënten al ‘gewend’ waren aan minder ef-
fectieve onderdelen van de aangeboren afweer en ter compensatie andere onderdelen 
van de afweer extra hadden benut. Een patiënt die van nature geen ongunstige genva-
rianten had en dus geen compensatiemechanismen had ontwikkeld en een lever met 
een verminderde productie van effectief MBL2 en FCN2 ontvangt heeft daardoor mis-
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schien op een moment van sterk onderdrukte afweer ook nog eens een minder optima-
le aangeboren afweer. In de toekomst kan het in detail bepalen van onderdelen van de 
afweer bij een patiënt vóór transplantatie mogelijk leiden tot betere risico inschattingen 
en preventie van CMV infecties na transplantatie.
Conclusie
Concluderend kan gesteld worden dat langdurige infecties met HSV, VZV en CMV fre-
quent voorkomen bij immuungestoorde patiënten. Resistent virus is bij een minderheid 
van de patiënten een oorzaak van een blijvende infectie. Echter, infecties met resistent 
virus kunnen ernstig verlopen. Daarom is bij blijvende infecties tijdig onderzoek naar 
resistentie noodzakelijk. Hiervoor kunnen onder andere de beschreven nieuwe tech-
nieken gebruikt worden. 
 Om in de toekomst infecties met herpesvirussen bij immuungestoorde patiënten 
beter te kunnen voorkómen en behandelen is meer kennis nodig over het voorspel-
len en versterken van de afweer tegen herpesvirussen, over aanvullende technieken 
voor resistentiebepaling en over nieuwe middelen voor behandeling van infecties met 
resistente virussen. Ook is meer inzicht nodig in de optimale behandelduur van deze 
infecties om het beleid bij een langdurige infectie beter te kunnen vaststellen.
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